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Flavonoids are a broad collection of polyphenolic compounds ubiquitously found in 
foods of plant origin.  Previous studies suggested that they are beneficial in protecting 
against many chronic diseases, such as cancers, cardiovascular diseases and 
neurological disorders.  There is also evidence that flavonoids have beneficial effects on 
modifying glucose absorption and are thus regarded as potential anti-diabetic agents.  
To address this we investigated the effects of a flavonoid-rich berry extract on glucose 
transport in intestinal epithelial Caco-2 cells and C2C12 muscle cells. 
 
In Caco-2 cells, acute exposure to berry extract inhibited glucose uptake.  Prolonged 
incubation down-regulated the gene expression of GLUT2 and SGLT1, with a 
concomitant up-regulation of let-7a miRNA.  Using bioinformatic tools, let-7a is 
predicted to target the mRNA of GLUT2, potentially down-regulating its expression.  In 
C2C12 myotubes, chronic incubation of berry extract did not have any effect on basal or 
insulin-stimulated glucose uptake. 
 
Taken together, these data suggested that the acute inhibitory effects of berry flavonoids 
on glucose transport are specific to intestinal glucose transporters.  These compounds 
may be useful for regulating the rate of glucose absorption from the diet; however, they 
are less effective modifiers of peripheral glucose transport. 
 
Studies were also carried out on the molecular basis of alcoholic myopathy, using the 
C2C12 muscle cell model.  This provides not only an opportunity to study the 
pathogenic basis of a common disorder but also to compare putative pathways that may 
be modulated by myotoxins and myoprotectants.  The results of microarray studies 
showed that alcohol altered the expression of genes related to multiple cellular 
functions, including insulin signalling, muscle contraction and protein synthesis.  On the 
other hand, microarray studies demonstrated that berry extract was a potent inducer of 
cellular antioxidant defence system.  This indicated that berry extract might act as a 
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1.1 Literature review 
Glucose is the primary energy source for mammalian cells.  In humans, under normal 
physiological conditions, glucose is the only source of energy for the brain 
(Nieuwenhuys et al., 1998), though in starvation, it can adapt to utilise ketone bodies.  
Glucose can be obtained from the diet in various forms of carbohydrates and is also 
produced in the liver from non-carbohydrate substrates by gluconeogenesis.  It is 
transported in the bloodstream and taken up by body cells, most importantly the muscle 
cells and adipocytes.  The level of glucose in the blood is tightly regulated as a part of 
the body’s metabolic homeostasis (Langfeldt, 1921).  In the following section, the 
mechanisms of glucose transport in human enterocytes and skeletal muscle cells, as well 
as their regulation will be described. 
 
1.1.1 Glucose transport in human enterocytes 
Carbohydrates comprise a major source of energy in the diet.  Prior to absorption, 
carbohydrates are digested into simple monosaccharides, such as glucose, fructose and 
galactose.  Glucose is the principal circulating sugar in blood as a major source of 
energy and is an important metabolic intermediate.  Transport of glucose across the 
intestinal epithelium has been known for decades to be mediated by glucose transporter 
proteins, namely sodium/glucose co-transporter 1 (SGLT1, encoded by the SLC5A1 
gene) (Crane, 1962, Hediger et al., 1987) and facilitated glucose transporter 2 (GLUT2, 
encoded by the SLC2A2 gene) (Thorens et al., 1988) and to be highly regulated.  
However, until now, there is still no consensus on the precise mechanisms for the 
transport of glucose across the brush-border membrane and the basolateral membrane of 




1.1.1.1 Intestinal glucose transport model 
In the classical model of intestinal glucose transport (Figure 1), glucose is actively 
transported across the brush-border membrane of intestinal epithelial cells by the 
sodium/glucose co-transporter 1 (SGLT1) against an ‘uphill’ gradient (Crane, 1962, 
Wright, 1998).  This active transport process, at the expense of metabolic energy from 
the hydrolysis of ATP, allows glucose to be absorbed even when the luminal 
concentration is lower than the circulating blood glucose concentration.  Glucose 
molecules that enter the epithelial cells are then transported out of the cells across the 
basolateral membrane by the facilitated glucose transporter 2 (GLUT2) (Thorens et al., 
1988).  
 
Figure 1. The classical intestinal glucose transport model 
Glucose is actively transported across the brush-border membrane of intestinal epithelial 
cells by SGLT1 against an ‘uphill’ gradient.  The energy for this ‘uphill’ transport 
comes from the sodium ion electrochemical potential gradient across the brush-border 




-ATPase that pumps the co-transported 
sodium ions out across the basolateral membrane at the expense of metabolic energy 
from hydrolysis of ATP.  Glucose molecules are then transported out of the cells across 
the basolateral membrane by the low-affinity high-capacity transporter, GLUT2.  
Proposed by Wright (1998). 
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1.1.1.2 Regulation of SGLT1 
SGLT1 is one of the most important sugar transporters in the gastrointestinal tract.  
Defects in the function of SGLT1 give rise to the glucose-galactose malabsorption 
(Martin et al., 1996), a disorder which is life-threatening to affected individuals unless 
glucose and galactose are removed from their diets.  In the following section, the 
regulation of SGLT1 in the intestine will be described. 
 
Sorting and expression of SGLT1 
The activation of protein kinase A (PKA) has been found to induce a rapid increase in 
the number of rabbit SGLT1 proteins in the plasma membranes expressed in Xenopus 
laevis oocytes (i.e. within minutes).  This led to increased maximal glucose transport 
rates (Hirsch et al., 1996).  These changes were accompanied by an increased area of the 
plasma membrane, suggesting that regulation occurred by modulating the rate of 
SGLT1 being inserted into, or retrieved from, the plasma membrane, through exocytosis 
or endocytosis, respectively (Hirsch et al., 1996, Wright et al., 1997, Khoursandi et al., 
2004). 
 
Furthermore, increases in intracellular levels of cyclic AMP (cAMP), a second 
messenger that activates PKA (Reimann et al., 1971), was also shown to enhance the 
protein expression of SGLT1 but decrease that of GLUT2 in jejunal enterocytes 
(Williams and Sharp, 2002).  These changes were most prominent in the mid and low 
villus cells (Williams and Sharp, 2002), which have been suggested to be important 




Direct phosphorylation of SGLT1 
More recently, Subramanian et al. (2009) were able to detect an increase in both Vmax 
and affinity of glucose transport by rabbit SGLT1 expressed in hamster ovary cells after 
activation of PKA.  In their study, they reported that, in addition to the sorting of 
SGLT1 between the intracellular space and the plasma membrane, activation of PKA 
also had a direct effect on SGLT1 by phosphorylation at the PKA consensus site.  This 
resulted in a conformational change in the transporter, altering its functional properties 
and increasing its transport affinity (Subramanian et al., 2009). 
 
Regulation by dietary sugar and artificial sweetener 
Dyer et al. (2003) found that both dietary sugars and artificial sweeteners were able to 
regulate SGLT1 by altering its mRNA and protein expression (Dyer et al., 2007, 
Margolskee et al., 2007).  This inducible regulation was dependent on the sweet taste 
receptor, T1R3 and the coupled G-protein, α-gustducin, and acted through the 
cAMP/PKA signalling cascade (Margolskee et al., 2007).  However, these receptors 
were only present in enteroendocrine cells (Margolskee et al., 2007).  The authors 
proposed that the sweet taste receptors in enteroendocrine cells mediated the release of 
glucagon-like peptide-1 and glucose-dependent insulinotrophic peptide.  These 
hormones then served as the signal between the sensory enteroendocrine cells and 
absorptive enterocytes to regulate SGLT1 (Margolskee et al., 2007).  They also 
postulated that de novo protein synthesis was required for induction of SGLT1 
expression (Dyer et al., 2003), as opposed to other research groups that reported 




1.1.1.3 Regulation of GLUT2 
Since 1935, it has been reported that intestinal glucose absorption is comprised of two 
components (Donhoffer, 1935), the active component mediated by SGLT1 that shows 
simple kinetics with saturation occurring at around 30 mM glucose, and the apparently 
non-saturable component that displays linear kinetics from 30 mM to over 100 mM 
glucose (Debnam and Levin, 1975).  Therefore, it is believed that in addition to SGLT1, 
there is another mechanism by which glucose is transported across the brush-border 
membrane of intestinal epithelial cells. 
 
The theory of paracellular solvent drag 
The first model to explain the diffusive component of intestinal glucose transport was 
proposed by Pappenheimer and Reiss (1987) as the theory of paracellular solvent drag.  
It was observed that absorption of glucose through SGLT1 induced the contraction of 
the perijunctional actomyosin ring and caused the widening of intercellular tight 
junctions (Madara and Pappenheimer, 1987).  The SGLT1-mediated transport of 
glucose into the cells also provided an osmotic force for solvent flow which permits 
more glucose molecules to be absorbed through the intercellular space, in a paracellular 
manner (Pappenheimer and Reiss, 1987). 
 
The theory of negligible diffusive component 
Ferraris et al. (1990) argued that the luminal glucose concentration had been over-
estimated by other researchers and that the concentration measured in rats on 
physiological diets in their study ranged from only 0.2 mM to a maximum of 48 mM, 
which lies within the effective glucose concentration of SGLT1 transport.  This 
supported their view that intestinal glucose absorption could be explained effectively by 
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the activity of SGLT1 and that the diffusive component of glucose transport was 
negligible (Ferraris and Diamond, 1997). 
 
The apical GLUT2 trafficking model 
The latest model for glucose transport is the rapid insertion of the high-capacity glucose 
transporter GLUT2 into the brush-border membrane, proposed by Kellett’s research 
group (Helliwell et al., 2000a, Helliwell et al., 2000b, Kellett and Helliwell, 2000) 
(Figure 2).  In this model, the level and intrinsic activity of GLUT2 at the brush-border 
membrane are low when the luminal glucose concentration is low, while SGLT1 acts as 
the major glucose transporter on the brush-border membrane at this stage (Kellett and 
Helliwell, 2000).  After a meal, when the local concentration of glucose in the intestinal 
lumen increases, intense SGLT1-mediated transport of glucose across the brush-border 
membrane activates protein kinase C βII (PKCβII). This in turn increases the intrinsic 
activity of GLUT2 already at the brush-border membrane, and more importantly, 
promotes the trafficking of additional GLUT2 to the membrane (Kellett and Helliwell, 
2000).  This notion was supported by studies which showed that the increase in both the 
GLUT2 protein expression and the GLUT2-mediated glucose uptake in response to a 
glucose bolus were blunted in SGLT1
-/-
 mice (Gorboulev et al., 2012).  This rapid 
translocation of GLUT2 towards the brush-border membrane provides a cooperative 
mechanism by which the absorptive capacity of glucose can be rapidly and precisely 




Figure 2. The apical GLUT2 trafficking model 
1) Intense Na
+
-coupled transport of glucose depolarises the brush-border membrane, triggering an influx of extracellular Ca
2+
 ions through the Cav1.3 
calcium channel; 2) increased level of cytosolic Ca
2+
 ions induces a re-arrangement of cytoskeleton and contraction of the terminal web, as well as the 
translocation of PKCβII to the brush-border membrane; 3) stimulation of the T1R2+T1R3 taste receptors by sugars or artificial sweeteners activates 
PLCβ2 through α-gustducin; 4) PLCβ2 activates PKCβII at the brush-border membrane; 5) fully activated PKCβII, together with the re-arrangement of 
cytoskeleton, promotes trafficking of GLUT2 to the brush-border membrane. Drawing was based on information from various sources: Kellett and 
Helliwell (2000), Morgan et al. (2007), Mace et al. (2009). 
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Calcium-dependent regulatory pathway 
Following initial findings, Kellett’s research group has further investigated the 
molecular mechanisms by which the insertion of GLUT2 proteins into the brush-border 
membrane is regulated (Mace et al., 2007a, Mace et al., 2007b, Morgan et al., 2007, 
Mace et al., 2009) (Figure 2).  They observed that apical GLUT2 insertion requires an 
increase in cytosolic Ca
2+
 concentration (Mace et al., 2007b, Morgan et al., 2007).  
When luminal glucose level rises to a concentration of 20 mM, Na
+
-coupled transport of 
glucose depolarises the brush-border membrane, triggering an influx of extracellular 
Ca
2+
 ions through the voltage-dependent L-type Cav1.3 calcium channel (Morgan et al., 
2003).  The increased level of cytosolic Ca
2+
 ions induces a re-arrangement of the 
cytoskeleton and contraction of the terminal web, thus providing the prerequisite for the 
trafficking of GLUT2 to the apical membrane (Mace et al., 2007b).  The increased 
intracellular Ca
2+
 level also promotes the translocation of phosphorylated, but not yet 
fully activated, PKCβII, from the cytosol to the brush-border membrane (Newton, 1997), 
which requires activation by additional taste receptor signals to finally induce the 
GLUT2 translocation process (Mace et al., 2007a, Mace et al., 2009). 
 
Sweet taste receptor signalling pathway 
An increase in intracellular Ca
2+
 level is a prerequisite for, but is not sufficient to trigger, 
GLUT2 translocation.  A second signal from the sweet taste receptor signalling pathway 
is also necessary (Mace et al., 2007a, Mace et al., 2009).  Sugars as well as non-
metabolisable artificial sweeteners contribute to the migration of GLUT2 into the brush-
border membrane (Mace et al., 2007a).  Sugars at high concentrations (up to 100 mM) 
or artificial sweeteners at low concentrations (< 5 mM) (Li et al., 2002) activate the 
sweet taste receptor heterodimer T1R2+T1R3 located at the brush-border membrane.  
Stimulation of T1R2+T1R3 activates its coupled G-protein α-gustducin which 
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subsequently completes the activation of PKCβII to promote the translocation of 
GLUT2 to the apical membrane within minutes (Adler et al., 2000; Mace et al., 2009).  
However, a recent study in humans failed to demonstrate any effects of intraduodenal 
administration of sucralose, an artificial sweetener, on the rate of glucose absorption 
from the lumen of the small intestine (Ma et al., 2010).  This argued against the 
involvement of sweet taste receptors in the regulation of intestinal glucose absorption. 
 
Hormonal regulation 
In addition to the rapid adjustment of glucose absorptive capacity according to changes 
in dietary intake, intestinal glucose transport was also found to be under hormonal 
regulation (Helliwell et al., 2000a, Shepherd et al., 2004, Tobin et al., 2008).  The 
pancreas secretes insulin in response to increased blood glucose level.  The level of 
insulin release is further enhanced by the secretion of incretins (glucagon-like peptide 1, 
GLP-1 and glucose-dependent insulinotropic peptide, GIP) by enteroendocrine cells in 
response to exposure of the gut to nutrients (Baggio and Drucker, 2007).  Insulin 
reaches the enterocytes and promotes the internalisation of GLUT2 from the brush-
border membranes to the intracellular membrane stores (Tobin et al., 2008), possibly by 
acting through the extracellular signal-regulated kinase, p38 mitogen-activated kinase 
and phosphatidylinositol 3-kinase intracellular signalling pathways (Helliwell et al., 
2000a).  This returns the GLUT2 transporter to its configuration during low luminal 
glucose levels and limits the transepithelial transport of glucose. 
 
1.1.1.4 Alternative pathway for glucose transport across the basolateral 
membrane 
It is generally believed that after glucose molecules enter the intestinal epithelial cells, 
the majority of the glucose, if not all, is then released into the interstitial space across 
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the basolateral membrane by facilitated diffusion via GLUT2.  In this regard, Stümpel et 
al. (2001) have demonstrated that glucose might be able to exit the enterocytes by 
another transport mechanism independent of GLUT2.  They reported normal kinetics of 
intestinal glucose absorption in GLUT2-null mice, whereas the intestinal glucose 
transport was inhibited dose-dependently by a glucose-6-phosphate translocase inhibitor.  
Furthermore, they found that the GLUT2-null mice were unable to transport 3-O-
methylglucose, a non-metabolisable glucose analogue that cannot be phosphorylated 
(Stümpel et al., 2001).  These studies suggested that there might be an alternative 
pathway for glucose exit across the basolateral membrane, which requires glucose 
phosphorylation, transport of the glucose-6-phosphate into endoplasmic reticulum, and, 
after dephosphorylation, release out of the cells by means of vesicle transport (Stümpel 
et al., 2001).  A human study on a GLUT2-deficient patient also showed that GLUT2 
was not required for intestinal transepithelial glucose transport (Santer et al., 2003). 
 
1.1.1.5 GLUT1, GLUT3 and GLUT5 
In addition to the two major glucose transporters, GLUT2 and SGLT1, other hexose 
transporters are also present in the gastrointestinal tract.  These include GLUT1 
(erythrocyte-type), GLUT3 (brain-type) and GLUT5 (specific fructose transporter). 
 
GLUT1 is highly expressed in all fetal tissues and is also widely expressed in various 
adult tissues (Olson and Pessin, 1996).  Its ubiquitous distribution and transport kinetics 
(Km close to normal blood glucose level, i.e. around 5 mM) suggest that GLUT1 plays 
an important role in maintaining low level of basal glucose uptake required to sustain 
respiration in all cells.  Specifically, expression of GLUT1 is low in the small intestine 
and is predominantly located intracellularly and on the basal side of the intestinal 
epithelial cells (Boyer et al., 1996, Yoshikawa et al., 2011). 
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GLUT3 is a high-affinity and high-capacity glucose transporter.  It is highly expressed 
in tissues with high energy demand, such as brain, neurons and sperms (Simpson et al., 
2008).  Abundance of GLUT3 mRNA was found to be very low in normal small 
intestine tissue (Yano et al., 1991) but its expression was elevated in various cancers 
(Yamamoto et al., 1990). 
 
GLUT5 is a transporter with high stereospecificity for fructose.  Along the 
gastrointestinal tract, mRNA of GLUT5 was detected predominantly from the proximal 
to middle parts of the small intestine (Yoshikawa et al., 2011).  Within the enterocyte, 
GLUT5 transporters are mainly present on the brush-border membrane, but has also 
been detected in the basolateral membrane (Blakemore et al., 1995).  Regulation of 
GLUT5 expression by sugars is specific to its substrate, fructose (or sucrose which 
undergoes hydrolysis to fructose and glucose) (Miyamoto et al., 1993).  It is believed 
that de novo GLUT5 mRNA and protein synthesis is required for the observed increases 
in fructose transport after fructose feeding (Lan and Ronaldo, 2001).  On the other hand, 
cAMP has also been demonstrated to activate transcription of GLUT5 by interacting 
with the cis-regulatory sequences in the GLUT5 promoter region, resulting in increases 
in both mRNA, protein levels of GLUT5 and fructose transport activity in Caco-2 cells 
(Mahraoui et al., 1994b). 
 
1.1.2 Glucose transport in skeletal muscle cells 
Skeletal muscle contributes approximately 40% of body weight and is the principal site 
of postprandial glucose disposal (Zurlo et al., 1990).  It has been estimated that under 
insulin-stimulated conditions, skeletal muscle accounts for approximately 75-80% of 
whole body glucose uptake following glucose infusion (Defronzo et al., 1985). 
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Glucose uptake into skeletal muscle cells is primarily mediated by the insulin-
responsive glucose transporter type 4 (GLUT4), although GLUT1, GLUT5 and 
GLUT12 are also present (Stuart et al., 2000, Stuart et al., 2006).  Being the major 
glucose transporter in skeletal muscle, as well as in adipose tissues, GLUT4 is 
indispensable for normal whole-body glucose homeostasis. 
 
1.1.2.1 Regulation of GLUT4 
In order to tightly regulate blood glucose concentration under various physiological 
conditions, the distribution of GLUT4 between the cell surface and intracellular sites is 
rapidly regulated in response to specific stimuli such as insulin and muscle contraction 
independent of changes in transcription and translation.  For instance, in non-stimulated 
cells, the majority of GLUT4 resides within intracellular membrane compartments with 
less than 5% of the total GLUT4 pool localised at the plasma membrane.  However, 
following insulin stimulation, up to 50% of the total GLUT4 pool redistributes from its 
intracellular locations to the plasma membrane (Leney and Tavare, 2009).  In addition 
to acute regulation of its distribution through translocation to the cell surface, GLUT4 is 
also subjected to transcriptional regulation.  One example is the increase in GLUT4 
expression in response to exercise and physical training (Maclean et al., 2002). 
 
GLUT4 translocation 
GLUT4 transporters are capable of trafficking between the plasma membrane and 
intracellular membrane compartments in response to various stimuli such as insulin, 
contraction, depolarisation and energy deprivation.  However, translocation of GLUT4 
is mediated by distinct mechanisms under different stimulations.  The two most studied 
signal transduction pathways involved in GLUT4 trafficking in muscle are the insulin 
signalling and AMPK pathways. 
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Insulin signalling pathway 
Figure 3. The insulin signalling pathway 
1) Binding of insulin induces autophosphorylation of IR tyrosine kinase; 2) activated IR 
phosphorylates IRS1/2 and subsequently 3) leads to recruitment of PI3K to the plasma 
membrane; 4) PI3K converts the membrane-bound PIP2 to PIP3 which activates PDK1, 
which 5) further activates AKT; 6) downstream targets of AKT that leads to stimulation 
of glucose uptake include, the Rab GTPase-activating protein, AS160; 7) 
phosphorylation of AS160 suppresses its inhibitory effect on Rab proteins, thus 
promoting the transclocation of GLUT-4 storage vesicles (GSVs) to the plasma 
membrane.  Drawing was based on information from various sources: Kahn et al. 
(1985), Sanchezmargalet et al. (1994), Berwick et al. (2004), Larance et al. (2005), 
Geraghty et al. (2007), Leney and Tavare (2009). 
 
Upon binding of insulin to the insulin receptor (IR) tyrosine kinase, it undergoes 
autophosphorylation (Figure 3).  This leads to phosphorylation of insulin receptor 
substrate proteins (IRS1/2) and the recruitment of phosphatidylinositol 3-kinase (PI3K) 
to the plasma membrane, which subsequently catalyses the conversion of the membrane 
bound phosphatidylinositol 4,5-bisphosphate (PIP2) to phosphatidylinositol 3,4,5-
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triphosphate (PIP3).  PIP3 in turn recruits and activates the serine/threonine kinase 
phosphoinositide-dependent kinase 1 (PDK1), which further activates another protein 
kinase, AKT.  Downstream targets of AKT include the Rab GTPase-activating proteins, 
TBC1 (Tre-2/USP6, BUB2, cdc16) domain family member 1 (TBC1D1) and AKT 
substrate of 160 kDa (AS160, also known as TBC1D4) and FYVE domain-containing 
PI3P 5-kinase (PIKfyve) (Berwick et al., 2004, Chen et al., 2008, Peck et al., 2009). 
 
AMPK pathway 
Muscle contraction and insulin stimulation are believed to target separate pools of 
intracellular GLUT4-containing membranes.  Moreover, there is convincing evidence 
demonstrating that muscle contraction-induced GLUT4 translocation is mediated by 
signalling mechanism different from the insulin signalling pathway, namely the AMPK 
pathway.  Two cellular responses, increases in either AMP/ATP or ADP/ATP ratios, or 
an increase in intracellular Ca
2+
 concentrations, during muscle contraction were 
demonstrated to trigger the activation of the 5’ adenosine monophosphate-activated 
protein kinase (AMPK) (Hayashi et al., 1998) (Figure 4). 
 
Changes in energy status 
As an energy sensor, AMPK can be activated by an increase in energy demand as 
indicated by a rise in either AMP/ATP or ADP/ATP ratios during muscle contraction.  
Binding of AMP to AMPK causes allosteric activation of the kinase (Suter et al., 2006).  
In addition, the upstream kinase, LKB1, constitutively phosphorylates AMPK but in the 
presence of high ATP concentration, it is constantly dephosphorylated by protein 
phosphatases.  AMP or ADP binding to AMPK induces a conformational change that 
reduces the accessibility of phosphatases to the kinase, thus preventing its 




Figure 4. The AMPK signalling pathway 
1) Increases in either AMP/ATP or ADP/ATP ratios triggered by energy-demanding 
conditions, such as exercises, activates AMPK; 2) the upstream kinase, LKB1, 
constitutively phosphorylates AMPK but it is constantly dephosphorylated by protein 
phosphatases when ATP level is high, in contrast, AMP or ADP binding to AMPK 
induces a conformational change that reduces the accessibility of phosphatases to the 
kinase, thus preventing its dephosphorylation; 3) an increase in cytosolic Ca
2+
 
concentration also activates AMPK through another upstream kinase, CAMKKα/β; 4) 
AMPK phosphorylates the Rab GTPase-activating protein, TBC1D1; 5)  
phosphorylation of TBC1D1 suppresses its inhibitory effect on Rab proteins, thus 
promoting the transclocation of GLUT-4 storage vesicles (GSVs) to the plasma 
membrane. Drawing was based on information from various sources: Davies et al. 
(1995), Hurley et al. (2005), Suter et al. (2006), Abbott et al. (2009), Witczak et al. 
(2010). 
 
Intracellular calcium concentrations 
As mentioned above, increased intracellular Ca
2+
 concentrations also trigger 
phosphorylation of AMPK.  This occurs through binding of Ca
2+
/calmodulin to, and 
subsequent activation of, the upstream kinases, calmodulin-dependent kinase kinase-α 
and -β (CaMKKα and β) (Hurley et al., 2005, Witczak et al., 2010). 
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Transcriptional regulation of GLUT4 
In addition to translocation of the GLUT4 transporter between intracellular regions and 
the plasma membrane, expression of the GLUT4 gene is also subjected to homeostatic 
regulation.  One example is the ability of exercise to induce a transient increase in 
GLUT4 gene transcription in skeletal muscle (Neufer and Dohm, 1993, Kraniou et al., 
2000). 
 
Cis-DNA sequences in the GLUT4 promoter region bind the transcription factors, 
myocyte enhancer factor 2 (MEF2) and GLUT4 enhancer factor (GEF) (Maclean et al., 
2002, Holmes et al., 2005).  Regulation of the activities of these transcription factors 
and their binding to the GLUT4 promoter has been suggested to signal through AMPK, 
CaMK and p38 MAPK (Maclean et al., 2002, Al-Khalili et al., 2004, Murgia et al., 
2009, Ojuka et al., 2012). 
 
1.1.3 Glucose transport and type 2 diabetes 
Type 2 diabetes is a complex metabolic disorder.  The major defect of type 2 diabetes is 
insulin resistance- a pathophysiological condition in which cells fail to respond to the 
normal action of insulin for glucose homeostasis, most importantly for glucose disposal 
in skeletal muscle and suppression of endogenous glucose production in the liver 
(Dinneen et al., 1992).  Physiological and molecular changes relating to aberrations in 
glucose transport have been reported in type 2 diabetes. 
 
1.1.3.1 Gastrointestinal tract 
The gastrointestinal tract is the first site where food from the external environment is 
digested and the resultant nutrients are taken up into cells.  Alterations in the normal 
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digestion and absorption processes have been reported in type 2 diabetic patients, as 
described below. 
 
Expression and sub-cellular localisation of intestinal glucose transporters 
Enhanced intestinal glucose absorption has been reported in diabetic rats (Fedorak et al., 
1987).  Although this can be partly accounted for by generalised mucosal hypertrophy 
in diabetic conditions (Fedorak et al., 1987), studies have attributed the enhanced 
glucose absorption to the increased expression of the glucose transporters GLUT2 and 
SGLT1 (Fedorak et al., 1987, Miyamoto et al., 1991, Burant et al., 1994).  However, 
these aforementioned studies were performed using streptozotocin-induced diabetic rats, 
which are considered as an animal model for type 1 diabetes.  Later investigations have 
been made using a more suitable model, namely obese type 2 diabetic Otsuka Long-
Evans Tokushima Fatty (OLETF) rat (Kawano et al., 1994).  Increased glucose 
absorption was also observed in this model.  This was found to be the result of an 
increased level of SGLT1 protein concomitant with intestinal hypertrophy in the 
OLETF rats (Fujita et al., 1998). 
 
In humans, enhanced intestinal glucose transport was observed in brush-border 
membrane vesicles isolated from type 2 diabetic patients in comparison to healthy 
subjects and this was explained by the increase in the expressions of GLUT2 and 
SGLT1 (Dyer et al., 2002).  In accordance with the above finding, apical GLUT2 in 
jejunal enterocytes was observed in most morbidly obese human subjects (76%) in the 





In addition, abundance of the fructose transporter GLUT5, and abundances as well as 
activities of sucrase and lactase were also up-regulated in the duodenum of type 2 
diabetic patients (Dyer et al., 2002). 
 
Secretion and insulinotropic action of incretin hormones 
Incretins, mainly referring to glucagon-like peptide-1 (GLP-1) and glucose-dependent 
insulinotropic polypeptide (GIP), are peptide hormones secreted by the gut endocrine 
cells.  Both GLP-1 and GIP are able to induce the release of insulin from pancreatic β-
cells.  Mixed results have been published on the level of GIP in type 2 diabetic patients 
compared to non-diabetic subjects, i.e. either increases, no change or decreases in GIP 
secretion were observed.  In comparison to GIP, reports of impairments in GLP-1 
secretion in response to oral glucose or meal ingestion in type 2 diabetes are more 
consistent (summarised in Table 1). 
 
Table 1. Changes of secretion and responsiveness of GIP and GLP-1 in type 2 
diabetes 
  Changes in type 2 diabetes References 
Secretion GIP Basal ↑; postprandial ↑ Coxe et al. (1981) 
Postprandial ↓, NC, ↑ Creutzfeldt et al. (1983) 
Postprandial ↓ Service et al. (1984) 
Basal ↑/NC; postprandial ↑/NC Lardinois et al. (1985) 
Postprandial ↑ Schauder et al. (1977); Ross et 
al.  (1977); Takemura et al. 
(1981); Crockett et al. (1976) 
Basal ↑; postprandial ↓ Elahi et al. (1984) 
Basal NC; postprandial NC Vilsboll et al. (2001, 2003) 
GLP-1 Postprandial ↓ Vilsboll et al. (2001, 2003); 
Vaag et al. (1996); Toft-Nielsen 
et al. (2001) 
Responsiveness GIP Postprandial ↓ Elahi et al. (1994); Nauck et al. 
(1993); Jones et al. (1987); 
Krarup et al. (1987) 
GLP-1 Postprandial NC Elahi et al. (1994); Nauck et al. 
(1993) 
GIP: glucose-dependent insulinotropic polypeptide; GLP-1: glucagon-like peptide-1. ↑: 




In addition to the alterations in the amounts of incretin secreted, changes in the 
responsiveness of pancreatic β-cells to these incretins to release insulin in type 2 
diabetes also occur.  Several research groups have reported marked attenuation in the 
insulinotropic action of GIP in type 2 diabetic patients.  On the other hand, the 
insulinotropic action as well as the glucagon lowering property of GLP-1 were shown to 
be preserved in type 2 diabetic patients, in spite of a slight reduction of the incremental 
response of insulin secretion compared to healthy volunteers (summarised in Table 1). 
 
1.1.3.2 Skeletal muscle 
In the postprandial state, when blood glucose rises and insulin is released in response to 
the increased blood glucose level, skeletal muscle accounts for about 75-80% of whole 
body glucose disposal (Defronzo et al., 1985).  In skeletal muscle of type 2 diabetic 
patients, glucose uptake stimulated by insulin is reduced by about 50% compared to 
healthy controls (Defronzo et al., 1985, Andreasson et al., 1991, Bonadonna et al., 
1996).  Researchers revealed that this defect was related to impairments along the 
insulin receptor signalling cascade. 
 
Insulin receptor (IR) 
The binding of insulin to the insulin receptor (IR) on the cell surface and the subsequent 
auto-phosphorylation of the tyrosine kinase are the first recognised events that initiate 
glucose transport in muscle cells (Kahn, 1985).  In skeletal muscle of type 2 diabetic 
patients, binding efficiency and protein level of IR were generally believed to be 
unaltered (Arner et al., 1987, Krook et al., 2000).  However, some studies demonstrated 
that reduced muscle IR tyrosine kinase activity occurs in type 2 diabetic patients (Arner 
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et al., 1987, Maegawa et al., 1991, Nolan et al., 1994), though others observed no 
significant differences (Klein et al., 1995, Krook et al., 2000) (summarised in Table 2). 
 
Insulin receptor substrate-1 (IRS-1) and phosphatidylinositol 3-kinase (PI3K) 
Activation of IR triggers phosphorylation on tyrosine residues of downstream targets, 
including insulin receptor substrate-1 (IRS-1), the predominant downstream signalling 
molecule of IR in human skeletal muscle.  Extensive investigations have been carried 
out into the impairment of IRS-1 phosphorylation in type 2 diabetes.  Reports of a 
reduction in tyrosine phosphorylation of IRS-1 were consistent (Goodyear et al., 1995, 
Bjornholm et al., 1997, Krook et al., 2000, Pratipanawatr et al., 2001).  In addition, it 
has been shown that in cultured skeletal muscle cells from type 2 diabetic patients, there 
was an increased basal serine phosphorylation of IRS-1, which reduced the ability of 
IRS-1 to be tyrosine-phosphorylated by IR, resulting in impaired insulin signalling 
(Aguirre et al., 2002).  This provides evidence for the pathogenesis of type 2 diabetes, 
as serine phosphorylation of IRS-1 can be induced by fatty acids (Yu et al., 2002), 
chronic insulin exposure (hyperinsulinemia) (Pederson et al., 2001, Rui et al., 2001, 
Zhande et al., 2002), tumor necrosis factor-α (Rui et al., 2001, Plomgaard et al., 2005), 
to name a few processes.  In contrast, adiponectin, an adipokine that shows reduced 
levels in obesity (Weyer et al., 2001, Gil-Campos et al., 2004) and type 2 diabetes 
(Hotta et al., 2000, Weyer et al., 2001), was found to sensitise insulin signalling by 
inhibiting serine phosphorylation of IRS-1 (Wang et al., 2007). 
 
Phosphatidylinositol 3-kinase (PI3K) is an insulin signal transducer which is activated 
via interaction with IRSs.  In accordance with the reduction in IRS-1 tyrosine 
phosphorylation in type 2 diabetes, impairment in kinase activity of PI3K also occurs 
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(Goodyear et al., 1995, Bjornholm et al., 1997, Kim et al., 1999, Krook et al., 2000) 
(summarised in Table 2). 
 
Table 2. Changes along the insulin signalling pathway in muscle in type 2 diabetes 
  Change References 
IR Protein level NC Arner et al. (1987); Krook et al. (2000) 
Activity NC Klein et al. (1995); Krook et al. (2000) 
↓ Arner et al. (1987); Maegawa et al. (1991); 
Nolan et al. (1994) 
IRS-1 Phosphorylation ↓ Goodyear et al. (1995); Bjornholm et al. 
(1997); Krook et al. (2000); Pratipanawatr et al. 
(2001); Aguirre et al. (2002) 
PI3K Phosphorylation ↓ Goodyear et al. (1995); Bjornholm et al. 
(1997); Kim et al. (1999); Krook et al. (2000) 
AKT Thr phosphrylation ↓ Krook et al. (1998); Karlsson et al. (2005) 
AS160 Protein level NC Karlsson et al. (2005) 
Phosphorylation ↓ Karlsson et al. (2005) 
GLUT4 Protein level NC Garvey et al. (1998) 
Translocation ↓ Ryder et al. (2000) 
IR: insulin receptor; IRS-1: insulin receptor substrate-1; PI3K: phosphatidylinositol 3-
kinase; AKT: V-akt murine thymoma viral oncogene; AS160: AKT substrate of 160 
kDa; GLUT4: facilitative glucose transporter 4.  ↑: increase; ↓: decrease; NC: no change.  
Materials compiled from various sources as indicated.  
 
AKT, AKT substrate of 160 kDa (AS160) and glucose transporter 4 (GLUT4) 
AS160 is the GTPase-activating protein linking insulin-stimulated PI3K-dependent 
signalling to GLUT4 translocation (Larance et al., 2005).  The expression of GLUT4 
protein was shown to be unchanged in type 2 diabetes (Garvey et al., 1998).  However, 
reduction of GLUT4 translocation to the cell surface was reported in skeletal muscle of 
type 2 diabetic patients, consistent with an impairment in insulin-stimulated AS160 
phosphorylation (Ryder et al., 2001, Karlsson et al., 2005).  These defects were 
attributed to a reduction in Thr
308 
phosphorylation of the upstream serine/threonine 
kinase, AKT (Krook et al., 1998, Karlsson et al., 2005), which may, in turn, be 
explained by impaired signalling events at upstream levels of IRS-1/PI3K (Karlsson et 




1.1.4.1 Flavonoid biochemistry 
Flavonoids are a broad collection of polyphenolic compounds that are found 
ubiquitously in foods of plant origin (Hollman and Katan, 1999).  They contain a C6-C3-
C6 carbon framework, consisting of two benzene rings, designated as A and B, 
connected by a three carbon chain (Figure 5), which is closed in most flavonoids to 
form the heterocyclic ring C (Stafford, 1990, Grotewold, 2006).  Depending on the 
position of linkage of the B-ring to the benzopyran moiety and the degrees of saturation 
and oxidation of the heterocyclic C-ring, flavonoids are classified into six major 
subgroups, flavones, flavonols, flavanones, flavanols, anthocyanidins and isoflavones 
(Figure 6).  Figure 7 shows the structures of the representative flavonoids, quercetin, 
cyanidin and cyanidin-3-O-glucoside. 
 
 
Figure 5. The basic C6-C3-C6 carbon skeleton of flavonoids 
The basic C6-C3-C6 unit contains two aromatic rings, A and B, connected by a three-






Figure 6. Molecular structures of the six flavonoid subgroups 
Flavonoids are divided into six subgroups- flavones, flavonols, flavanones, flavanols, 
anthocyanidins and isoflavones.  Adapted from Hollman and Katan (1999). 
 
 
Figure 7. Molecular structures of three representative flavonoids- quercetin, 
cyanidin and cyanidin-3-O-glucoside 
Adapted from Hollman et al. (1997) and Tsuda et al. (2003). 
 
Flavonoids are susceptible to a variety of substitutions which include glycosylation, 
hydrogenation, hydroxylation, malonylation, methylation, prenylation and sulphation 
(Harborne, 1986, Stafford, 1990).  The resulting differences in the chemical structure 
and relative orientation of various moieties on the molecule determine the biological 
activities of flavonoids and their metabolites (Aherne and O'brien, 2002).  The 
conjugation patterns also modify the hydrophilicity of the flavonoids.  Flavonoid 
molecules without any sugar moieties are referred to as the aglycone form, whereas 
those attached to sugar moieties are called flavonoid glycosides, which are more polar. 
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1.1.4.2 Flavonoid dietary intake 
Fruits, vegetables, and beverages such as tea and red wine are especially rich sources of 
flavonoids (Hertog et al., 1992, Hertog et al., 1993b, Crozier et al., 1997) (Table 3).  
Most of the flavonoids exist in plants with sugars attached as glycosides, although 
occasionally they are found as aglycones (Prior et al., 2006).  Previous studies that 
reported dietary flavonoid intakes and flavonoid content in food were mostly based on 
the measurement of only three flavonols, namely quercetin, myricetin, and kaempferol, 
and two flavones, namely apigenin and luteolin.  However, the flavonoid profiles in 
food consumed by human kind are much more diverse than those typically analysed.  
Therefore, total flavonoid intake and content in foods can be assumed to be greater than 
those reported (Aherne and O'brien, 2002).  Table 4 shows a list of studies that 
estimated the flavonoid intakes in several countries. 
 
Table 3. Occurrence of flavonoids in common foods  
Flavonoid subclass Major food sources 
Anthocyanidins Cherries, grapes 
Catechins Apples, tea 
Flavanones Citrus fruits 
Flavones Parsley, thyme 
Flavonols Onions, kale, broccoli, apples, cherries, berries, tea, red wine 
Isoflavones Soybeans, legumes 
Reproduced from Hollman and Katan (1997). 
 
Table 4. Estimated average daily flavonoid intake in different countries 
Country Subject Flavonoid 
intake 
(mg/day) 
Major source Reference 
Australia Adult men and 
women 
454 Apples, onions Johannot & 
Somerset 
(2006) 
Fiji Adult men and 
women 
18 Not specified Lako et al. 
(2006) 
Finland Adult men 131 Not specified Mursu et al. 
(2008) 
Germany Adult men and 
women 
54 Fruit, fruit product, 
fruit juice 








Adult men 26 Black tea, onions, 
apples 




Not specified 182 & 177, 
respectively 
Grapes, oranges, 
beer, wine, apples, 
onions and tea 
Beking & 
Vieira et al. 
(2011) 
USA Adult men and 
women 
20-22 Onions, tea, apples Sampson et al. 
(2002) 
USA Adult men and 
women 
190 Tea Song & Chun  
(2008) 
Materials compiled from various sources as indicated. 
 
1.1.4.3 Flavonoid absorption and metabolism 
Dietary flavonoids differ in the arrangements of hydroxyl, methoxy, and glycosidic side 
groups, and in the conjugation between the A- and B- rings.  The most common 
glycosidic unit is glucose, but other examples include glucorhamnose, galactose, 
arabinose, and rhamnose (Cook and Samman, 1996).  Flavonoids conjugated to 
different glycosidic units have different metabolic fates and thus separate locations of 
uptake.  For example, quercetin-3-O-glucoside is hydrolysed to its aglycone by lactase 
phloridzin hydrolase found on the brush border of the mammalian small intestine (Day 
et al., 1998, Day et al., 2000, Sesink et al., 2003).  The aglycone is subsequently 
absorbed in the small intestine (Spencer et al., 1999, Crespy et al., 2001).  In contrast, 
rutin (quercetin-3-O-rutinoside) is not hydrolysed in the small intestine but passes 
through it to enter the cecum and colon, where it is hydrolysed by enterobacteria and 
absorbed (Macdonald et al., 1983, Bokkenheuser et al., 1987).  
 
Due to the hydrophobic nature of flavonoid aglycones, they can be transported across 
the phospholipid bilayer of cellular membrane by passive diffusion (Hollman et al., 
1995).  On the other hand, some evidence suggested that anthocyanidin glycosides are 
absorbed intact (Cao et al., 2001, Mcghie et al., 2003, Talavéra et al., 2004).  The 
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increased hydrophilicity of the flavonoid glycosides reduces the possibility of passive 
transport.  Instead, the sodium-glucose co-transporter (SGLT1), sodium-dependent 
vitamin C transporter (SVCT1) and bilitranslocase have been reported to be involved in 
the active transport of the glycosides (Aherne and O'brien, 2002, Passamonti et al., 
2009).  It was estimated that total polyphenol concentrations in the gut lumen can reach 
the lower milimolar range (Williamson, 2013).  With a bioavailability of about 1%, the 
maximum plasma concentrations after single-dose administration of flavonoids to 
humans were found to be in the low micromolar range (e.g. to a maximum of 5 μM for 
quercetin-3-O-glucoside) (Hollman, 2004).  Flavonoids not absorbed in the small 
intestine pass to the large intestine where they are hydrolysed by colonic microflora and 
the products absorbed, or otherwise degraded as described below (Hollman et al., 1995, 
Walle et al., 2000). 
 
After absorption, flavonoids and their derivatives are thought to undergo subsequent 
reactions such as hydroxylation, methylation, reduction or conjugation to glucuronide or 
sulphate either in the intestine or in the liver (Hackett, 1986, Zhang et al., 2007).  The 
flavonoid metabolites that circulate in the blood stream are bound to albumin (Terao et 
al., 2008).  Flavonoid glucuronides and sulfates are readily excreted by mammals in 
urine and bile as they are polar and water soluble.  When excreted in bile, the flavonoid 
metabolites are passed into the duodenum to be metabolised by intestinal microflora, 
which either hydrolyse them to the aglycone form to be reabsorbed, or degrade them to 





1.1.5 Flavonoids and glucose transport 
Flavonoids are ubiquitously found in fruits and vegetables, as well as certain beverages, 
such as tea and wine.  Studies have suggested that flavonoids are beneficial in 
protecting against many chronic diseases, such as cancers, cardiovascular diseases and 
neurological disorders (Hertog, 1996, Yao et al., 2004, Letenneur et al., 2007).  There is 
also evidence that flavonoids have beneficial effects on modifying glucose absorption 
and are thus regarded as potential anti-diabetic agents (Kwon et al., 2007).  In fact, a 
recent cohort study suggested that a higher consumption of anthocyanins and 
anthocyanin-rich fruits (comparison of ≥ 2 servings/week with < 1 serving/month) was 
associated with a lower risk of type 2 diabetes in US adults (Wedick et al., 2012). 
 
1.1.5.1 Flavonoids and intestinal glucose transport 
Previous scientific studies have investigated the potencies of various flavonoids to alter 
glucose transport in the intestine as well as in other tissues, for instance, adipocytes and 
muscle cells (Cao et al., 2007, Lee et al., 2010a, Martel et al., 2010).  In the intestine, 
some of the flavonoids, including anthocyanidins, catechins and flavonols and their 
conjugated counterparts were shown to inhibit glucose uptake, which will be discussed 
below. 
 
Effect of pure flavonoids on intestinal glucose transport 
As mentioned previously, transport of glucose into intestinal cells is mediated by the 
sodium-glucose co-transporter SGLT1, and the facilitative glucose transporter GLUT2 
located at the apical membrane.  Release of glucose from the enterocytes into the blood 
circulation is accomplished by GLUT2 at the basolateral membrane.  Previous 
46 
 
investigations have demonstrated that certain flavonoids disturb intestinal transport of 
glucose by interacting with either or both of these transporters. 
 
Welsch et al. (1989) showed that the phenolic compounds, tannic acid, catechol, 
catechin, chlorogenic, ferulic and caffeic acids, were able to reduce glucose uptake into 
SGLT1-containing brush border membrane vesicles (BBMV) isolated from rat small 
intestine, but gallic acid had a negligible effect.  Two other studies using similar 
approaches demonstrated that both quercetin-3-O-glucoside and quercetin-4’-O-
glucoside reduced sodium-dependent intestinal glucose uptake, with an increased Km 
but only slight changes in Vmax (Ader et al., 2001, Cermak et al., 2004).  In contrast, 
quercetin-3-O-galactoside, quercetin-3-O-rutinoside, the aglycone quercetin, as well as 
naringenin-7-O-glucoside, genistein-7-O-glucoside and cyanidin-3,5-O-diglucoside did 
not cause any effects (Ader et al., 2001, Cermak et al., 2004).  Taken together, it was 
believed that quercetin glucosides inhibited intestinal glucose uptake by competitive 
inhibition of SGLT1 and that the positions of glucose residues on the quercetin were 
unimportant (Ader et al., 2001, Cermak et al., 2004). 
 
To investigate the interaction between flavonoids and the intestinal facilitative glucose 
transporters, Chen et al. (2007) measured glucose uptake using GLUT2-containing 
basolateral membrane vesicles (BLMV) isolated from rat jejunum.  Most flavonoids 
tested (both glycosides and aglycones), which included epicatechin gallate (ECg), 
quercetin-3-O-glucoside, fisetin and gossypin, inhibited glucose uptake in BLMV in a 
competitive manner (Chen et al., 2007).  These results indicated that the intestinal 




A wider range of polyphenols were tested on their ability to alter intestinal glucose 
uptake in the Caco-2 cell line (Johnston et al., 2005).  Under sodium-dependent 
conditions which favour uptake via SGLT1, glucose uptake was inhibited by the 
flavonoid glucosides neohesperidin dihydrochalcone and phloridzin, as well as by the 
non-glycosylated dietary polyphenols, catechin, epicatechin, epigallocatechin gallate 
(EGCg), epicatechin gallate (ECg) and epigallocatechin (EGC). However, the aglycones 
and phenolic acids, caffeic acid, chlorogenic acid, ellagic acid, gallic acid, p-coumaric 
acid and ferulic acid did not alter glucose uptake (Johnston et al., 2005).  Under sodium-
independent conditions that favours GLUTs-mediated transport, the polyphenol 
aglycones, phloretin, quercetin, apigenin and myricetin, and also the non-glycosylated 
dietary polyphenols, EGCg, ECg and EGC caused significant reductions in glucose 
uptake, while the glucosides and phenolic acids were ineffective (Johnston et al., 2005).  
These aforementioned authors believed that the aglycones inhibited 
facilitated glucose uptake whereas glycosides inhibited the active transport of glucose.  
The non-glycosylated dietary polyphenols appeared to exert their effects via steric 
hindrance (Johnston et al., 2005). 
 
In addition to using intestinal models with naturally present glucose transporters, Kwon 
et al. (2007) studied the uptake of 2-deoxyglucose and fructose, both of which are 
substrates of the GLUT2 transporter, into Xenopus oocytes or pituitary cells injected 
with human GLUT2 cRNA.  Both 2-deoxyglucose and fructose were inhibited by 
quercetin aglycone, quercetin-3-O-glucoside and quercetin-4’-O-glucoside, but not 
quercetin-3-O-rutinoside (Song et al., 2002, Kwon et al., 2007).  However, neither the 
aglycone nor the glycosides of quercetin had any effects on glucose or fructose transport 
into Xenopus oocytes when treated to express SGLT1 or GLUT5 (intestinal fructose 
transporter) (Kwon et al., 2007). 
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Effect of flavonoid-rich food extracts on intestinal glucose transport 
In addition to investigating the inhibitory effects of pure flavonoids on intestinal 
glucose transport, researchers have also tested the efficacy of various food extracts that 
are rich in flavonoids. 
 
Tea has one of the highest contents of flavonoids among common food and beverage 
products and catechins comprise a major proportion of its polyphenolic content 
(Peterson et al., 2005).  Makoto et al. (2000) observed an inhibitory effect of tea extracts 
(green, black, roasted and oolong teas) on glucose uptake in Caco-2 cells.  Further 
investigations of glucose uptake using pure tea polyphenols showed that catechins 
possessing the galloylester group, i.e. ECg, EGCg and theaflavins, inhibited glucose 
uptake but those without, i.e. epicatechin, EGC and thearubidin, did not.  In BBMVs 
from rabbit small intestine, which contain SGLT1 as the major glucose transporter, ECg 
was not transported by SGLT1 but inhibited glucose transport via SGLT1 in a 
competitive manner (Kobayashi et al., 2000, Makoto et al., 2000).  Wang et al. (2008) 
also reported inhibition of glucose uptake, regardless of Na
+
 dependency, by aqueous 
extracts of Kuding tea, chrysanthemum and purple sweet potato stem, in Caco-2 cells.  
The authors suggested that the constituent dicaffeoylquinic acids and flavanols 
contributed to the inhibitory effects of the abovementioned beverages (Wang et al., 
2008). 
 
Fruits are good sources of flavonoids such as anthocyanins and flavonols.  Chronic 
exposure (96 hours) of anthocyanins extracted from red grape skin was found to 
increase the mRNA expression of GLUT2 in Caco-2 cells (Faria et al., 2009).  
However, glucose uptake decreased in the presence of anthocyanins.  This was possibly 
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due to competition between glucose and anthocyanins with glucose residues for the 
GLUT2 transporter.  This was confirmed by the ability of malvidin-3-glucose but not 
the aglycone malvidin to inhibit glucose uptake (Faria et al., 2009).  Moreover, extracts 
of strawberry and apple also inhibited uptake of glucose into Caco-2 cells, as well as 
transport of glucose from the apical to the basolateral side of Caco-2 monolayers 
(Manzano and Williamson, 2010).  The inhibition of GLUT2 was greater than SGLT1, 
a supposition deduced from studies which compared transports under sodium-
containing and sodium-free conditions.  The constituent polyphenols, quercetin-3-O-
rhamnoside, phloridzin and 5-caffeoylquinic acid, were shown to contribute to the 
glucose transport inhibitory activity of the apple extract.  In contrast, pelargonidin-3-O-
glucoside contributed to the inhibitory effect of the strawberry extract (Manzano and 
Williamson, 2010). 
 
One study has systematically screened medicinal plants that have putative anti-diabetic 
and anti-obesity activities to naturally treat type 2 diabetes and obesity in Canadian 
native populations (Nistor Baldea et al., 2010).  Thus, crude ethanol extracts of 
seventeen Boreal forest medicinal plants, which were rich in flavonoids such as 
quercetin, were tested for their inhibitory effect on intestinal glucose absorption in vitro 
using Caco-2 cells (Nistor Baldea et al., 2010).  Extracts from thirteen of these 
medicinal plants tested acutely inhibited the uptake of deoxyglucose in Caco-2 cells 
during co-incubation, whilst five extracts exerted an inhibitory effect after a 6-hour pre-
incubation.  Western blot analysis demonstrated that the reduction in glucose uptake 
might be explained by a decrease in the protein expression of GLUT2 or SGLT1 





Skopec et al. (2010) evaluated the effect of various flavonoids (i.e. quercetin, quercetin-
3-O-glucoside and phloridzin in rats and American robins, and naringenin, naringenin-
7-glucoside, genistein, epigallocatechin gallate (EGCg), and phloretin in rats only) on 
the bioavailability of the non-metabolisable analogue of glucose, 3-O-methyl D-glucose 
(3MG).  None of the flavonoids tested in robins significantly decreased the 
bioavailability of 3MG.  This can be explained by the fact that small birds such as 
robins rely largely on non-mediated intestinal absorption of glucose through the 
paracellular pathway.  On the other hand, mammals such as rats absorb glucose across 
the enterocytes using glucose transporters, SGLT1 and GLUT2.  Six of eight flavonoids 
(i.e. quercetin-3-O-glucoside, phloridzin, naringenin, naringenin-7-glucoside, EGCg 
and phloretin) inhibited 3MG uptake in rats (Skopec et al., 2010). 
 
Human studies 
In addition to using in vitro models and animals for investigating the effect of 
flavonoids on intestinal glucose transport, human trials have also been carried out to 
study the glycaemic effect of flavonoid-rich foods. 
 
Consumption of commercially available apple juices, clear or cloudy, was demonstrated 
to trigger delays in glucose absorption as shown by a reduction in the incremental area 
under the curve following juice consumption, compared to consumption of a control 
beverage with an adjusted sugar content (Johnston et al., 2002).  Consistent with the 
delay in intestinal glucose absorption, proximal intestinal secretion of the gut hormone 
glucose-dependent insulinotropic polypeptide (GIP) was suppressed whilst secretion of 
glucagon-like peptide-1 (GLP-1) in the distal region of the gut was enhanced (Johnston 
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et al., 2002). The aforementioned authors attributed the delaying effect on intestinal 
glucose absorption by apple juice to the well-established SGLT1 inhibitor, phloridzin, 
without excluding the possibility of modification by phenolic acids present in the 
beverage.  A similar study on coffee carried out by the same research group also showed 
delayed intestinal glucose absorption, which was observed after consumption of either 
caffeinated or decaffeinated coffee compared to control beverage (Johnston et al., 
2003).  This effect was believed to be exerted by the coffee polyphenol, 5-
caffeoylquinic acid.  In contrast, the increased postprandial plasma glucose after 
consumption of caffeinated coffee compared to decaffeinated coffee or control beverage 
might suggest a mildly impaired glucose tolerance caused by caffeine (Johnston et al., 
2003). 
 
Törrönen et al. (2010) examined the glycemic effect of a mixed berry puree made of 
bilberries, blackcurrants, cranberries and strawberries, sweetened with sucrose in 
healthy human subjects.  In subjects who consumed the berry meal, the time to reach the 
peak plasma glucose concentration was delayed by 15 minutes after consumption of the 
berry meal, whilst the peak plasma glucose increase from baseline was also reduced, 
compared to the control meal.  It was suggested that berries rich in polyphenols had an 
effect of delaying and reducing the postprandial glucose response of sucrose (Törrönen 
et al., 2010).  The delayed postprandial glucose response due to the mixed berries puree 
was similar to the results of another study carried out by the same group using 
blackcurrant and lingonberry puree or nectar (Törrönen et al., 2012a).  They further 
demonstrated that the berry meals stimulated a lower and prolonged insulin response 
compared with control meals, whilst plasma free fatty acid concentrations were 
suppressed (Törrönen et al., 2012a). 
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Another study further investigated the effect of consumption of berries on the 
postprandial glycaemic response to a solid starchy food (Clegg et al., 2011).  The results 
showed that consumption of pancakes supplemented with either raspberries or 
blueberries did not alter either the glycaemic response, glycaemic response area under 
the curve nor the satiety index in healthy human subjects, as compared to consumption 
of control pancakes containing similar amounts of fructose and glucose.  This indicated 
that the ability of berries to attenuate blood glucose level in response to starch-based 
foods, as represented by pancakes in this study, is unsubstantiated (Clegg et al., 2011). 
 
1.1.5.2 Flavonoids and glucose utilisation in diabetic animal models 
The efficacy of various flavonoids to modulate plasma glucose level has been studied 
using a range of animal models.  In streptozotocin-induced diabetic rats that lack 
endogenous insulin, myricetin, a flavonol with a similar structure as quercetin and 
commonly found in tea, fruits and vegetables, was demonstrated to attenuate plasma 
glucose levels (Liu et al., 2005).  Increases in glucose utilisation in the soleus (type I, 
aerobic) muscle as well as enhancement of hepatic glycogen synthesis were observed 
along with decreased plasma glucose levels (Liu et al., 2005).  Similarly, an extract 
from seeds of the tropical fruit jambul, which is rich in flavonoids such as rutin and 
quercetin, also improved glucose tolerance, glycogen biosynthesis and glucose uptake 
in streptozotocin-induced diabetic mice (Sharma et al., 2008). 
 
Feeding experimental animals with a high fructose diet was demonstrated to induce 
glucose intolerance and hyperinsulinaemia, which mimics type 2 diabetic conditions 
(Huang et al., 2004).  Intravenous injection of myricetin improved insulin sensitivity in 
high-fructose chow-fed rats as demonstrated by a reduction in high plasma glucose and 
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triglyceride levels induced by the high-fructose diet (Liu et al., 2007).  On the other 
hand, in young genetically insulin-resistant obese KKA
y
 mice, administration of a bio-
transformed blueberry juice reduced food intake and body weight, protecting them 
against the subsequent development of glucose intolerance and the onset of diabetes 
(Vuong et al., 2009). 
 
1.1.6 MicroRNA: from biogenesis to degradation 
MicroRNAs (miRNAs) are a family of short single-stranded non-coding RNAs, of 
about 22 nucleotides in length.  They extensively regulate gene expression post-
transcriptionally in animals, plants and protozoa.  It is believed that in mammals, 
miRNAs can control the expression of more than 60% of all protein-coding genes 
(Fabian et al., 2010).  Specifically, miRNAs have been implicated in the control of 
glucose homeostasis and the pathogenesis of diabetes (Tang et al., 2008, Frost and 
Olson, 2011).  Therefore, it would seem reasonable that the repeated changes in mRNA 
expression due to the exposure of cells to berry extract may be initiated firstly by 
changes in miRNA rather than direct actions on the synthesis of mRNA via 
transcription.  In other words, the changes in miRNA allow for a more in-depth 
analytical insight into hypothesis-driven research that examines nutrient-nucleic acid 
interactions. 
 
1.1.6.1 MicroRNA biogenesis 
Genomic distribution 
There are several types of genomic distribution of miRNA genes.  Some exist as 
clusters throughout the genome, which are transcribed as polycistronic primary 
transcripts, resulting in multiple miRNAs (Lee et al., 2002).  Some are transcribed as 
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independent units from genomic positions that lie within the introns or extrons of other 
protein-coding or non-coding transcripts (Rodriguez et al., 2004), while the others are 
transcribed from intergenic regions (Lee and Ambros, 2001, Grad et al., 2003). 
 
MicroRNA transcription 
MicroRNAs are generally believed to be transcribed by RNA polymerase II as primary 
miRNA transcripts (pri-miRNAs) that contain a 5’-end 7-methylguanosine cap structure 
and a 3’-end poly(A) tail, which are unique characteristics of class II gene transcripts 
(Lee et al., 2004) (see Figure 8).  However, Borchert and colleagues revealed that 
miRNAs in the human chromosome 19 miRNA cluster are interspersed among Alu 
repeats.  Since Alu transcription occurs by recruiting RNA polymerase III (pol III), they 





Figure 8. Biogenesis of miRNA 
1) miRNA is transcribed as a primary miRNA transcript (pri-miRNA) that contains a 
5’-end 7-methylguanosine cap structure (5’m7G) and a 3’-end poly(A) tail ((A)n3’), 
presumably by RNA polymerase II (Pol II); 2) pri-miRNA is cleaved into a ~70-
nucleotide long stem loop structure called precursor miRNA (pre-miRNA) by the 
endonuclease, Drosha; 3) pre-miRNA is exported to the cytoplasm by exportin-5; 4) 
cytoplasmic cleavage by another endonuclease, Dicer, gives rise to a miRNA/miRNA* 
duplex; 5) the less stable strand of miRNA from the duplex form the miRNA-induced 
silencing complex (miRISC) with effector proteins including Argonaute proteins. 
Binding of miRISC to target mRNA leads to its post-transcriptional regulation. Adapted 
from Bartel (2004) and Murchison and Hannon (2004). 
 
Processing of miRNA transcripts 
MicroRNAs are transcribed as several kilobase-long pri-miRNAs bearing hairpin-
shaped structures.  These pri-miRNAs are cleaved by Drosha, an RNase III 
endonuclease enzyme that complexes with the double-stranded RNA binding domain 
protein DGCR8 (Lee et al., 2003).   The transcripts are released as an approximately 70-
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nucleotide long stem loop structures called precursor miRNAs (pre-miRNAs), with a 2-
nucleotide long 3’-end flanking region (Zeng and Cullen, 2004).   Pre-miRNAs are 
subsequently exported, by exportin-5, out of the nucleus to the cytoplasm (Kim, 2004, 
Lund et al., 2004).  Further cytoplasmic processing by another RNase III enzyme, 
Dicer, assisted by the transactivation-responsive RNA binding protein (TRBP), cleaves 
the pre-miRNAs to generate miRNA/miRNA* duplexes about 22-nucleotide in length 
(Hutvagner et al., 2001).  Depending on the thermodynamic stability of the 5’ end, the 
less stable strand will be selected as the guide strand to be incorporated into the 
miRNA-induced silencing complex (miRISC), which usually contains Argonaute 
(AGO) proteins and glycine-tryptophan protein of 182 kDa (GW182) as the effector 
components (Schwarz et al., 2003).  The passenger strand that remains from the 
miRNA/miRNA* duplex, on the other hand, is released and degraded (Schwarz et al., 
2003). 
 
1.1.6.2 Mechanisms of miRNA-mediated regulation 
Target recognition 
After a series of cleavage events and incorporation into the miRISC, the miRNAs pair 
to sites in mRNAs to direct post-transcriptional regulation.  In plants, miRNAs might 
hybridise to any regions on their target mRNAs with perfect or near-perfect 
complementarity and often trigger mRNA cleavage (Rhoades et al., 2002).  On the other 
hand, in animals, functional miRNA-target pairing can be more variable with 
mismatches and bulges, and contain only short stretches of complementary sequence 
(Brennecke et al., 2005).  Most of these matching involve interaction between the seed 
regions (nucleotides 2-7 from 5’ end) of miRNAs and the conserved sites in the 3’ 
untranslated regions (3’UTR) of mRNAs (Lewis et al., 2003).  Less commonly, 
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miRNAs may also target 5’UTR or coding regions of mRNAs (Orom et al., 2008, Gu et 
al., 2009). 
 
In addition to the complementarity of the seed region, an A residue across from miRNA 
nucleotide 1 and an A or U residue across from nucleotide 9 were found to improve 
miRNA target recognition (Lewis et al., 2005, Nilsen, 2007).  Pairing to the 3’ region of 
the miRNA helps stabilise the interaction between the miRNA and the mRNA.  
Positioning of the functional site within a high local AU content also increases site 
efficacy (Grimson et al., 2007, Nilsen, 2007). 
 
Modes of regulation 
MicroRNAs mediate regulation of target mRNAs via multiple mechanisms, which 
include 1) cleavage of mRNA transcripts (slicing, which requires perfect or near-perfect 
complementarity); 2) repression of mRNA translation; 3) destabilisation through de-
adenylation and 4) localisation in the processing bodies (P-bodies) (Nilsen, 2007, Jung 
et al., 2009). 
 
mRNA cleavage (slicing) 
For miRNAs that bind to their target mRNAs with perfect or near-perfect 
complementarity, as in the case of most plant miRNAs, mRNA cleavage is believed to 
be a predominant mechanism by which gene expression is regulated (Carrington and 
Ambros, 2003).  To trigger mRNA cleavage, the AGO component of miRISC cleave a 
single phosphodiester bond of the target mRNA that pairs to the nucleotides 10 and 11 
of the miRNA (Hutvágner and Zamore, 2002, Llave et al., 2002).  The cleaved 
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fragments are then released and degraded, freeing the miRISC to recognize and regulate 
another target mRNA (Jung et al., 2009). 
 
Translational repression 
Direct effects of miRNAs on translation may occur at different stages of this process.  It 
might be caused by the impairment of cap recognition in the initiation of protein 
synthesis, causing a defect in ribosome recruitment to the mRNA at the initiation stage 
(Pillai et al., 2005).  It might also occur at the post-initiation stage, in which the 
elongating peptide is degraded concomitantly with translation, or premature ribosomes 
drop off during elongation, leading to premature termination of translation (Humphreys 
et al., 2005, Nottrott et al., 2006, Petersen et al., 2006). 
 
De-adenylation of mRNA 
GW182 protein of the miRISC brings about mRNA de-adenylation of the 3’ poly(A) 
tail and degradation of mRNAs by recruiting deadenylase complex to the target mRNA 
(Behm-Ansmant et al., 2006).  Following de-adenylation, the 5’-end 7-methylguanosine 
cap structure of the mRNA is removed by de-capping complex and the 5’→3’ 
exonuclease directs exonucleolytic degradation of the mRNA (Garneau et al., 2007, 
Chekulaeva and Filipowicz, 2009). 
 
mRNA sequestration in P-bodies 
The deadenylation-decapping degradation process of mRNAs mediated by miRNAs is 
believed to localise in cytoplasmic foci called P-bodies (Kulkarni et al., 2010).  In 
addition to serving as a site for mRNA decay, there is also evidence that P-bodies can 
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act as a repository for repressed mRNAs, where they are sequestered from ribosomes 
for translation (Brengues et al., 2005, Bhattacharyya et al., 2006).  The stored mRNAs 
can be released from the P-bodies and can undergo translation again (Brengues et al., 
2005, Bhattacharyya et al., 2006). 
 
1.1.6.3 MicroRNA degradation 
MicroRNA regulation of mismatch target mRNAs is multiple-turnover, i.e. each 
miRNA incorporated into the miRISC can direct multiple rounds of target mRNA 
regulation  (Hutvágner and Zamore, 2002). Target regulation can increase the miRNA’s 
rate of decay in a manner that is dependent on target concentration and 
complementarity.  It was suggested that target interaction could lead to uridylation of 
the miRNA , accelerating its decay (Baccarini et al., 2011). 
 
The 5’→3’ exonuclease XRN-2 catalyzes the degradation of single-stranded mature 
miRNAs that fail to be incorporated into AGO proteins or that are released from the 
effector complex. Interaction of the miRNA-AGO complex with its target prevents 
release and subsequent destabilisation of the miRNA (Kai and Pasquinelli, 2010). 
 
1.1.7 The use of Caco-2 cells as a model for intestinal epithelial glucose 
transport 
Caco-2 is a cell line isolated from human colorectal adenocarcinoma, which was 
established in the 1970s originally characterised for cancer studies (Fogh et al., 1977).  
In culture, this cell line differentiates spontaneously at confluence to form a monolayer 
of highly polarized cells, which develop microvilli expressing small intestine hydrolase 
enzyme activities (i.e. sucrose-isomaltase, lactase, aminopeptidase N, 
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dipeptidylpeptidase IV) on the apical membrane, and tight junctions between adjacent 
cells.  These resemble morphological and functional characteristics of small intestine 
enterocytes (Pinto et al., 1983).  However, because of their colonocytic tumour origin, 
differentiated Caco-2 cells also exhibit some of the characteristics of colon crypt cells, 
including electrical properties and ionic conductivity (Grasset et al., 1984). 
 
1.1.7.1 Choices of intestinal epithelial models 
To investigate the characteristics of absorption of nutrients and orally administered 
therapeutic agents at the intestinal level in vitro, several cultured intestinal epithelial cell 
models have been used.  These include primary cell cultures, cell lines from normal 
tissue and established cell lines of tumour origin (reviewed in Sambruy et al., 2001). 
 
Among these cell models, the Caco-2 cell line has been suggested to be one of the best 
models for intestinal absorption studies (Sambruy et al., 2001).  This is because primary 
intestinal cell cultures obtained either from the small intestine or colon lose their 
differentiated characteristics rapidly once they are isolated (Fonti et al., 1994).  It is also 
difficult to obtain reproducible and quantitative data from the use of primary cultures 
(Sambruy et al., 2001).  The IEC cell lines were derived from normal small intestine of 
newborn and germ-free rats (Quaroni et al., 1979).  They express some typical epithelial 
markers but do not form functional tight junctions between adjacent cells, nor develop a 
fully polarized columnar morphology.  They also do not express significant levels of the 
small intestinal disaccharidases and peptidases and thus are regarded as a cell line that 
resembles proliferative crypt cells (Quaroni et al., 1979).  Comparing the morphological 
and biochemical characteristics of different cell models, Caco-2 is suggested to be the 
best model for studies of intestinal absorption (Quaroni and Hochman, 1996). 
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1.1.7.2 Caco-2 subclones 
The Caco-2 cell line is characterised by a heterogeneous population with respect to the 
differences in morphological and functional differentiation (reviewed in Sambuy et al., 
2005).  In order to improve homogeneity of the cell population to suit different studies, 
several clonal cell lines were isolated and characterized.  Among different subclones, 
one of the low glucose-consuming clones, Caco-2/TC7, was found to express 
concomitantly the sodium/glucose co-transporter SGLT1, the facilitative glucose 
transporter GLUT2 and the facilitative fructose transporter GLUT5 (Mahraoui et al., 
1994a), which are normally present in human small intestinal enterocytes, making it 
more suitable for intestinal glucose transport studies. 
 
1.1.7.3 Distribution of glucose transporters in Caco-2 cells 
In the small intestine, glucose is transferred across the enterocyte apical membrane by 
the facilitated glucose transporter GLUT2, in addition to the sodium-dependent SGLT1 
active glucose transporter (Kellett and Helliwell, 2000), which was once considered to 
be the only transporter that carried glucose from the intestinal lumen into the 
enterocytes (Shirazi-Beechey, 1995).  Grefner et al. (2010) evaluated and compared the 
distributions of SGLT1 and GLUT2 in enterocytes of rat small intestine and Caco-2 
cells by an immunocytochemical analysis using confocal microscopy.  In rat 
enterocytes, localization of SGLT1 was revealed to be at the edge of intestinal villi, 
while GLUT2 was observed in both the apical and basal parts of the cells (Grefner et al., 
2010).  On the other hand, in Caco-2 cells, SGLT1 was found to distribute throughout 
the entire cytoplasm thickness but more in the apical and subapical parts of the cells, 
while GLUT2 was located predominantly in the basal area and was absent in the apical 
area, which is at variance with the distribution in rat enterocytes (Grefner et al., 2010).  
Nevertheless, Tobin et al. (2008) was able to observe co-localisation of GLUT2 and 
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sucrase-isomaltase on the apical membrane in Caco-2/TC7 subclone.  These studies 
confirmed that the Caco-2/TC7 subclone is suitable as an in vitro cell model for 
intestinal epithelial glucose transport studies. 
 
1.1.7.4 GLUT2 translocation 
In response to high luminal concentrations of glucose (≥ 25 mM), it is believed that a 
mechanism involving the translocation of cytosolic GLUT2 into the apical membrane of 
enterocytes occur within a few minutes, allowing the enterocyte to rapidly increase its 
glucose absorption capacity to match dietary intake (Mace et al., 2007a, Morgan et al., 
2007). 
 
Zheng et al. (2012) explored the mechanisms of glucose uptake in several intestinal 
epithelial cell lines, including Caco-2 cells.  They demonstrated that in Caco-2 cells, at 
low glucose concentrations (≤ 10mM), glucose molecules entered the cells through 
SGLT1 and GLUT2 transporters that were constitutively located on the apical 
membrane.  When the cells were exposed to high glucose concentrations (≥ 25mM), 
both Km and Vmax of glucose uptake increased within ten minutes.  This rapid increase 
in carrier-mediated glucose absorption required the activation of PKC and an intact 
cytoskeleton, supporting the theory of intracellular trafficking of GLUT2 (Zheng et al., 





1.1.8 The use of C2C12 cells as a model for glucose transport in 
skeletal muscle cells  
1.1.8.1 Origin of the C2C12 cell line 
The mouse myogenic cell line C2 is an immortal line of mouse skeletal myoblasts 
originally obtained by Yaffe and Saxel (1977) from satellite cells harvested from the 
thigh muscle of a two-month-old female C3H mouse 70 hours after a crush injury.  The 
diploid subclone, C2C12, was isolated and karyotyped by Blau et al. (1985) for its 
ability to differentiate rapidly and produce extensive contracting myotubes expressing 
characteristic muscle proteins.  The cells are adherent in culture and undergo 
differentiation to form multi-nucleated myotubes when the growth factor content in the 
cell culture medium is reduced, which can be achieved by switching supplemental fetal 
bovine serum to horse serum. 
 
1.1.8.2 The insulin signalling pathway in C2C12 cells 
Differentiated C2C12 myotubes display carrier-mediated glucose uptake and this is 
further stimulated by insulin (Sarabia et al., 1990).  This aforementioned study provides 
evidence that C2C12 myotubes possess intact cellular machinery for insulin signalling 
and additional studies which followed have shown that this occurs via the 
IRS/PI3K/AKT pathway.  Indeed, exposure of C2C12 cells to insulin induces 
phosphorylation and activation of IR (Wang et al., 2007), IRS-1 (Berti et al., 1997, 
Wang et al., 2007), PI3K (Berti et al., 1997) and AKT (Schmitz-Peiffer et al., 1999, 
Wang et al., 2007), and the subsequent stimulation of glucose uptake (Berti et al., 1997, 
Doi et al., 2003) as well as glycogen synthesis (Schmitz-Peiffer et al., 1999). 
 
In addition to the activation of the PI3K signalling cascade by insulin, intriguingly, 
chronic exposure of C2C12 to insulin also results in reduced tyrosine phosphorylation 
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of IRS-1 and subsequent impairment of PI3K activation and insulin-stimulated glucose 
uptake (Kumar and Dey, 2003).  This development of insulin resistance in C2C12 by 
insulin itself is suggested to be a consequence of serine/threonine phosphorylation of 
IRS-1 by insulin, leading to reduced tyrosine phosphorylation and degradation of IRS-1 
proteins (Pederson et al., 2001, Mussig et al., 2005).  
 
The insulin signalling pathway has also been shown to be affected by a number of 
analytes.  These include the protein hormones, IGF-1 (Rommel et al., 2001), leptin 
(Berti et al., 1997) and adiponectin (Wang et al., 2007), the branched-chain amino acid 
isoleucine (Doi et al., 2003), long-chain saturated fatty acids such as palmitate 
(Schmitz-Peiffer et al., 1999, Chavez and Summers, 2003) and cytokine TNF-α (Rui et 
al., 2001). 
 
1.1.8.3 The AMPK pathway in C2C12 cells 
Contraction-stimulated glucose uptake in skeletal muscle is regulated by an insulin-
independent signalling pathway (Hayashi et al., 1998).  This distinct signalling 
mechanism, which is activated by an increase in the AMP/ATP or ADP/ATP ratios as 
well as intracellular Ca
2+
 concentrations, is identified as the AMPK pathway (Wright et 
al., 2004).  In C2C12 cells, it has been shown that muscle contraction leads to 
phosphorylation and activation of endogenous AMPK (Nedachi et al., 2008, Niu et al., 
2010).  The resultant downstream signalling of AMPK induces changes in cellular 
energy metabolism via stimulation of glucose uptake and fatty acid oxidation 




1.1.8.4 GLUT4 translocation 
Insulin stimulates glucose uptake in C2C12 myotubes and this is accompanied by an 
increase in the GLUT4 content within the plasma membrane (Galante et al., 1995, Lee 
et al., 2011).  Insulin-induced surface expression of GLUT4 was completely inhibited 
by the PI3K inhibitor wortmannin (Nedachi and Kanzaki, 2006) strongly suggesting 
that differentiated C2C12 cells to be endowed with the basic GLUT4 translocation 
machinery needed to respond to insulin stimulation.  Furthermore, contraction- or 
metformin-induced phosphorylation of AMPK also triggered an increase in cell surface 
GLUT4 density (Niu et al., 2010, Lee et al., 2011). 
 
1.1.9 Alcohol 
Heavy alcohol consumption is associated with increased morbidity and mortality 
(Preedy and Watson, 2005, Watson et al., 2013).   Although the lifestyles typical to 
heavy drinkers might contribute to the abovementioned association (for instance,  poor 
nutrition and injuries attributed to excessive drinking) (Morgan, 1982, Cherpitel, 1993), 
the toxicological effects of alcohol (and/or its metabolite, acetaldehyde) per se account 
for a substantial part of the increased risk of medical conditions (Darke et al., 2013, 
Watson et al., 2013).  Previous studies have shown that chronic alcoholism is associated 
with higher risks of various human diseases, to name a few, alcoholic cardiomyopathy, 
alcoholic liver diseases, alcoholic myopathy, peripheral neuropathy and cancers (Martin 
et al., 1985, Komajda et al., 1986, Sheehy, 1992, Monforte et al., 1995, Walsh and 
Alexander, 2000, Bagnardi et al., 2001). 
 
1.1.9.1 Alcoholic myopathy 
Alcoholic skeletal myopathy is one of the most common alcohol-related diseases (see 
Table 5) (Estruch et al., 1993) and occurs in 40-60% of chronic alcoholics (Martin et 
al., 1985, Urbano-Marquez et al., 1989, Urbano-Marquez et al., 1995).  These 
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susceptible subjects were characterised by gradual loss of muscle mass, muscle 
weakness and abnormal gait.  With respect to molecular mechanism, the reduction of 
muscle mass is attributed to reduced protein synthesis and subsequent atrophy of muscle 
fibres (Preedy and Peters, 1988b).  This occurs selectively in the type II skeletal muscle 
fibres (anaerobic, glycolytic, fast-twitch), particularly, in the type II B subset fibres, 
which have the lowest oxidative capacity and the fewest mitochondria (Hanid et al., 
1981, Fernández-Solá et al., 1995, Reilly et al., 2000). The oxidative type I (aerobic, 
slow-twitch) muscle fibres are protected in early stages but are affected in some 
individuals after reduction of type II fibre diameters (Slavin et al., 1983). 
 
Table 5. Number of chronic alcoholic patients who had alcohol-related 
complications 
Alcohol-related disesases Number of cases/ total (%) 
No complications 99/250 (44) 
Cardiomyopathy 20/232 (9) 
Cirrhosis 20/232 (9) 
Peripheral neuropathy 41/250 (16) 
Skeletal myopathy 117/250 (48) 
Patients were chronically alcoholic men entering an alcoholism treatment program in 
the mentioned clinical study.  Adapted from Estruch et al. (1993). 
 
 
Regulation of transcription and protein synthesis  
The c-MYC proto-oncogene encodes for a transcription factor that is involved in the 
regulation of cell development and growth (Evan et al., 1994).  Constitutive expression 
of c-MYC up-regulates many genes involved in cell proliferation and is implicated in 
many cancers (Spencer and Groudine, 1991, Evan et al., 1994).  Expression of c-MYC 
has also been shown to increase in muscle hypertrophy (Whitelaw and Hesketh, 1992).  
Intriguingly, although impairment in protein synthesis has been observed consistently in 
muscles exposed to ethanol in vitro and in vivo (Preedy and Peters, 1988a, Hong-Brown 
et al., 2006), both mRNA and protein levels of c-MYC were up-regulated in rat skeletal 
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and cardiac muscles in response to alcohol administration (Paice et al., 2002).  The 
authors suggested the increase in c-MYC expression might be a cellular adaptation 
against the insults of ethanol (Paice et al., 2002). 
 
Since earlier investigations had suggested impairment in translational efficiency as a 
possible explanation for the alcohol-induced reduction in protein synthesis (Preedy et 
al., 1988), Lang and co-workers examined the changes of several eukaryotic 
translational initiation factors (eIFs) in response to alcohol administration in rats (Lang 
et al., 1999, Lang et al., 2000).   In both acute (2.5 hours after intraperitoneal ethanol 
injection) and chronic studies (14-week ethanol feeding), ethanol induced an increase in 
the binding of eIF4E protein to the translational repressor 4E-binding protein 1 (4E-
BP1) but a decrease in the level of the active eIF4E-eIF4G complex (Lang et al., 1999, 
Lang et al., 2000).  In rats chronically fed with alcohol, a reduction in eIF2B activity 
was also observed in type II muscles (Lang et al., 1999).  Altogether, these suggested 
the involvement of eIFs in alcohol-induced impairment of muscle protein synthesis. 
 
Myosin and other myofibrillary proteins 
Myosin is a motor protein complex composed of two heavy chains and two pairs of 
light chains.  The expression profile of myosin heavy chain isoform proteins exerts a 
strong influence on the contractile properties of the muscle fibre (Harridge et al., 1996).  
Interactions between myosin and associated contractile proteins, including actin, 
troponin and tropomyosin, also play a pivotal role in muscle contraction (El-Saleh et al., 
1986). 
 
In chronically ethanol-fed rats, a reduction in the total myofibrillary protein content in 
the type II fibre-predominant plantaris muscle has been reported (Reilly et al., 2000).  A 
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concomitant reduction in total myosin content, as a consequence of specific declines in 
the myosin heavy chain (MYH) Ib, IIx and IIb protein isoforms, was observed (Reilly et 
al., 2000).  There were no significant changes in both the total and specific MYH 
isoform contents in the type I-predominant soleus muscle (Reilly et al., 2000).  At the 
mRNA level, only the expression of MYH-Ib showed significant reduction in response 
to chronic ethanol feeding, in both muscle types (Reilly et al., 2000). 
 
In the abovementioned study, the researchers also examined the changes in the levels of 
several other myofibrillary proteins, namely actin, α-actinin, desmin, troponins and 
tropomyosin, in ethanol-fed rats (Reilly et al., 2000).  In soleus muscle, only troponin-C 
showed a significant decrease, whilst in plantaris muscle, ethanol feeding triggered 
significant reductions in actin, desmin and troponin-I (Reilly et al., 2000). 
 
Alcoholism and glucose utilisation in muscles 
In healthy man, acute infusion of ethanol has been shown to decrease glucose disposal 
under basal condition as well as during euglycaemic hyperinsulinaemia, indicating 
development of insulin resistance (Yki-Jarvinen and Nikkila, 1985, Shelmet et al., 
1988).  Acute ethanol administration to rats demonstrated that this inhibitory effect was 
tissue-specific, as ethanol infusion attenuated glucose utilisation in skeletal muscles and 
the heart, but not in diaphragm, lung, liver, skin, ileum and adipose tissue (Spolarics et 
al., 1994).  Xu et al. (1996) demonstrated that the inhibitory effect of acute ethanol 
exposure on whole-body glucose disposal was associated with marked decreases in 
glucose uptake and glycogen synthesis in most skeletal muscles.  These changes may be 
explained by a defect in glycogen synthase activation in response to insulin in oxidative 




Beside the acute inhibitory effect of ethanol on glucose utilisation, chronic ethanol 
exposure has also been shown to impair glucose disposal and/or insulin sensitivity 
(Onishi et al., 2003, Wan et al., 2005, Qu et al., 2011).  Previous studies have suggested 
an interaction between the insulin signalling and G-protein-mediated pathways 
(Moxham and Malbon, 1996).  Wan et al. (2005) demonstrated that an increase in 
Gsα (G stimulatory α subunit) expression in muscle of ethanol-fed rats may contribute 
to the ethanol-induced impairment of insulin signal transduction.  Other studies reported 
inhibition of insulin/IGF/IRS and changes in the downstream PI3K/AKT signalling in 
muscle in response to ethanol, including reductions in IRS-1 and AKT phosphorylation 
(Qu et al., 2011, Nguyen et al., 2012).  Ethanol-induced defects in the PI3K/AKT 
signalling cascade have also been reported in other tissues, such as liver and adipose 
tissue (Yi and Jhun, 2004, He et al., 2006). 
 
In addition to defects in the insulin signalling pathway, alcoholic skeletal myopathy in 
chronic alcoholic patients is also accompanied by reduced activities of glycogen 
phosphorylase, phosphofructokinase and fructose 1,6-bisphosphatase, key regulatory 
enzymes in the anaerobic glycolytic pathway, as well as the subsequent reduction in 
glycogen content in the muscle biopsies of the patients (Martin et al., 1984). 
 
However, despite the prevalence of alcoholic myopathy, the precise molecular 
mechanisms remain poorly understood.  This may be due to the fact that multiple 
pathophysiological processes occur in muscle such as adduct formation, altered 





Previous studies carried out by our research group showed, using mRNA expression 
microarrays, that flavonoid-rich berry extract exerted cellular effects on multiple 
membrane transport systems in the intestinal epithelial Caco-2 cell model, including 
those related to glucose transport.  In the present project for this thesis, we aimed to 
address the hypotheses that, 
1. berry extract will acutely affect glucose transport in Caco-2 cells, by exerting 
direct inhibitory effects of glucose transporter activity; 
2. berry extract will chronically affect glucose transport in Caco-2 cells, by 
suppressing the expression of glucose transporters; 
3. the post-transcriptional regulators, microRNAs, are involved in the modulation 
of glucose transporter expression in Caco-2 cells by berry extract; 
4. berry extract can modulate glucose transport in peripheral tissues, as represented 
by skeletal muscle, using the C2C12 muscle cell model; 
5. in addition to glucose transport, berry extract can modulate other cellular 
functions in C2C12 muscle cells; 
6. ethanol alters multiple cellular functions in C2C12 muscle cells; 
7. berry extract can protect C2C12 muscle cells from ethanol-induced cell damage. 
 
1.2.1 Objectives 
1. To evaluate the acute effects of berry extract and related polyphenols on glucose 
transport in the intestinal Caco-2 cells by measuring glucose uptake following 
short-term exposure (15 minutes).  This will be performed using [
3
H]-labelled 
D-glucose under sodium-containing or sodium-free conditions (jointly with Dr 
Fawaz Alzaid, another PhD student from our group); 
71 
 
2. To evaluate the chronic effects of berry extract and related polyphenols on 
glucose transport in Caco-2 cells by measuring changes in the gene expression 
of glucose transporters and glucose uptake after longer-term exposure (16 
hours).  Relative gene expression will be measured by qRT-PCR (jointly with Dr 
Fawaz Alzaid, another PhD student from our group); 
3. To investigate the changes in global microRNA expression in Caco-2 cells in 




4. To evaluate the chronic effects (24-hour-incubation) of berry extract on glucose 
uptake in differentiated C2C12 muscle cells under basal or insulin-stimulated 
conditions, with the use of [
3
H]-labelled D-glucose; 
5. To evaluate the chronic effects (24-hour-incubation) of berry extract and insulin 
on the gene expression of glucose transporters in C2C12 muscle cells, measured 
by qRT-PCR; 
6. To investigate the changes in global gene expression in C2C12 muscle cells in 
response to 24-hour-incubation with berry extract.  This will be carried out using 
Affymetrix Mouse Genome 430A microarrays; 
7. To evaluate the chronic effects (24-hour-incubation) of ethanol on the gene 
expression of glucose transporters in C2C12 muscle cells, by qRT-PCR; 
8. To investigate the changes in global gene expression in C2C12 muscle cells in 
response to 24-hour-incubation with ethanol, using Affymetrix Mouse Genome 
430A microarrays and validated by qRT-PCR. 
 
There was a final objective, namely to investigate if the berry extract, or its 
polyphenolic components, could act as a myoprotectant, especially in the presence 
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of ethanol.  However, lack of time precluded such studies being carried out within 




2 Materials and methods 
 
2.1 Cell culture 
2.1.1 Caco-2 
The TC7 sub-clone of the human intestinal adenocarcinoma cell line, Caco-2, was 
obtained from Dr Monique Rousset and Dr Edith Brot-Laroche (INSERM U505, Paris, 
France).  Caco-2 cells were cultured in Dulbecco’s Modified Eagle’s Medium (DMEM, 
4500 mg/l glucose) (Sigma, UK), supplemented with 10% (v/v) fetal bovine serum 
(FBS) (Sigma, UK), 1% (v/v) L-glutamine (Invitrogen, UK), 1% (v/v) MEM non-
essential amino acids (NEAAs) (Invitrogen, UK), 50 units/ml penicillin and 50 μg/ml 
streptomycin (Sigma, UK) and 5 μg/ml plasmocin (Source BioScience, UK), in a 
humidified atmosphere containing 5% CO2 at 37˚C.  Cell culture medium was changed 
three times a week.  Caco-2 cells were used between passages 40-50.  Cells were sub-
cultured at confluence by incubating with TrypLE™ Express (Invitrogen, UK) for 15 
minutes at 37˚C.  For experiments, Caco-2 cells were seeded at a density of 10,000 
cells/cm
2
 and used 14 days after seeding unless otherwise specified. 
 
2.1.2 C2C12 
The murine myoblast cell line, C2C12, was purchased from LGC Standards (UK).  
Cells were maintained in DMEM (4500 mg/l glucose) (Sigma, UK), supplemented with 
10% (v/v) FBS (Sigma, UK), 1% (v/v) L-glutamine (Invitrogen, UK), 1% (v/v) MEM 
NEAAs (Invitrogen, UK), 50 units/ml penicillin and 50 μg/ml streptomycin (Sigma, 
UK) and 5 μg/ml plasmocin (Source BioScience, UK), in a humidified atmosphere 
containing 5% CO2 at 37˚C.  Cell culture medium was changed two to three times a 
week.  Differentiation of myoblasts into myotubes was induced at 90-100% confluency 
by replacing FBS with 10% (v/v) horse serum (Sigma, UK).  C2C12 myotubes were 
used between passages 4-14.  Cells were sub-cultured at 80% confluence by incubating 
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with TrypLE™ Express (Invitrogen, UK) for 15 minutes at 37˚C.  For experiments, 
C2C12 cells were seeded at 5,000 cells /cm
2
 and used 7 days after induction of 
differentiation unless otherwise specified. 
 
2.2 Berry extract and polyphenols 
The berry extract (OptiBerry
®
, InterHealth Nutraceuticals; USA) used in this study is 
derived from a unique blend of wild blueberry, strawberry, cranberry, wild bilberry, 
elderberry and raspberry prepared by ethanol extraction.  It is sugar-free and does not 
have detectable vitamin C.  Table 6 shows a typical analysis of the berry extract 
provided by the manufacturer. Attempts were made to investigate its composition in 
more detail using nuclear magnetic resonance (NMR) spectroscopy, but lack of time 
precluded this (see Section 6 on Future Investigations).  Since OptiBerry
®
 is a 
commercialised product, no other information is available.  The berry extract was stored 
in an air-tight container at -20˚C. 
 




 (μmol TE2/g)  ≥3700  
Polyphenolic content (mg GAE
3
/g)  ≥200  
Total anthocyanins content (mg/g)  ≥80  
     Malvidin (mg/g)     ≥8.0  
     Cyanidin (mg/g)     ≥30  
     Delphinidin (mg/g)     ≥30  
     Petunidin (mg/g)     ≥8.0  
pH (1g/100 ml in water)  2.5-3.5  
1
ORAC: Oxygen Radical Absorbance Capacity 
2
TE: Trolox equivalent  
3
GAE: Gallic acid equivalent 





All other polyphenols, cyanidin chloride, cyanidin-3-O-glucoside chloride, cyanidin-3-
O-rutinoside chloride, phloretin, phloridzin, quercetin and quercetin-3-O-glucoside, 
were purchased from Sigma (UK). 
 
2.3 Quantitative real time-polymerase chain reaction (qRT-
PCR) 
2.3.1 RNA extraction 
Total RNA was isolated from cells using TRIzol
®
 reagent (Invitrogen, UK) according to 
manufacturer’s instructions described as follows.  Cultured cells were homogenised in 
TRIzol
®
 reagent directly in the culture dish by pipetting up and down several times.  
Homogenised cells were transferred to a centrifuge tube followed by the addition of 
chloroform.  After being subject to vigorous shaking and centrifugation at 12,000 g at 
4˚C, RNA was then isolated in the aqueous phase by phase separation and precipitated 
with ice-cold isopropanol.  The resultant RNA pellet recovered after another 
centrifugation at 12,000 g at 4˚C was further washed with ethanol. 
 
2.3.2 Reverse transcription 
Extracted RNA pellet was re-suspended in nuclease-free water and reverse transcribed 
into cDNA using High Capacity cDNA Reverse Transcription Kit (Applied Biosystems, 
UK), which contains the MultiScribe
TM
 reverse transcriptase, dNTP, random primers 
and RNase inhibitor, according to manufacturer’s protocol, on MJ Research PTC-225 
Peltier Thermo Cycler (Labtech, UK).  Thermal cycling conditions for reverse 





Table 7. Thermal cycling conditions for reverse transcription (High Capacity 









Temperature  25˚C 37˚C 85˚C 4˚C 




Specific primers for qRT-PCR were designed using the Primer-BLAST primer 
designing tool (http://www.ncbi.nlm.nih.gov/tools/primer-blast/).  PCR product sizes 
were restricted to between 60 and 300 base pairs.  Table 8 and Table 9 show the primer 
sequences of the genes tested and their amplicon sizes. 
 
qRT-PCR was performed using either SYBR
®
 Green PCR Master Mix (Applied 
Biosystems, UK), which contains SYBR
®
 Green I Dye, AmpliTaq
®
 Gold DNA 
Polymerase and dNTPs with dUTP, or Fast SYBR
®
 Green Master Mix (Invitrogen, 
UK), which contains SYBR
®
 Green I Dye, AmpliTaq
®
 Fast DNA Polymerase and 
dNTPs, and custom-made primers (Eurofins MWG Operon, Germany) at a final 
concentration of 400 nM.  Thermal cycling conditions for qRT-PCR are shown in Table 
10 and Table 11. Typical PCR standard curve and dissociation curves are shown in 
Figure 45, page 224 and Figure 46, page 225 in the Appendix.  DNA agarose gel 
electrophoresis was performed to confirm the sizes of PCR products.  Figure 47 (page 
225, in the Appendix) shows typical images of DNA agarose gel electrophoresis. 
 
To analyse the relative changes in the expression of genes of interest, the delta delta Ct 
method was used (Livak and Schmittgen, 2001).  In this method, the PCR signals of the 
target transcript were normalised to at least one housekeeping gene.  The changes in 
expression were subsequently quantified in relation to the values of the respective 
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control treatment.  In Caco-2 cells, at least one of the following stably-expressed 
housekeeping genes were used for normalisation- 18S ribosomal RNA, beta-actin, beta-
2 microglobulin, glyceraldehyde 3-phosphate dehydrogenase and beta-tubulin 2C.  In 
C2C12 cells, normalisation was performed using glyceraldehyde 3-phosphate 
dehydrogenase and/or hypoxanthine phosphoribosyltransferase 1.  Selection was based 
on a number of criteria, which included their abundance, their stability and how 
common they were used by other groups in the literature. 
 
Table 8. List of primer sequences (Homo sapiens) 
Gene 
symbol* 
Forward primer Reverse primer 
Amplicon 
length (bp) 
18S AACTTTCGATGGTAGTCGCCG CCTTGGATGTGGTAGCCGTTT 105 
ACTB TCCTTCCTGGGCATGGAGT GCACTGTGTTGGCGTACAG 103 
B2M CCACTGAAAAAGATGAGTATGCCT CCAATCCAAATGCGGCATCTTCA 126 
GAPDH ACCCACTCCTCCACCTTTGA CTGTTGCTGTAGCCAAATTCGT 101 
TUBB2C TTGGGAGGTGATCAGCGATGAG CTCCAGATCCACGAGCACGGC 148 
SLC2A1 CCAGCTGCCATTGCCGTT GACGTAGGGACCACACAGTTGC 99 
SLC2A2 AGTTAGATGAGGAAGTCAAAGCAA TAGGCTGTCGGTAGCTGG 165 
SLC2A3 CAATGCTCCTGAGAAGATCATAA AAAGCGGTTGACGAAGAGT 172 
SLC2A5 CACCCACTTACTTAGCCAAAC GCACTGAATGGAGAGAGAAGAC 169 
SLC5A1 CGCCTATCCAACCTTAGTGGTG CGCTGTTGAAGATGGAGGTCAG 110 
SI CATCCTACCATGTCAAGAGCCA GCTTGTTAAGGTGGTCTGGTTT 196 
* Listed genes encoded the following products:  18S- 18S ribosomal RNA; ACTB- beta-
actin; B2M- beta-2 microglobulin; GAPDH- glyceraldehyde 3-phosphate dehydrogenase; 
TUBB2C- beta-tubulin 2C; SLC2A1- glucose transporter 1 (GLUT1); SLC2A2- glucose 
transporter 2 (GLUT2); SLC2A3- glucose transporter 3 (GLUT3); SLC2A5- glucose 




Table 9. List of primer sequences (Mus musculus) 
Gene 
symbol* 
Forward primer Reverse primer 
Amplicon 
length (bp) 
GAPDH ATGACCACAGTCCATGCCATC CCTGCTTCACCACCTTCTTG 271 
HPRT1 GCAAACTTTGCTTTCCCTGG ACTTCGAGAGGTCCTTTTCACC 85 
SLC2A1 CTTCCTGCTCATCAATCGT AGCTCCAAGATGGTGACCTT 150 
SLC2A4 TGCTCTCCTGCAGCTGATT TTCAGCTCAGCTAGTGCGTC 147 
* Listed genes encoded the following products: GAPDH- glyceraldehyde 3-phosphate 
dehydrogenase; HPRT1- hypoxanthine phosphoribosyltransferase 1; SLC2A1- glucose 





Table 10. Thermal cycling conditions for qRT-PCR (SYBR
®






Hold Cycle (40 cycles) 
Temperature  95˚C 95˚C 60˚C 
Time 10 min 15 sec 1 min 
 
Table 11. Thermal cycling conditions for qRT-PCR (Fast SYBR
®






Hold Cycle (40 cycles) 
Temperature 95˚C 95˚C 60˚C 
Time 20 sec 3 sec 30 sec 
 
2.4 Trypan blue exclusion viability test 
Trypan blue is a diazo dye that does not pass through cell membrane.  Cells with intact 
membrane are devoid of staining by trypan blue.  It therefore distinguishes living cells 
from dead cells by the presence of intact membrane. 
 
Adhered cells were washed with phosphate buffered saline (PBS) twice before being 
subject to dissociation with TrypLE™ Express (Invitrogen, UK) at 37˚C for 15 minutes.  
Normal cell culture medium was added to harvest the cells.  The cell suspension was 
centrifuged at 600 rpm for 5 minutes using the Eppendorf centrifuge 5804R (Eppendorf, 
UK).  After decanting the supernatant, the cell pellet was re-suspended in cell culture 
medium.  For each millilitre of cell suspension, 0.1 ml of 0.4% trypan blue solution 
(Sigma, UK) was added and loaded onto a hemocytometer, and examined under Nikon 
Eclipse TS100 inverted microscope (Nikon, UK) at 100 times magnification.  The 
numbers of total cells and blue-staining cells were counted and percentage of viable 
cells was calculated as followed: 
 
% viable cells = [1.00 – (Number of blue cells ÷ Number of total cells)] × 100% 
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2.5 MTS viability assay 
MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium) is a yellow tetrazolium compound.  In metabolically active cells, the 
NADPH or NADH generated by dehydrogenase enzymes reduce MTS into a purple-
coloured formazan product that has an absorbance maximum at 490 nm (Berridge and 
Tan, 1993).  Figure 9 shows the structures of MTS and its formazan product. 
 
 
Figure 9. Reduction of MTS tetrazolium into formazan product 
Adapted from the instruction manual of the CellTiter 96
®
 AQueous One Solution Cell 
Proliferation Assay. 
 
MTS viability assay was performed using CellTiter 96
®
 AQueous One Solution Cell 
Proliferation Assay (Promega, UK).  Briefly, C2C12 cells were seeded on 96-well 
plates at a density of 5,000 cells/cm
2
.  After treatment with berry extract, incubating 
solutions were changed to 100 μl cell culture medium, followed by addition of 20 μl of 
CellTiter 96
®
 AQueous One Solution Reagent.  After incubation at 37˚C for 45 minutes, 
absorbance at 490 nm was read using BioTek Synergy HT Multidetection Microplate 




2.6 Giemsa staining 
Differentiation of C2C12 myoblasts into myotubes was monitored by Giemsa staining 
(Freshney, 2010).  Giemsa stain (BDH, UK) stains the nuclei pink, the chromosomes 
dark purple, the cytoplasm pale grey-pink and the protein-rich myotubes dark red-
purple. 
 
Staining was started by washing adherent cells with PBS after discarding the cell culture 
medium.  The cells were fixed in PBS/methanol (1:1) for 2 minutes followed by another 
10 minutes in fresh anhydrous methanol.  After a brief rinse with fresh methanol, the 
cells were either dried and stored, or stained directly.  To stain, neat Giemsa stain was 
added to cover the cell monolayer for 2 minutes.  Water was added to dilute the stain 
with agitation of the dish gently for further 2 minutes.  The stain was then displaced 
upward and washed under running tap water until any pink cloudy background stain 
was removed.  The monolayer was finally rinsed in deionised water.  Stained cells were 
examined using Nikon Eclipse TE200 microscope (Nikon, UK) attached to Nikon 
digital camera DXM 1200 (Nikon, UK). 
 
2.7 Global gene expression studies 
Global gene expression studies with the use of microarrays were performed with the 
assistance on equipment from technicians, Dr Matthew Arno, Dr Estibaliz Aldecoa-
Otalora Astarloa and Dr Yuen Fei Wong, in the Genomics Centre, Waterloo Campus, 
King’s College London.  Otherwise, samples were handled by the PhD candidate. 
 
2.7.1 Ethanol precipitation for RNA purification 
To purify RNA samples for microarray studies, sodium acetate (pH 5.2) was added to 
the RNA samples dissolved in nuclease-free water.  Subsequently, ice-cold 100% 
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ethanol was added, mixed thoroughly with the RNA and kept at -20°C overnight.  The 
precipitated RNA was separated by centrifugation at 13,000 g at 4°C and further 
washed with ice-cold ethanol.  The resultant purified RNA pellet was then dissolved in 
nuclease-free water for subsequent use.  RNA integrity was checked using Agilent RNA 
6000 Nano Kit on the 2100 Agilent Bioanalyzer Instrument (Agilent, UK).  Figure 10 
shows a typical RNA integrity report for our RNA samples. 
 
 
Figure 10. Typical Agilent Bioanalyzer report of total RNA samples 
Figures shown are gel-like image (A) and electropherogram (B) of total RNA samples.  
The 18S and 28S rRNAs appeared as peaks at around 1800 and 4000 nt respectively. 
The RNA integrity numbers (RIN) of all RNA samples used are between 9.80 and 10.0. 
 
2.7.2 RNA amplification and labelling 
Purified RNA samples were pooled and 500 ng of each pooled sample in 5 μl was used 
in the reactions.  Reverse transcription to synthesise first strand cDNA, second strand 
cDNA synthesis and in vitro transcription (IVT) to synthesise biotin-modified aRNA 
were carried out using MessageAmp
TM
 Premier RNA Amplification Kit (Invitrogen, 
UK) according to manufacturer’s protocol.  Table 12 shows the thermal cycling 
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conditions for the above-mentioned reactions.  After synthesis, the biotin-modified 
aRNAs were purified to remove enzymes, salts and unincorporated nucleotides using 
the same kit.   
 
Table 12. Thermal cycling conditions for the reactions performed using 
MessageAmp
TM
 Premier RNA Amplification Kit 
Reaction Temperature and time 
First strand cDNA synthesis 42˚C for 2 hr 4˚C indefinite hold 
Second strand cDNA synthesis 16˚C for 1 hr 65˚C for 10 min 4˚C indefinite hold 
IVT 40˚C for 14 hr 4˚C indefinite hold 
 
2.7.3 aRNA fragmentation and hybridisation 
Following purification, the biotin-modified aRNAs were subjected to fragmentation 
using the GeneChip
®
 3’ IVT Express Kit (Affymetrix, UK).  Sizes of the fragmentation 
reaction products were analysed on the Agilent 2100 Bioanalyzer (Agilent, UK) with 
Agilent RNA 6000 Nano Kit (Agilent, UK).  The fragmented aRNAs had a distribution 
of 35-200 nt with a peak at approximately 100-120 nt.  Figure 11 shows typical 
Bioanalyzer electropherograms of unfragmented and fragmented cRNAs.  Afterwards, 
12 μg of aRNAs were hybridised onto the Affymetrix Mouse Genome 430A 2.0 Array 
(Affymetrix, UK), which is comprised of over 22,600 probe sets representing over 
14,500 well-substantiated mouse genes.  The arrays were subsequently washed, stained 
and scanned in the Fluidics Station 400 and the GeneArray Scanner (Affymetrix, UK) 




Figure 11. Typical Agilent Bioanalyzer electropherograms of cRNAs 
Unfragmented cRNA (A) shows a distribution of sizes from 250 to 5500 nt with most of 
the cRNA between 600 and 1200 nt; fragmented cRNA (B) shows a size distribution of 
35–200 nt with a peak at approximately 100-120 nt. 
 
2.7.4 Microarray data analysis 
Microarray Suite version 5.0 (MAS 5.0) algorithm was used for normalisation and 
generation of gene expression summaries from the array images.  The MAS 5.0 
algorithm normalises data at probe set level using linear scaling method.  It generates 
detection calls that indicate whether the target sequence is present (P), marginally 
present (M) or absent (A) in the given sample by comparing the signal intensities from 
perfect-match probes to their corresponding mismatch probes in a specific probe set.  In 
the present study, targets that were either called as P or M in at least one group were 




2.7.5 Gene functional classification 
Altered gene lists were imported into the bioinformatics resource, the Database for 
Annotation, Visualisation and Integrated Discovery (DAVID) version 6.7 
(http://david.abcc.ncifcrf.gov/home.jsp) (National Institute of Allergy and Infectious 
Diseases, NIH).  Using the gene functional classification tool, as well as our own 
literature search, the differentially expressed genes were classified into functionally-
related gene clusters. 
 
2.7.6 Validation by qRT-PCR 
Validation of microarray results by qRT-PCR was performed using TaqMan
®
 Universal 
PCR Master Mix (Applied Biosystems, UK), which contains the AmpliTaq
®
 Gold DNA 
polymerase and dNTPs with dUTP.  Universal ProbeLibrary (UPL) probes, which are 
labelled at the 5' end with fluorescein (FAM) and at the 3' end with a dark quencher dye, 
and target-specific PCR primers were designed using the ProbeFinder software 
available online at the Universal ProbeLibrary Assay Design Center 
(https://www.roche-applied-science.com) (see Table 13 for primer sequences and probe 
identities).  The probes were purchased from Roche Diagnostics (UK) and used at a 
final concentration of 100 nM.  The primers were obtained from Eurofins MWG 
Operon (Germany) and used at a final concentration of 200 nM.  Thermal cycling 
conditions for TaqMan qRT-PCR are shown in Table 14.  The delta delta Ct method 
was used to analyse the relative changes in gene expression.  Glyceraldehyde 3-
phosphate dehydrogenase and hypoxanthine phosphoribosyltransferase 1 were stably 















































ACCCCCAGGAAGATGGTC #99 71 
TNNI3 GCAGGTGAAGAAGGAGGA
CA 






* Listed genes encoded the following products:  AKT2- V-akt murine thymoma viral 
oncogene homolog 2; ANKRD2- Ankyrin repeat domain-containing protein 2; GAPDH- 
glyceraldehyde 3-phosphate dehydrogenase; HPRT1- hypoxanthine 
phosphoribosyltransferase 1; INSR- insulin receptor; IRS2- insulin receptor substrate 2; 
MYH2- myosin heavy chain IIa; MYH7- myosin heavy chain β; PIK3CB- 
phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit beta isoform; 
TBC1D1- TBC1 (tre-2/USP6, BUB2, cdc16) domain family, member 1; TNNI3- 
troponin I, type 3 and TPM1A- tropomyosin 1 alpha. 
 
Table 14. Thermal cycling conditions for qRT-PCR (TaqMan
®










Cycle (40 cycles) 
Denature Anneal/ extend 
Temperature 50˚C 95˚C 95˚C 60˚C 
Time 2 min 10 min 15 sec 1 min 
*UNG: AmpErase
®
 uracil-N-glycosylase, a component of the TaqMan
®
 Universal PCR 
Master Mix that can prevent the re-amplification of carryover-PCR products by 







2.8 MicroRNA studies 
2.8.1 MicroRNA expression profiling 
Total RNA was extracted using TRIzol
®
 reagent (Invitrogen, UK) according to 
manufacturer’s protocol, except for an additional overnight precipitation step at -20°C 





 Biotin HSR RNA Labeling Kit (Affymetrix, UK) and miRNA profiling was 
performed using the GeneChip
®
 miRNA array (Affymetrix, UK), which contains 847 
specific probe sets for human miRNAs derived from the Sanger miRBase miRNA 
database v11.  Robust multiarray average algorithm (RMA) was used for summarising 
probe level data, by quantile normalisation.  miRNA target prediction was performed 
using the bioinformatics algorithm, TargetScanHuman version 6.2 
(http://www.targetscan.org/). 
  
2.8.2 Validation by qRT-PCR 
Validation of miRNA expressions of five selected miRNAs (let-7a, let-7d, let-7f, miR-
92b and miR-106b) was performed according to miRCURY LNA
TM
 Universal RT 
microRNA PCR instruction manual.  Extracted RNA (10 ng) was reverse transcribed 
using the Universal cDNA synthesis kit (Exiqon, Denmark) and qRT-PCR was 
performed using commercially available miRNA-specific primers and SYBR
®
 Green 
master mix (Exiqon, Denmark).  Thermal cycling conditions for reverse transcription 
and qRT-PCR are shown in Table 15 and Table 16.  Figure 12 shows the schematic 
outline of the principles of miRCURY LNA
TM 
Universal RT microRNA PCR system.  
Analysis of PCR data was carried out using delta delta Ct method with two stably 




Table 15. Thermal cycling conditions for reverse transcription (miRCURY LNA™ 
Universal RT microRNA PCR kit) 
 Reverse transcription Enzyme inactivation Cooling 
Temperature  42˚C 95˚C 4˚C 
Time 60 min 5 min ∞ 
 
 
Table 16. Thermal cycling conditions for qRT-PCR (miRCURY LNA™ Universal 





Hold Cycle (40 cycles) 
Temperature  95˚C 95˚C 60˚C 




Figure 12. Schematic outline of the miRCURY LNA
TM
 Universal RT microRNA 
PCR system 
A poly-A tail is added to the mature microRNA template (step 1A).  cDNA is 
synthesised using a poly-T primer with a 3’ degenerate anchor and a 5’ universal tag 
(step 1B).  The cDNA template is then amplified using microRNA-specific and LNA
TM
- 
enhanced forward and reverse primers (step 2A).  SYBR
®
 Green is used for detection 
(step 2B).  Reproduced from miRCURY LNA
TM






2.9 Uptake studies 
Sugar uptake assays were carried out in HEPES-buffered salt solution (pH 7.4; 130 mM 
NaCl, 4 mM KH2PO4, 1 mM MgSO4, 1 mM CaCl2, 30 mM HEPES, and 0.2% (w/v) 
bovine serum albumin) with D-glucose and 0.15 μCi/ml D-[6-3H]-glucose 
(PerkinElmer, UK), or D-fructose and 0.15 μCi/ml D-[14C]-fructose (American 
Radiolabeled Chemicals, UK). 
 
Caco-2 cells or C2C12 myotubes were incubated for 15 minutes at room temperature in 
HEPES buffer prior to experiments.  Uptake was initiated by the addition of either the 
control or test solutions and was terminated after 2 minutes by aspiration of the uptake 
buffer, immediately followed by the addition of ice-cold PBS.  Rate of glucose uptake 
at 2 minutes at room temperature has been demonstrated previously by our research 
group to be linear (unpublished data, Dr Paul Sharp).  Thus, it was considered prudent 
to determine the influence of analytes during the linear kinetic phase of glucose uptake.  
Cells were washed twice more with ice-cold PBS and solubilised at 37˚C in 0.2% (w/v) 
sodium dodecyl sulfate (SDS) for 1 hour prior to scintillation counting (LS 
6500, Beckman Coulter, UK).  Aliquots of cell lysate were taken to determine protein 
content by Bradford protein assay (Bradford, 1976). 
 
2.10 Statistical analyses 
All data are expressed as mean ± standard error of mean (SEM) and tested for outliers 
by Grubb’s test using the free web calculator provided by GraphPad Software 
(http://graphpad.com/quickcalcs/Grubbs1.cfm).  Sample sizes are described in the 
legend to each figure.  Independent-sample t-test was used for two group comparisons.  
For multiple group comparisons, data were first tested for normality using Shapiro-Wilk 
test.  In case of significant deviation from normal distribution, data were analysed using 
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the non-parametric independent-samples Kruskal-Wallis test with Mann-Whitney test.  
Otherwise, data analyses were performed using one-way ANOVA with Dunnett’s or 
Tukey post-hoc tests.  In all studies, statistical significance was reached when P-value is 






3.1 Intestinal Caco-2 cells 
3.1.1 Characterisation of the intestinal Caco-2 cells 
3.1.1.1 Morphology 
 
Figure 13. Morphological changes of Caco-2 cells during cell culture  
The day of seeding was regarded as Day 0.  Images were taken at Day 3 (A); Day 7 (B); 
Day 10 (C); Day 14 (D).  The Caco-2 cell monolayer reached 100% confluence at Day 
10 (determined by personal observation).  Arrows indicate location of domes (100X 
magnification). 
 
Caco-2 cells were used at passages 40 to 50 and were seeded at a density of 10,000 
cells/ cm
2
 on plastic culture dishes.  Cells attached on the plastic surface within one 
hour after seeding and appeared as round and flattened cells (not shown).  As the cells 
continued to grow in the following week, they became colloidal in shape and formed 
clusters by attaching to adjacent cells (Figure 13A and B).  By Day 10 (Figure 13C), 
confluence was reached and small domes were observed on the cell monolayer.  The 
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formation of domes is the consequence of secretion of solutes and water through the 
basolateral membrane.  This suggested there was development of tight junctions 
between neighbouring cells and ion transport activities, indicating cell differentiation 
(Grasset et al., 1984).  During the culture period after reaching confluence, the number 
of domes rose progressively and, eventually, small domes fused to form larger domes 
(Figure 13D).  Multilayers of cells appeared and cells increased in height, becoming 
increasingly columnar in shape (personal observation). 
 
3.1.1.2 Gene expression 
Relative gene expressions of glucose transporters, GLUT1-3, 5 and SGLT1, as well as 
the differentiation marker, sucrase-isomaltase, were investigated at several time points 
during cell culture.  In order to represent the three phases of cell growth, i.e. 
proliferating, confluent and differentiated, three time points (Days 7, 10 and 14) were 
chosen for analysis.  
 
As shown in Figure 14, the gene expression of the differentiation marker, sucrase-
isomaltase (SI) increased dramatically from Day 7 to Day 10 by 3.4-fold (P< 0.005).  
There was no further change in the expression of SI after the Caco-2 cells were further 
cultured for 4 days at Day 14.  The relative mRNA levels of GLUT1 and 5 increased 
progressively from Day 7 to Day 14 (P< 0.05) (Figure 14).  For GLUT2 and 3, the 
mRNA levels peaked at Day 10 (P< 0.05) and decreased thereafter (Figure 14).  No 
significant difference was observed in the gene expression of SGLT1 at all three time 
points, although there was a slight rise from Day 7 to Day 10, which was maintained at 




In order to compare the relative abundance of mRNAs of the genes investigated, we 
examined the Ct values (threshold cycle, defined as the number of cycles required for 
the fluorescent signal to reach the threshold) of those genes from the qRT-PCR.  As 
shown in Table 17, at Day 14, the Ct values of GLUT1 and 3 were around 17, whilst 
the values of GLUT5 and SGLT1 were almost double, i.e. between 30 and 35.  The Ct 
values of GLUT2 and SI were, on the other hand, around 26.  As a low Ct value 
represents higher mRNA level, these results indicated that at Day 14, the mRNA 
abundances of GLUT1 and 3 were higher than GLUT2 and SI, while those of GLUT5 
and SGLT1 were the lowest among all. 
 
Table 17. Ct values of SLC2A1-3 and 5, SLC5A1 and SI in Caco-2 cells at Day 14 
obtained from qRT-PCR 
Gene name (Encoded protein) Ct value at Day 14 (Mean ± SEM, n=4) 
SLC2A1 (GLUT1) 17.18 ± 0.05 
SLC2A2 (GLUT2) 26.85 ± 0.40 
SLC2A3 (GLUT3) 17.00 ± 0.05 
SLC2A5 (GLUT5) 31.31 ± 0.06 
SLC5A1 (SGLT1) 33.98 ± 0.19 






Figure 14. Relative gene expression of SLC2A1-3 and 5, SLC5A1 and SI of Caco-2 
cells during differentiation 
Data are presented as mean ± SEM (n= 4).  Gene symbols are indicated above each 
graph with the encoded proteins in parentheses.  
#






3.1.1.3 Sugar uptake 
 
Figure 15. Specific uptake of glucose or fructose by Caco-2 cells cultured for 
different lengths of time 
Uptake of 10 mM glucose with trace of [
3
H]-labelled D-glucose was measured in the 
presence (Glu +Na) or absence (Glu –Na) of Na+, and uptake of 10 mM fructose with 
trace of 
14
C-labelled fructose was measured in the presence of Na
+
 (Fru +Na).  Data are 
presented as mean ± SEM (n= 6). *P< 0.05, **P< 0.005.  
 
To characterise the Caco-2 cells at the functional level, we investigated the changes in 
glucose or fructose uptake in Caco-2 cells during differentiation.  In the presence of 
sodium, where uptake occurred via all glucose transporters, i.e. both GLUTs and 
SGLT1, glucose uptake into Caco-2 cells decreased progressively from Day 7 to Day 
14, by around 30% (P< 0.005) (Figure 15).  Comparing the glucose uptake in the 
presence and absence of sodium, the latter which favours uptake via GLUTs only, 
glucose uptake was reduced by around 30% at Day 7 (P< 0.005) (Figure 15), when the 
Caco-2 cells were proliferating.  However, there were no significant differences in 




Two fructose transporters, GLUT5, which specifically transports fructose only, and 
GLUT2, which transports both glucose and fructose, are expressed in Caco-2 cells.  In 
the current characterisation experiment, fructose uptake increased progressively during 
the cell culture period.  Compared to Day 7, fructose uptake increased by 27% (P< 
0.05) and 39% (P< 0.005) at Day 10 and Day 14, respectively (Figure 15). 
 
3.1.2 Acute effects of berry extract and polyphenols on glucose uptake 
in the intestinal Caco-2 cells 
3.1.2.1 Berry extract 
 
Figure 16. Acute effect of 0.125% (w/v) berry extract on glucose uptake in Caco-2 
cells 
Uptake of 1 mM D-glucose with trace of [
3
H]-labelled D-glucose was measured in the 
presence (A) or absence of Na
+
 (B) after exposure of Caco-2 cells to 0.125% (w/v) 
berry extract for 15 minutes.  Data are presented as mean ± SEM (n= 9).  *P< 0.01, 
**P< 0.001 compared to respective controls. 
 
Caco-2 cells were exposed acutely to 0.125% (w/v) berry extract for 15 minutes.  One 
millimolar [
3
H]-D-glucose was then added for another 2 minutes and its uptake was 
measured.  Inhibition of glucose uptake was observed in Caco-2 cells incubated with the 
berry extract.  In the presence of sodium, glucose uptake was reduced by around 50% 
(P< 0.001) (Figure 16A), whilst in sodium-free condition which favours transport via 
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the sodium-independent GLUTs only, a 25% (P< 0.01) inhibition was observed (Figure 
16B). 
 
3.1.2.2 Cyanidin and cyanidin glycosides 
The polyphenol analysis report from the manufacturer of the berry extract used in this 
study showed that cyanidin is one of the most abundant constituent anthocyanidins in 
the berry extract (≥ 30 mg/g) (see Table 6, page 74).  In this regard, it is of particular 
interest whether cyanidin, or its glycosides contribute to the cellular effects of the berry 
extract on glucose transport in Caco-2 cells.  Thus, we investigated the acute effects of 
the cyanidin aglycone, and two of its glycosides commonly found in natural food, 
cyanidin-3-O-glucoside and cyanidin-3-O-rutinoside, on glucose uptake in Caco-2 cells. 
 
Results showed that in sodium-containing buffer, all three tested compounds, i.e. 
cyanidin, cyanidin-3-O-glucoside and cyanidin-3-O-rutinoside significantly reduced 
glucose uptake into Caco-2 cells at a concentration of 100 μM by 27% (P< 0.005), 30% 
(P< 0.005) and 16% (P< 0.05), respectively (Figure 17A).  Under sodium-free 
condition, however, only the glycosides showed inhibitory effect on glucose uptake by 
26% (P< 0.005) for the glucoside and 21% (P< 0.05) for the rutinoside.  However, the 





Figure 17. Acute effect of 100 μM cyanidin and its glycosides on glucose uptake in 
Caco-2 cells 
Uptake of 1 mM D-glucose with trace of [
3
H]-labelled D-glucose was measured in the 
presence (A) or absence of Na
+
 (B) after exposure of Caco-2 cells to 100 μM of 
cyanidin (Cy), cyanidin-3-O-glucoside (Cy glucoside) or cyanidin-3-O-rutinoside (Cy 
rutinoside) for 15 minutes.  Data are presented as mean ± SEM (n= 4).  *P< 0.05, **P< 




3.1.2.3 Inhibitors of glucose transporters 
 
Figure 18. Acute effect of 100 μM of phloretin, phloridzin or quercetin on glucose 
uptake in Caco-2 cells 
Uptake of 1 mM D-glucose with trace of [
3
H]-labelled D-glucose was measured in the 
presence (A) or absence of Na
+
 (B) after exposure of Caco-2 cells to 100 μM of 
phloretin, phloridzin or quercetin for 15 minutes.  Data are presented as mean ± SEM 
(n= 8-9).  
#
P< 0.05, *P< 0.01, **P< 0.001 compared to control. 
 
We also compared the effects of berry extract on glucose uptake in Caco-2 cells with 
known inhibitors of glucose transporters, namely phloretin, phloridzin and quercetin.  
As shown in Figure 18A and B, 100 μM phloretin inhibited glucose uptake by 35% (P< 
0.01) and 20% (P< 0.05) in the presence and absence of sodium, respectively.  At the 
same concentration, quercetin reduced glucose uptake by 58% (P< 0.001) and 42% (P< 
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0.001) in the presence and absence of sodium, respectively.  Phloridzin also inhibited 
glucose uptake by 20% in the presence of sodium albeit not reaching statistical 
significance (P> 0.05). 
 
Investigations of the dose response relationship of the quercetin aglycone and quercetin-
3-O-glucoside (12.5-200 μM) on glucose uptake revealed that concentrations as low as 
12.5 μM exerted a significant inhibitory effect (P< 0.001) (Figure 19A and B).  The 
aglycone (IC50 ~37 μM) was a more potent inhibitor than the glucoside (IC50 ~55 μM).  
There was no significant difference between glucose uptake in the presence or absence 





Figure 19. Dose response acute effect of quercetin and quercetin-3-O-glucoside on 
glucose uptake in Caco-2 cells 
Uptake of 1 mM D-glucose with trace of [
3
H]-labelled D-glucose was measured after 
exposure of Caco-2 cells to 6.25-200 μM of quercetin (A) or quercetin-3-O-glucoside 
(B) for 15 minutes.  Data are presented as mean ± SEM (n= 12).  *P< 0.001 compared 










3.1.3 Chronic effects of berry extract and polyphenols on glucose 
transport in the intestinal Caco-2 cells 
3.1.3.1 Gene expression 
Berry extract 
In addition to acute treatments (15 minutes), Caco-2 cells were also subjected to an 
exposure period of 16 hours to investigate the chronic effects on glucose transport. 
 
 
Figure 20. Dose response effect of berry extract on gene expression of SLC2A2 
(GLUT2) and SLC5A1 (SGLT1) in Caco-2 cells 
Caco-2 cells were treated with various concentrations of berry extract (0.016-0.125% 
(w/v)) for 16 hours.  Relative gene expression of SLC2A2 (GLUT2) and SLC5A1 
(SGLT1) was determined by qRT-PCR.  Data are presented as mean ± SEM (n= 8).  
#
P< 0.05, *P< 0.01, 
##
P< 0.005 compared to respective controls. 
 
Dose response studies demonstrated that berry extract at concentrations ranging from 
0.016 to 0.125% (w/v) triggered a biphasic change in the gene expression of GLUT2 
(Figure 20).  At a lower dose of berry extract (0.016% (w/v)), expression of GLUT2 
was elevated by 27% (P< 0.05), but at higher doses, i.e. 0.063 and 0.125% (w/v), it was 
reduced by 40% (P< 0.005) and 27% (P< 0.05), respectively.  Significant changes were 
observed in the gene expression of SGLT1 only at high doses, i.e. 0.063 and 0.125% 
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(w/v) (Figure 20), where the berry extract induced down-regulation by 53% (P< 0.01) 
and 49% (P< 0.005), respectively. 
 
In addition to investigating the effects of berry extract on the two major intestinal 
glucose transporters, GLUT2 and SGLT1, we also investigated the effects on the 
expression of GLUT1 GLUT3 and GLUT5.  GLUT1 and GLUT3 are glucose 
transporters present in the Caco-2 cell line and GLUT5 is a fructose transporter 
expressed in human intestinal epithelium.  As shown in Figure 21, there was no 
significant change in the expression of GLUT1 across all concentrations of berry extract 
tested (P> 0.05).  On the other hand, both GLUT3 and GLUT5 were down-regulated 
upon treatment with the highest concentration of berry extract at 0.125% (w/v), by 39% 




Figure 21. Dose response effect of berry extract on gene expression of SLC2A1, 3 
and 5 (GLUT1, 3, and 5) in Caco-2 cells 
Caco-2 cells were treated with various concentrations of berry extract (0.016-0.125% 
(w/v)) for 16 hours.  Relative gene expression of SLC2A1, 3 and 5 (GLUT1, 3, and 5) 









Time-dependent studies showed that at a concentration of 0.125% (w/v), berry extract 
down-regulated the gene expression of both GLUT2 and SGLT1 significantly at all time 
points investigated (4-24 hours) (P= 0.005 or P< 0.001) (Figure 22). 
 
 
Figure 22. Time dependent effect of berry extract on gene expression of SLC2A2 
(GLUT2) and SLC5A1 (SGLT1) in Caco-2 cells 
Caco-2 cells were treated with 0.125% (w/v) berry extract for different lengths of time.  
Relative gene expression of SLC2A2 (GLUT2) and SLC5A1 (SGLT1) was determined 
by qRT-PCR.  Data are presented as mean ± SEM (n= 12-40).  
#
P= 0.005, *P< 0.001 
compared to respective controls. 
 
Quercetin 
Dose response effect of the most abundant dietary flavonoid, quercetin, on the gene 
expression of GLUT2 and SGLT1 in Caco-2 cells was also evaluated.  Using qRT-PCR, 
quercetin was shown to down-regulate the expression of GLUT2 in a dose-dependent 
manner (6.25-100 μM) (Figure 23).  The lowest concentration of quercetin used in this 
study (6.25 μM) reduced the expression of GLUT2 by 28% (P< 0.05) while the highest 
concentration (100 μM) caused a dramatic 80% decline (P< 0.001) (Figure 23).  On the 
other hand, the expression of SGLT1 in response to increasing concentrations of 
quercetin showed a biphasic change (Figure 23).  Quercetin at a concentration of 25 
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μM up-regulated the expression of SGLT1 by 22% (P< 0.05) but 100 μM decreased it 
by 80% (P< 0.001) (Figure 23). 
 
 
Figure 23. Dose response effect of quercetin on gene expression of SLC2A2 
(GLUT2) and SLC5A1 (SGLT1) in Caco-2 cells 
Caco-2 cells were treated with various concentrations of quercetin (6.25-100 μM) for 16 
hours.  Relative gene expression of SLC2A2 (GLUT2) and SLC5A1 (SGLT1) was 
determined by qRT-PCR.  Data are presented as mean ± SEM (n= 8-34).  
#
P< 0.05, *P< 
0.001 compared to respective controls. 
 
Investigations into the time course effect of quercetin revealed that the gene expression 
of GLUT2 in Caco-2 cells was down-regulated significantly after incubation with 100 
μM quercetin for 8 hours (P< 0.05) and thereafter over the course of the experiment 
(Figure 24).  On the other hand, the gene expression of SGLT1 was reduced 





Figure 24. Time dependent effect of quercetin on gene expression of SLC2A2 
(GLUT2) and SLC5A1 (SGLT1) in Caco-2 cells 
Caco-2 cells were treated with 100 μM of quercetin for different lengths of time.  
Relative gene expression of SLC2A2 (GLUT2) and SLC5A1 (SGLT1) was determined 
by qRT-PCR.  Data are presented as mean ± SEM (n= 12-41).  
#
P< 0.05, *P< 0.005, 
##
P< 0.001 compared to respective controls. 
 
3.1.3.2 Glucose uptake 
Berry extract or inhibitors of glucose transporters 
There was no significant change in glucose uptake into Caco-2 cells after incubation 
with 0.125% (w/v) berry extract for 16 hours in both sodium-containing and sodium-
free conditions (Figure 25A and B).  Similar results were obtained from glucose uptake 
studies where Caco-2 cells had been pre-incubated with 100 μM of phloretin, phloridzin 




Figure 25. Chronic effect of 0.125% (w/v) berry extract on glucose uptake in Caco-
2 cells 
Uptake of 1 mM D-glucose with trace of [
3
H]-labelled D-glucose was measured in the 
presence (A) or absence (B) of Na
+
 after incubating Caco-2 cells with 0.125% (w/v) 
berry extract for 16 hours.  Data are presented as mean ± SEM (n= 8-9).  N.S.- not 





Figure 26. Chronic effect of 100 μM of phloretin, phloridzin or quercetin on 
glucose uptake in Caco-2 cells 
Uptake of 1 mM D-glucose glucose with trace of [
3
H]-labelled D-glucose was measured 
in the presence (A) or absence (B) of Na
+
 after incubating Caco-2 cells with 100 μM of 
phloretin, phloridzin or quercetin for 16 hours.  Data are presented as mean ± SEM (n= 
6-9).  N.S.- not significant (P> 0.05). 
 
3.1.3.3 Global miRNA expression 
As mentioned in the above section, berry extract at a concentration of 0.125% (w/v) 
down-regulated the gene expression of GLUT2 and SGLT1.  We speculated the 
involvement of microRNAs (miRNAs), a class of small non-coding RNA molecules, in 





In this study, using Affymetrix GeneChip
®
 miRNA arrays, changes in global miRNA 
expression in Caco-2 cells in response to 16-hour treatment with 0.125% (w/v) berry 
extract were evaluated.  The miRNA arrays used in the present study contain probe sets 
that detect 847 human mature miRNAs.  Of these, 347 were present in the human 
intestinal epithelial Caco-2 cell line (true detection (P< 0.05) in at least one group).  
Upon treatment with 0.125% (w/v) berry extract, 158 miRNAs were differentially 
expressed by greater than two fold.  Specifically, 41 miRNAs were up-regulated (Table 
18) and 117 were down-regulated (Table 19). 
 
















































Caco-2 cells were treated with 0.125% (w/v) berry extract for 16 hours.  Changes in 
global miRNA expression were determined using miRNA arrays.  A two-fold change 
was set as a threshold. 
 
Following miRNA expression profiling using microarrays, qRT-PCR was performed in 
an attempt to validate the changes in the miRNA expression shown in the microarray.  
Five miRNAs were selected, namely let-7a, let-7d, let-7f, miR-92b and miR-106b.  The 
let-7 miRNA family has been implicated in the control of glucose metabolism and the 
pathogenesis of Type II diabetes (Frost and Olson, 2011).  Therefore, three miRNAs 
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from the let-7 family- let-7a, let-7d and let-7f- which were identified as potential 
regulators of GLUT2, were chosen.  Among these three miRNAs, let-7a and let-7f were 
up-regulated as shown in the microarray, while let-7d did not change.  miR-106b was 
selected as it is also a potential GLUT2 regulator but was down-regulated.  For 
comparison, we also validated the changes in miR-92b, which does not seem to bind to 
either GLUT2 or SGLT1.  In other words, miR-92b acted as a negative control where no 
change was expected using qRT-PCR (see Table 20 for changes in the expression of the 































































































































Caco-2 cells were treated with 0.125% (w/v) berry extract for 16 hours.  Changes in 
global miRNA expression were determined using miRNA arrays.  A two-fold change 





Validation of miRNA microarray data by qRT-PCR 
 
Figure 27. Validation of miRNA microarray data for selected miRNAs by qRT-
PCR 
Five miRNAs- let-7a, let-7d, let-7f, miR-92b and miR-106b- were selected for 
validation by qRT-PCR.  Microarray: data are presented as mean; qRT-PCR: data are 
presented as mean ± SEM (n= 8).  
#
P< 0.005, *P< 0.001 compared with control. 
 
Table 20. Changes in the expression of the five selected miRNAs in the microarray 
and in qRT-PCR 
MicroRNA Change call in microarray Change in qRT-PCR (P-value) 
let-7a Increase Increase (P= 0.004) 
let-7d No change No change (P= 0.164) 
let-7f Increase Decrease (P= 0.001) 
miR-92b No change No change (P= 0.618) 
miR-106b Decrease Increase (P< 0.001) 
 
 
Results from qRT-PCR did not validate the data obtained from miRNA microarray (see 
Table 20), i.e. direction of changes of two out of five selected miRNAs, namely let-7f 
and miR-106b, are opposite in the microarray and in the qRT-PCR.  Nevertheless, we 
found an up-regulation in the expression of let-7a in both microarray and qRT-PCR.  
Using the bioinformatics algorithm, TargetScanHuman version 6.2, the mRNA of 
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GLUT2 is predicted to be one of the targets of let-7a.  Figure 28 shows the predicted 
consequential pairing of the 3’-UTR of GLUT2 mRNA and let-7a miRNA. 
 
 
Figure 28. Interaction between the 3'UTR of GLUT2 mRNA and let-7a miRNA 
The match type between SLC2A2 and let-7a miRNA belongs to the 7mer-A1 type, i.e. 
base-pairing between the seed regions (nucleotides 2-7 from 5’ end) of the miRNA and 
the conserved sites in the 3’UTR (3’-untranslated region) of mRNAs and an A across 
from nucleotide 1 (highlighted in gray).  Prediction of miRNA target was performed 





3.2 C2C12 muscle cells 
3.2.1 Characterisation of the C2C12 muscle cells 
3.2.1.1 Giemsa staining of the C2C12 muscle cells 
Differentiation of C2C12 myoblasts into myotubes was monitored by Giemsa staining.  
Giemsa stain (BDH, UK) stains the nuclei pink, the chromosomes dark purple, the 
cytoplasm pale gray-pink and the protein-rich myotubes dark red-purple. 
 
 
Figure 29. Giemsa staining of C2C12 cells during differentiation (100X) 
C2C12 cells were differentiated at Day 0.  Images shown were C2C12 cells at Day -1 




At Day -1 (1-2 days post-seeding and 1 day before initiation of differentiation), C2C12 
myoblasts appeared as fusiform or star-shaped mononucleated cells (Figure 29A and 
Figure 30A).  The myoblasts proliferated and reached about 90-100% confluence at 
Day 0 (Figure 29B and Figure 30B).  At Day 0, myogenic differentiation was induced 
by switching fetal bovine serum-supplemented cell culture medium to horse serum.  
One day after the change of serum supplementation (Day 1), the C2C12 cells were 
characterised by lengthening and appearance of thin dark-red-purple-stained filaments, 
indicating formation of protein-rich muscle fibres (Figure 29C and Figure 30C).  By 
Day 3, mononucleated cells began to fuse and become multinucleated, forming long 
myotubes (Figure 29D and Figure 30D).  From Day 5 onwards, myogenesis increased 
progressively as the myotubes thickened, branched and frequently overpassed the 





Figure 30. Giemsa staining of C2C12 cells during differentiation (400X)  
C2C12 cells were differentiated at Day 0.  Images shown were C2C12 cells at Day -1 
(A), Day 0 (B), Day 1 (C), Day 3 (D), Day 5 (E) and Day 7 (F) (400X magnification). 
 
3.2.1.2 Gene expression of glucose transporters 
Changes in the gene expression of the two main glucose transporters in muscle cells, 
GLUT1 and GLUT4, were evaluated over the course of culture during C2C12 
differentiation.  At Day-1, a time point where C2C12 cells appeared as actively 
proliferating myoblasts, gene expression of GLUT1 was relatively high compared to 
that of GLUT4 (Figure 31).  Upon reaching confluence at Day 0, although the cells still 
existed as undifferentiated myoblasts, a dramatic decline in the expression of GLUT1 
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(P< 0.001) and a sudden rise in the expression of GLUT4 (P< 0.001) were already 
observed (Figure 31).  There were no further changes in the expression of both GLUT1 
and GLUT4 from Day 0 to Day 7. 
 
 
Figure 31. Relative gene expression of SLC2A1 and 4 of during C2C12 
differentiation 
Relative gene expression of SLC2A1 and 4 (GLUT1 and 4) was determined by qRT-
PCR.  Data are presented as mean ± SEM (n= 4).  
*
P< 0.001 compared with expression 
at Day -1.  C2C12 cells reached 90-100% confluence and were initiated to undergo 
differentiation at Day 0.  
 
Table 21. Ct values of SLC2A1 and 4 in C2C12 cells at Day 7 obtained from qRT-
PCR 
Gene name (Encoded protein) Ct value at Day 7 (Mean ± SEM, n=4) 
SLC2A1 (GLUT1) 21.33 ± 0.04 
SLC2A4 (GLUT4) 27.25 ± 0.08 
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3.2.2 Cell viability test 
3.2.2.1 Trypan blue exclusion 
Trypan blue is a diazo dye that distinguishes between viable and non-viable cells by 
staining non-viable cells that do not possess intact membrane blue (Strober, 2001).  
Using this trypan blue dye exclusion method, C2C12 cells were shown to be >80% 
viable after treatments with 3-300 mM ethanol for 24 hours (Figure 32). 
 
 
Figure 32. Trypan blue test for cell viability of C2C12 myotubes upon treatment 
with various concentrations of ethanol (0-300 mM) 
Data are obtained based on counting a total of 200-400 cells from a representative 
sample chosen at random for each group. 
 
3.2.2.2 MTS viability assay 
MTS (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium) is a yellow tetrazolium compound that, in metabolically active cells, is 
reduced to a purple-coloured formazan product that give a maximum absorbance at 490 
nm.  Results from trypan blue test for ethanol treatment on cell viability of C2C12 cells 
were confirmed using the MTS viability assay.  No significant changes in cell viability 





Figure 33. MTS assay for cell viability of C2C12 myotubes upon treatment with 
various concentrations of ethanol (0-300 mM) 
Data are presented as mean ± SEM (n= 7-8). 
 
Similarly, the MTS assay showed that there were no significant changes in C2C12 cell 




Figure 34. MTS assay for cell viability of C2C12 myotubes upon treatment with 
various concentrations of berry extract (0-0.125% (w/v)) 




3.2.3 Effect of berry extract on glucose uptake in the C2C12 myotubes 
3.2.3.1 Gene expression of glucose transporters 
At the lowest concentration of berry extract (0.008% (w/v)), gene expression of GLUT1 
was decreased by 20% (P< 0.05) (Figure 35).  In contrast, 0.125% (w/v) berry extract, 
the highest concentration investigated, increased it by 30% (P< 0.05).  On the other 
hand, berry extract did not cause any significant changes in the gene expression of 
GLUT4 (P> 0.05) (Figure 35). 
 
 
Figure 35. Dose response effect of berry extract on gene expression of SLC2A1 and 
4 (GLUT1 and 4) in C2C12 myotubes 
C2C12 myotubes were treated with various concentrations of berry extract (0-0.125% 
(w/v)) for 24 hours.  Relative gene expression of SLC2A1 and 4 (GLUT1 and 4) was 
determined by qRT-PCR.  Data are presented as mean ± SEM (n= 11-12).  
#
P< 0.05 
compared to control. 
 
3.2.3.2 Morphology of C2C12 myotubes pre-treated with insulin 
Morphology of C2C12 myotubes with or without 3-day insulin treatment was 
compared.  In C2C12 cells subjected to incubation with 100 nM insulin for 3 days 
(Figure 36B), a more extensive development of lengthened multinucleated myotube 
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network was observed.  Thus, the amount of myotubes was apparently higher, and the 
myotubes were more branched but thinner (smaller diameter) compared to the untreated 
cells (Figure 36A).  In addition, based on personal observations not shown here, 
spontaneous twitching was more vigorous in the insulin-treated myotubes and the 
metabolic rate also appeared to be higher, which was determined by a more orange 
colour of the cell culture medium (a drop in pH) indicating higher rate of acidic 
metabolic waste production. 
 
 
Figure 36. C2C12 myotubes at Day 7 with or without insulin pre-treatment 
C2C12 cells were differentiated at Day 0.  Images shown were C2C12 myotubes at Day 
7 without pre-treatment (A) or pre-treated with 100 nM insulin for 3 days (B) (100X 
magnification).  
 
3.2.3.3 Gene expression of glucose transporters after 3-day insulin pre-treatment 
In C2C12 myotubes without insulin pre-treatment (white bars in Figure 37), 0.125% 
(w/v) berry extract did not induce significant changes in the gene expression of GLUT1 
and GLUT4 (P> 0.05).  Comparing the glucose transporter expression in C2C12 
myotubes with or without 3-day insulin pre-treatment (black bars versus white bars in 
the control groups in Figure 37), the expression of GLUT4 was massively up-regulated 
by ~2.7-fold by insulin pre-treatment (P< 0.001).  The expression of GLUT1, in 
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contrast, decreased by more than 20%, albeit not reaching statistical significance in one-
way ANOVA (P> 0.05, Tukey’s post-hoc test). 
 
In C2C12 myotubes which had been pre-treated with insulin (black bars in Figure 37), 
0.125% (w/v) berry extract caused a ~2.4-fold up-regulation of the gene expression of 
GLUT1 (P< 0.001).  However, expression of GLUT4 did not show significant changes 
under the same condition (P> 0.05). 
 
 
Figure 37. Relative gene expression of SLC2A1 and 4 (GLUT1 and 4) after 24-hour 
treatment with 0.125% (w/v) berry extract in C2C12 myotubes 
C2C12 myotubes without pre-treatment or pre-treated with 100 nM insulin for 3 days 
were subjected to 24-hour incubation with 0.125% (w/v) berry extract.  Relative gene 
expression of SLC2A1 and 4 (GLUT1 and 4) was determined by qRT-PCR.  Data 
presented are mean ± SEM (n= 4-6).  
#
P= 0.001, *P< 0.001. 
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3.2.3.4 Glucose uptake under basal or insulin-stimulated conditions 
In C2C12 myotubes that had not been subjected to insulin pre-incubation (Figure 38A), 
0.125% (w/v) berry extract did not cause significant changes in glucose uptake, both in 
basal and insulin-stimulated conditions (P> 0.05).  It is noteworthy that stimulation with 
100 nM insulin alone for 30 minutes also did not significantly alter glucose uptake in 
C2C12 myotubes (P> 0.05) (Figure 38A). 
 
In C2C12 myotubes that had been pre-treated with 100 nM insulin for 3 days (Figure 
38B), the cells became insulin-responsive, i.e. insulin itself was able to stimulate 
glucose uptake (a 25% increase (P< 0.001)) (black bar versus white bar in control group 
in Figure 38B).  Berry extract at a concentration of 0.125% (w/v), on the other hand, 
did not alter basal glucose uptake in insulin-pre-treated C2C12 myotubes (P> 0.05).  
There were also no significant changes in insulin-induced glucose uptake in cells treated 
with 0.125% (w/v) berry extract, compared to 30-minute insulin incubation alone (P> 




Figure 38. Effects of 0.125% (w/v) berry extract (24 hours) on glucose uptake 
under basal or insulin-stimulated conditions in C2C12 myotubes 
C2C12 myotubes without pre-treatment (A) or pre-treated with insulin for 3 days (B) 
were treated with or without 0.125% (w/v) berry extract for 24 hours.    Uptake of 1 
mM D-glucose with trace of [
3
H]-labelled D-glucose was measured under basal or 
insulin-stimulated conditions.  Under insulin-stimulated condition, cells were pre-
incubated with 100 nM insulin for 30 minutes and uptake was measured in the presence 






3.2.4 Effect of ethanol on glucose transporter expression in the C2C12 
myotubes 
Ethanol at concentrations ranging from 3 mM to 300 mM did not trigger any changes in 
the gene expression of GLUT1 in C2C12 myotubes (P> 0.05) (Figure 39).  On the 
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other hand, at high concentrations (30, 100 and 300 mM), ethanol significantly 
suppressed the mRNA level of GLUT4, all by ~20% (P< 0.05) (Figure 39). 
 
`  
Figure 39. Dose response effect of ethanol on gene expression of SLC2A1 and 4 
(GLUT1 and 4) in C2C12 myotubes 
C2C12 myotubes were treated with various concentrations of ethanol (0-300 mM) for 
24 hours.  Relative gene expression of SLC2A1 and 4 (GLUT1 and 4) was determined 
by qRT-PCR.  Data are presented as mean ± SEM (n= 11-12). *P< 0.05 compared to 
respective controls. 
 
3.2.5 Global mRNA expression of the C2C12 myotubes 
3.2.5.1 Berry extract 
The global gene expression profile of C2C12 myotubes following exposure to 0.125% 
(w/v) berry extract for 24 hours was investigated using the Affymetrix Mouse Genome 
430A microarrays.  A two-fold change relative to control (signal log ratio ≥ 1.0 or ≤ -
1.0) was selected as a threshold to define differentially expressed genes.  Upon 
treatment with berry extract, the expression of 488 genes was altered by greater than 2-
fold, among which 136 were up-regulated and 352 were down-regulated.  Using the 
DAVID v6.7 gene functional classification tool (medium classification stringency) as 
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well as independent literature search, functionally-related altered genes were 
categorised into 7 groups, namely glutathione metabolism, transcriptional regulation, 
nucleic acid binding/ processing, membrane transport, signal peptide, leucine-rich 
repeat and extracellular structure/ cytoskeleton.  Data are presented in Table 22.  A full 
list of all 488 differentially expressed genes is presented in Table 26, page 203 and 
Table 27, page 207 in the Appendix. 
 
3.2.5.2 Ethanol 
The global gene expression profile of C2C12 myotubes following exposure to 300 mM 
ethanol for 24 hours was investigated using the Affymetrix Mouse Genome 430A 
microarrays.  Using a threshold cut-off at 2-fold change (signal log ratio ≥ 1.0 or ≤ -
1.0), we only identified 36 differentially expressed genes, while the detection signals for 
about half of these genes were very close to background (signal intensities< 50).  
Therefore, a 1.4-fold change relative to control (signal log ratio ≥ 0.5 or ≤ -0.5) was 
tentatively selected as a threshold to define differentially expressed genes.  Upon 
treatment with ethanol, the expression of 239 genes was altered by greater than 1.4-fold, 
among which 96 were up-regulated and 143 were down-regulated.  Using the DAVID 
v6.7 gene functional classification tool (medium classification stringency) as well as 
independent literature search, functionally-related altered genes were categorised into 5 
groups, namely insulin signalling/ glucose metabolism, muscle metabolism and 
contraction, transcription factor, cell cycle and protein synthesis.  Data are presented in 
Table 23.  A full list of all 239 differentially expressed genes is presented in Table 28, 




Table 22. List of functionally-related genes differentially expressed upon treatment with berry extract in C2C12 myotubes 
Affymetrix ID Gene symbol Functional category/ gene description Signal log ratio Fold change 
  Glutathione metabolism   
1448354_at G6PDX glucose-6-phosphate dehydrogenase X-linked 1.1 2.14 
1418627_at GCLM glutamate-cysteine ligase, modifier subunit 1.6 3.03 
1421041_s_at GSTA1 glutathione S-transferase, alpha 1 (Ya) 2.5 5.66 
1421040_a_at GSTA2 glutathione S-transferase, alpha 2 (Yc2) 3.7 13.00 
1423436_at GSTA3 glutathione S-transferase, alpha 3 4.7 25.99 
1416368_at GSTA4 glutathione S-transferase, alpha 4 1.8 3.48 
1416416_x_at GSTM1 glutathione S-transferase, mu 1 1.4 2.64 
1415897_a_at MGST1 microsomal glutathione S-transferase 1 1.2 2.30 
1452592_at MGST2 microsomal glutathione S-transferase 2 1.2 2.30 
  Transcriptional regulation   
1449363_at ATF3 activating transcription factor 3 1.2 2.30 
1418982_at CEBPA CCAAT/ enhancer binding protein (C/EBP), alpha 1.0 2.00 
1427844_a_at CEBPB CCAAT/ enhancer binding protein (C/EBP), beta 1.4 2.64 
1423233_at CEBPD CCAAT/ enhancer binding protein (C/EBP), delta 1.8 3.48 
1437247_at FOSL2 fos-like antigen 2 1.1 2.14 
1418936_at MAFF v-maf musculoaponeurotic fibrosarcoma oncogene family, protein F 1.1 2.14 
1426538_a_at TP53 tumour suppressor protein p53 1.0 2.00 
1433863_at BTF3 basic transcription factor 3 -1.0 0.50 
1419959_s_at CPHX cytoplasmic polyadenylated homeobox -1.5 0.35 
1425698_a_at CREBZF CREB/ATF bZIP transcription factor -1.3 0.41 
1436434_at E2F2 E2F transcription factor 2 -1.4 0.38 
1437820_at FOXS1 forkhead box S1 -1.1 0.47 
1433640_at FUBP1 far upstream element (FUSE) binding protein 1 -1.0 0.50 
1451285_at FUS fusion, derived from t(12;16) malignant liposarcoma (human) -1.1 0.47 
1418007_at GCFC1 GC-rich sequence DNA-binding factor 1 -1.0 0.50 
To be cont’d 
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Affymetrix ID Gene symbol Functional category/ gene description Signal log ratio Fold change 
1436932_at GRHL3 grainyhead-like 3 (Drosophila) -2.6 0.16 
1419302_at HEYL hairy/enhancer-of-split related with YRPW motif-like -1.1 0.47 
1418152_at HMGN5 high-mobility group nucleosome binding domain 5 -2.4 0.19 
1424252_at HNRPDL heterogeneous nuclear ribonucleoprotein D-like -1.5 0.35 
1451776_s_at HOPX HOP homeobox -1.3 0.41 
1439885_at HOXC5 homeo box C5 -1.3 0.41 
1416630_at ID3 inhibitor of DNA binding 3 -1.7 0.31 
1418301_at IRF6 interferon regulatory factor 6 -1.2 0.44 
1439847_s_at KLF12 Kruppel-like factor 12 -1.6 0.33 
1421028_a_at MEF2C myocyte enhancer factor 2C -1.0 0.50 
1452349_x_at MNDA myeloid cell nuclear differentiation antigen -1.0 0.50 
1434830_at MXD1 MAX dimerization protein 1 -1.1 0.47 
1444980_at ONECUT2 one cut domain, family member 2 -1.2 0.44 
1442148_at PSIP1 PC4 and SFRS1 interacting protein 1 -1.1 0.47 
1432232_at RCOR3 REST corepressor 3 -1.0 0.50 
1427988_s_at SAFB2 scaffold attachment factor B2 -1.0 0.50 
1427417_at SCML4 sex comb on midleg-like 4 (Drosophila) -2.0 0.25 
1416778_at SDPR serum deprivation response -1.0 0.50 
1430271_x_at TAF1D TATA box binding protein (Tbp)-associated factor, RNA polymerase I, D -1.1 0.47 
1428467_at TARDBP TAR DNA binding protein -1.1 0.47 
1450961_a_at TCEAL5 transcription elongation factor A (SII)-like 5 -2.3 0.20 
1435585_at TCEAL7 transcription elongation factor A (SII)-like 7 -1.1 0.47 
  Nucleic acid binding/ processing   
1455936_a_at RBPMS RNA binding protein gene with multiple splicing 1.4 2.64 
1455740_at HNRNPA1 heterogeneous nuclear ribonucleoprotein A1 -1.0 0.50 
1424252_at HNRPDL heterogeneous nuclear ribonucleoprotein D-like -1.5 0.35 
1424802_a_at LUC7L3 LUC7-like 3 (S. cerevisiae) -1.3 0.41 
To be cont’d 
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Affymetrix ID Gene symbol Functional category/ gene description Signal log ratio Fold change 
1422850_at PABPN1 poly(A) binding protein, nuclear 1 -1.8 0.29 
1443282_at PRPF38A PRP38 pre-mRNA processing factor 38 (yeast) domain containing A -1.0 0.50 
1452869_at PRPF38B PRP38 pre-mRNA processing factor 38 (yeast) domain containing B -1.3 0.41 
1428172_at PRPF39 PRP39 pre-mRNA processing factor 39 homolog (yeast) -1.1 0.47 
1455358_at RBFOX1 RNA binding protein, fox-1 homolog (C. elegans) 1 -1.1 0.47 
1429169_at RBM3 RNA binding motif protein 3 -1.3 0.41 
1443033_at RBM14 RNA binding motif protein 14 -1.0 0.50 
1443715_at RBM24 RNA binding motif protein 24 -1.2 0.44 
1425523_at RBM25 RNA binding motif protein 25 -1.5 0.35 
1435391_at RBM33 RNA binding motif protein 33 -1.0 0.50 
1426863_at RBMX RNA binding motif protein, X chromosome -1.8 0.29 
1429504_at RNPC3 RNA-binding region (RNP1, RRM) containing 3 -1.9 0.27 
1427988_s_at SAFB2 scaffold attachment factor B2 -1.0 0.50 
1427134_at SFRS12 splicing factor, arginine/serine-rich 12 -1.0 0.50 
1424452_at SLTM SAFB-like, transcription modulator -1.1 0.47 
  Membrane transport   
1419758_at ABCB1A ATP-binding cassette, sub-family B (MDR/TAP), member 1A 1.4 2.64 
1443870_at ABCC4 ATP-binding cassette, sub-family C (CFTR/MRP), member 4 1.8 3.48 
1456003_a_at SLC1A4 solute carrier family 1 (glutamate/neutral amino acid transporter), member 4 1.0 2.00 
1434773_a_at SLC2A1 solute carrier family 2 (facilitated glucose transporter), member 1 1.2 2.30 
1425364_a_at SLC3A2 solute carrier family 3 (activators of dibasic and neutral amino acid transport), 
member 2 
1.0 2.00 
1443536_at SLC7A11 solute carrier family 7 (cationic amino acid transporter, y+ system), member 11 2.9 7.46 
1415802_at SLC16A1 solute carrier family 16 (monocarboxylic acid transporter), member 1 1.1 2.14 
1449005_at SLC16A3 solute carrier family 16 (monocarboxylic acid transporter), member 3 1.3 2.46 
1417902_at SLC19A2 solute carrier family 19 (thiamine transporter), member 2 1.2 2.30 
1450409_a_at SLC48A1 solute carrier family 48 (heme transporter), member 1 1.2 2.30 
To be cont’d 
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Affymetrix ID Gene symbol Functional category/ gene description Signal log ratio Fold change 
1427371_at ABCA8A ATP-binding cassette, sub-family A (ABC1), member 8A -1.2 0.44 
1435752_s_at ABCC9 ATP-binding cassette, sub-family C (CFTR/MRP), member 9 -1.8 0.29 
1436602_x_at CACNA1B calcium channel, voltage-dependent, N type, alpha 1B subunit -1.4 0.38 
1438109_at CLCA5 chloride channel calcium activated 5 -1.2 0.44 
1454768_at KCNF1 potassium voltage-gated channel, subfamily F, member 1 -1.1 0.47 
1426633_s_at KCTD14 potassium channel tetramerisation domain containing 14 -1.9 0.27 
1435933_at SCN2A1 sodium channel, voltage-gated, type II, alpha 1 -1.3 0.41 
1458813_at SCN5A sodium channel, voltage-gated, type V, alpha -1.0 0.50 
1432798_at SLC12A6 solute carrier family 12 (potassium/chloride transporter), member 6 -1.3 0.41 
1457266_at SLC38A6 solute carrier family 38  (sodium-coupled neutral amino acid transporter), 
member 6 
-1.0 0.50 
  Signal peptide   
1420380_at CCL2 chemokine (C-C motif) ligand 2 3.6 12.13 
1421228_at CCL7 chemokine (C-C motif) ligand 7 2.2 4.59 
1419209_at CXCL1 chemokine (C-X-C motif) ligand 1 4.4 21.11 
1419728_at CXCL5 chemokine (C-X-C motif) ligand 5 4.3 19.70 
1417574_at CXCL12 chemokine (C-X-C motif) ligand 12 1.2 2.30 
1449195_s_at CXCL16 chemokine (C-X-C motif) ligand 16 2.5 5.66 
1418949_at GDF15 growth differentiation factor 15 1.2 2.30 
1421992_a_at IGFBP4 insulin-like growth factor binding protein 4 1.0 2.00 
1427747_a_at LCN2 lipocalin 2 2.9 7.46 
1451054_at ORM1 orosomucoid 1 3.4 10.56 
1425454_a_at IL12A interleukin 12a -1.1 0.47 
1423915_at OLFML2B olfactomedin-like 2B -1.0 0.50 
1451031_at SFRP4 secreted frizzled-related protein 4 -1.1 0.47 
1450004_at TSLP thymic stromal lymphopoietin -2.5 0.18 
  Leucine-rich repeat   
To be cont’d 
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Affymetrix ID Gene symbol Functional category/ gene description Signal log ratio Fold change 
1448421_s_at ASPN asporin -2.6 0.16 
1435779_at CEP110 centrosomal protein 110 -1.2 0.44 
1428427_at FBXL2 F-box and leucine-rich repeat protein 2 -1.2 0.44 
1437685_x_at FMOD fibromodulin -1.7 0.31 
1436218_at LGR6 leucine-rich repeat-containing G protein-coupled receptor 6 -1.7 0.31 
1429679_at LRRC17 leucine rich repeat containing 17 -1.1 0.47 
1451498_at LRRC26 leucine rich repeat containing 26 -1.1 0.47 
1445841_at LRRC39 leucine rich repeat containing 39 -1.3 0.41 
1423607_at LUM lumican -2.2 0.22 
1418745_at OMD osteomodulin -2.9 0.13 
1416321_s_at PRELP proline arginine-rich end leucine-rich repeat -1.3 0.41 
  Extracellular structure/ cytoskeleton   
1446326_at COL1A2 collagen, type I, alpha 2 -1.0 0.50 
1425476_at COL4A5 collagen, type IV, alpha 5 -1.3 0.41 
1424131_at COL6A3 collagen, type VI, alpha 3 -1.4 0.38 
1418440_at COL8A1 collagen, type VIII, alpha 1 -1.6 0.33 
1434667_at COL8A2 collagen, type VIII, alpha 2 -1.0 0.50 
1440911_at COL23A1 collagen, type XXIII, alpha 1 -1.5 0.35 
1438540_at COL25A1 collagen, type XXV, alpha 1 -1.3 0.41 
1417307_at DMD Dystrophin, muscular dystrophy -1.4 0.38 
1443745_s_at DMP1 dentin matrix protein 1 -1.4 0.38 
1418511_at DPT dermatopontin -1.5 0.35 
1423915_at OLFML2B olfactomedin-like 2B -1.0 0.50 
1451041_at ROCK2 Rho-associated coiled-coil containing protein kinase 2 -1.1 0.47 
1417860_a_at SPON2 spondin 2, extracellular matrix protein -1.7 0.31 
1438303_at TGFB2 transforming growth factor, beta 2 -1.0 0.50 
Global gene expression profile was evaluated in C2C12 cells after treatment with 0.125% (w/v) berry extract for 24 hours.  Genes that were changed 
by greater than 2-fold (signal log ratios ≥ 1 or ≤ -1) upon treatment were regarded as differentially expressed. 
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Table 23. List of functionally-related genes differentially expressed upon treatment with ethanol in C2C12 myotubes 
Affymetrix ID Gene symbol Functional category/ gene description Signal log ratio Fold change 
  Insulin signalling/ glucose metabolism   
1452014_a_at IGF1 insulin-like growth factor 1 0.5 1.41 
1418349_at HEGFL heparin-binding EGF-like growth factor -0.5 0.71 
1458268_s_at IGFBP3 insulin-like growth factor binding protein 3 -0.5 0.71 
1453069_at PIK3CB phosphatidylinositol 3-kinase, catalytic, beta polypeptide -0.8 0.57 
1419447_s_at TBC1D1 TBC1 domain family, member 1 -0.5 0.71 
1449334_at TIMP3 tissue inhibitor of metalloproteinase 3 -0.5 0.71 
  Muscle metabolism and contraction   
1419621_at ANKRD2 Ankyrin repeat domain-containing protein 2 0.5 1.41 
1428722_at CKMT2 creatine kinase, mitochondrial 2 0.9 1.87 
1417872_at FHL1 four and a half LIM domains 1 0.6 1.52 
1422536_at TNNI3 troponin I, cardiac 3 0.5 1.41 
1447713_at TPM1A tropomyosin 1, alpha 0.5 1.41 
1453588_at CAR3 carbonic anhydrase 3 -1.4 0.38 
1425153_at MYH2 myosin heavy chain IIa (MyHC-IIa), skeletal muscle, adult, fast-twitch -0.6 0.66 
1448553_at MYH7 myosin heavy chain β (MyHC-β), cardiac muscle -0.5 0.71 
  Transcription factor   
1418174_at DBP D site albumin promoter binding protein 0.8 1.74 
1422870_at HOXC4 homeo box C4 -0.5 0.71 
1418932_at NFIL3 nuclear factor, interleukin 3, regulated -0.6 0.66 
1422103_a_at STAT5B signal transducer and activator of transcription 5B -0.5 0.71 
  Cell cycle   
1448494_at GAS1 growth arrest-specific protein 1 0.5 1.41 
1417419_at CCND1 cyclin D1 -0.5 0.71 
1434830_at MXD1 MAX dimerisation protein 1 -0.7 0.62 
1450337_a_at NEK8 NIMA (never in mitosis gene a)-related expressed kinase 8 -0.5 0.71 
To be cont’d 
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Affymetrix ID Gene symbol Functional category/ gene description Signal log ratio Fold change 
  Protein synthesis   
1437071_at EIF1AX eukaryotic translation initiation factor 1-alpha, X-linked -0.5 0.71 
1440866_at EIF2AK2 eukaryotic translation initiation factor 2-alpha kinase 2 -0.7 0.62 
1455108_at EIF4E2 eukaryotic translation initiation factor 4E member 2 -0.6 0.66 
1417978_at EIF4E3 eukaryotic translation initiation factor 4E member 3 -0.6 0.66 
Global gene expression profile was evaluated in C2C12 cells after treatment with 300 mM ethanol for 24 hours.  Genes that were changed by greater 




3.2.5.3 Validation of microarray data with ethanol treatment by qRT-PCR 
Validation of the microarray data for C2C12 myotubes treated with ethanol was 
performed using a qRT-PCR approach.  Five differentially expressed (as shown in 
the microarray) genes which are related to muscle metabolism and contraction, as 
well as five other genes involved in insulin signalling were selected for validation.  
These were Ankyrin repeat domain-containing protein 2 (ANKRD2), myosin heavy 
chain IIa, adult, fast-twitch (MyHC-IIa) (MYH2), myosin, heavy chain β, cardiac 
(MyHC-β) (MYH7), troponin I type 3 (TNNI3) and tropomyosin 1 alpha (TPM1A), v-
akt murine thymoma viral oncogene homolog 2 (AKT2), insulin receptor (INSR), 
insulin receptor substrate 2 (IRS2), phosphatidylinositol 3-kinase, catalytic, beta 
polypeptide (PIK3CB) and TBC1 domain family, member 1 (TBC1D1). 
 
Figure 40. Comparison of fold changes in gene expression as shown in 
microarray and qRT-PCR 
Fold changes in the expression of the ten selected genes for validation as shown in 
microarray and qRT-PCR were compared.  Genes investigated are Ankyrin repeat 
domain-containing protein 2 (ANKRD2), myosin heavy chain IIa, adult, fast-twitch 
(MyHC-IIa) (MYH2), myosin, heavy chain β, cardiac (MyHC-β) (MYH7), troponin I 
type 3 (TNNI3) and tropomyosin 1 alpha (TPM1A), v-akt murine thymoma viral 
oncogene homolog 2 (AKT2), insulin receptor (INSR), insulin receptor substrate 2 
(IRS2), phosphatidylinositol 3-kinase, catalytic, beta polypeptide (PIK3CB) and 
TBC1 domain family, member 1 (TBC1D1).  Pearson’s correlation coefficient, R= 
0.885, P= 0.001. 
 
y = 0.8206x + 0.2989 

























Fold change in microarray 
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Pearson’s product moment test was performed to determine the correlation between 
results from microarray and qRT-PCR.  As shown in Figure 40, fold changes of the 
expression of the ten selected genes were highly concordant between the two 
detection methodologies (R= 0.885, P= 0.001). 
 
Fold changes of individual genes were also compared and presented as a bar chart in 
Figure 41.  As shown in this figure, fold changes of the gene expression showed 
similar directions in microarray and qRT-PCR, except for insulin receptor (INSR).  
This can be explained by the very low abundance of INSR mRNA in our samples and 
thus a relatively high background signal effect in the microarray analysis.  In fact, the 
changes of INSR expression did not reach significance in both microarray (MAS5.0 
algorithm) and qRT-PCR (see Table 24).  Furthermore, although the microarray 
showed a down-regulation for the gene of myosin heavy chain IIa (MYH2) and an 
up-regulation for troponin I type3 (TNNI3), the changes did not reach statistical 
significance in qRT-PCR (see Figure 41 and Table 24).  This was probably due to 
the use of pooled RNA samples in the microarray study and thus any variations 
between samples were not taken into consideration.  In contrast, a significant up-
regulation of insulin receptor substrate 2 (IRS2) was reported in the qRT-PCR but not 
in the microarray.  This was not surprising as qRT-PCR is generally regarded as a 
more sensitive methodology for measuring changes in gene expression (Klein, 2002).  
Otherwise, we confirmed that in C2C12 myotubes, upon treatment with ethanol, the 
gene expressions of Ankyrin repeat domain-containing protein 2 (ANKRD2) and 
tropomyosin 1 alpha (TPM1A) were increased, whereas the gene expressions of 
myosin, heavy chain β, cardiac (MYH7), phosphatidylinositol 3-kinase, catalytic, 
beta polypeptide (PIK3CB) and TBC1 domain family, member 1 (TBC1D1) were 




Figure 41. Validation of microarray data for ten selected genes by qRT-PCR 
Five muscle metabolism and contraction-related genes, Ankyrin repeat domain-
containing protein 2 (ANKRD2), myosin heavy chain IIa, adult, fast-twitch (MyHC-
IIa) (MYH2), myosin, heavy chain β, cardiac (MYH7), troponin I type 3 (TNNI3) and 
tropomyosin 1 alpha (TPM1A), and five genes involving in insulin signalling, v-akt 
murine thymoma viral oncogene homolog 2 (AKT2), insulin receptor (INSR), insulin 
receptor substrate 2 (IRS2), phosphatidylinositol 3-kinase, catalytic, beta polypeptide 
(PIK3CB) and TBC1 domain family, member 1 (TBC1D1),were selected for 
validation by qRT-PCR.  Microarray: data are presented as mean; qRT-PCR: data are 
presented as mean ± SEM (n= 9).  *P< 0.01, 
#
P< 0.005, **P< 0.001 compared with 





Table 24. Changes in the expression of the ten selected genes in the microarray 
and in qRT-PCR 
Gene Change call in microarray Change in qRT-PCR (P-value) 
Muscle development and contraction 
ANKRD2 Increase Increase (P< 0.001) 
MYH2 Decrease No change (P= 0.492) 
MYH7 Decrease Decrease (P= 0.006) 
TNNI3 Increase No change (P= 0.068) 
TPM1A Increase Increase (P< 0.001) 
Insulin signalling 
AKT2 No change No change (P= 0.103) 
INSR No change No change (P= 0.200) 
IRS2 No change Increase (P< 0.001) 
PIK3CB Decrease Decrease (P< 0.001) 
TBC1D1 Decrease Decrease (P= 0.002) 
 
Due to time limitations for the project for this thesis, qRT-PCR validation for the 
microarray data of berry extract-treated C2C12 muscle cells could not be performed.  
However, the microarray studies for berry extract and ethanol treatments were 
carried out simultaneously and using the same batch of materials, most importantly 
the microarray chips.  Given the high concordance in the changes of gene expression 
between microarray and qRT-PCR for the ethanol-treated cells (see Figure 40, 
Figure 41 and Table 24), we are confident that the microarray data for berry extract 




A summary of the main findings on the effects of berry extract and ethanol on 
glucose transport is presented in Table 25.  The ensuing section will then begin with 
an account of the acute and chronic effects of berry extract and related polyphenols 
on glucose transport in intestinal epithelial Caco-2 cells. This is followed by a 
scientific discussion into the cellular effects of chronic exposure to berry extract on 
glucose transport in C2C12 muscle cells.  I will then discuss the results obtained 
from microarray studies in C2C12 muscle cells following berry either extract or 
ethanol treatments. 
 
Table 25. A summary of the cellular effects of berry extract and ethanol on glucose 
uptake in Caco-2 intestnal cells and C2C12 muscle cells 
 Caco-2 intestinal cells C2C12 muscle cells 
Acute studies Berry extract and the related 
flavonoids- quercetin, cyanidin 
and their glycosides- acutely 
inhibited glucose uptake by 
directly interacting with glucose 
transporters. 
Not carried out. 
Chronic 
studies 
Berry extract down-regulated the 
gene expression of the two main 
intestinal glucose transporters, 
GLUT2 and SGLT1. 
At the highest dose tested 
(0.125% (w/v)), berry extract 
moderately up-regulated the 
gene expression of GLUT1. 
Berry extract also up-regulated 
the expression of the let-7a 
miRNA, a potential negative 
regulator of GLUT2. 
At the functional level, berry 
extract did not induce any 
changes in glucose uptake in 
C2C12 myotubes, neither in 
basal nor insulin-stimulated 
conditions. 
At the functional level, berry 
extract did not alter the initial 
rate of glucose uptake in Caco-2 
cells. 
At high doses, ethanol 
moderately down-regulated the 








4.1 Acute effects of berry extract and polyphenols on 
glucose uptake in the intestinal Caco-2 cells 
Data obtained from the acute studies indicated that berry extract significantly 
reduced glucose uptake into Caco-2 cells (Figure 16, page 95).  Comparing results in 
sodium-containing and sodium-free conditions, it is suggested that berry extract had 
similar inhibitory effects on transport through the facilitative glucose transporters 
(GLUTs) and sodium-dependent glucose transporter (SGLT1).  Cyanidin, one of the 
predominant anthocyanidins in the berry extract, and two of its glycosides, 3-O-
glucoside and 3-O-rutinoside also showed an inhibitory effect on glucose uptake in 
Caco-2 cells (Figure 17, page 97).  Anthocyanins occur naturally in foods mainly 
attached to sugar moieties (Zhang et al., 2004).  Our findings suggested that the 
glucose uptake-inhibitory activity of berry extract is attributed in part to its 
constituent anthocyanins such as cyanidin-3-O-glucoside and cyanidin-3-O-
rutinoside. 
 
Data in the scientific literature have shown that a wide range of polyphenols such as 
phloridzin, quercetin and its glucosides, catechins, caffeic acid and pelargonidin 
glucoside have inhibitory effects on glucose uptake in Caco-2 cells or related 
intestinal transport systems (Johnston et al., 2005, Chen et al., 2007, Manzano and 
Williamson, 2010).  Our studies showed similar effects of an anthocyanin-rich berry 
extract on intestinal glucose uptake in a Caco-2 cell model and suggested that 
cyanidin glycosides may contribute to its inhibition.  This is based on the observation 
that cyanidin glycosides markedly reduced glucose uptake. 
 
The importance of the inhibitory effects of berry extract on intestinal glucose 
transport does not seem to be triggering a reduction in the total amount of glucose 
absorbed.  This is evident in previous studies by other groups which showed no 
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difference in the areas under postprandial plasma glucose curves after consumption 
of apple juice, coffee, berry puree or cranberry juice, all of which are rich in 
polyphenols (Johnston et al., 2002, Johnston et al., 2003, Wilson et al., 2008, 
Törrönen et al., 2010, Törrönen et al., 2012b).  Instead, the attenuation of the rate of 
glucose absorption in the proximal jejunum, where the absorptive capacity for 
glucose is maximal (Mcmichael, 1971), could extend the length of intestinal lumen 
exposed to glucose, leading to delayed glucose absorption and reduced postprandial 
glycaemic excursions (see Figure 42). 
 
Increased exposure of the distal small intestine to glucose as a result of delayed 
glucose absorption further stimulates the release of the incretin, glucagon-like 
peptide-1 (GLP-1), from intestinal endocrine L-cells located mainly in the distal 
jejunum and ileum (Eissele et al., 1992).  This enhancement of GLP-1 secretion 
could be of particular significance in type 2 diabetic patients as postprandial 
secretion of GLP-1 is impaired in diabetic conditions, whereas the responsiveness of 
pancreatic β-cells to GLP-1 is preserved (Vaag et al., 1996, Toft-Nielsen et al., 
2001).  By promoting the release of GLP-1, the inhibition of proximal intestinal 
glucose absorption does not only elicit a bigger postprandial insulin response 
(Mojsov et al., 1987), but also inhibits glucagon secretion, suppresses intestinal 
motility and slows gastric emptying (Willms et al., 1996, Heller et al., 1997).  The 
abovementioned benefits were consistent with improved glucose tolerance in Goto-
Kakizaki type 2 diabetic rats that underwent duodenal-jejunal bypass that excludes 





Figure 42. Predicted effect of berry extract consumption on postprandial blood 
glucose profile 
The graph was drawn based on the results from Johnston et al. (2002) and Törrönen 
et al. (2012b). 
 
4.2 Effects of berry extract and polyphenols on glucose 
transporter expression in the intestinal Caco-2 cells 
Previous studies in the literature mainly focused on the inhibitory effects of 
polyphenols and food extracts on glucose transport via direct interaction with glucose 
transporters.  We also evaluated the potencies of berry extract and polyphenols to 
regulate glucose transport in Caco-2 cells through modulations of glucose transporter 
expression after prolonged incubation (16 hours). 
 
Intriguingly, in our studies, both berry extract and quercetin triggered biphasic 
changes in the gene expression of GLUT2 with increasing concentrations, i.e. an up-
regulation at low concentration but down-regulation at higher concentrations (see 
Figure 20, page 101 and Figure 23, page 105).  This compares with the expression 
of SGLT1 which was reduced only at the highest doses of berry extract, but also at 
all tested concentrations of quercetin.  At the highest concentration of berry extract 
(0.125% (w/v)), the inhibitory effects on the gene expressions of GLUT2 and SGLT1 
were evident as early as 4 hours after treatment (see Figure 22, page 104).  Most 
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prominent down-regulation of GLUT2 and SGLT1 mRNA levels by 100 μM of 
quercetin was observed after 12-16 hours of treatment (see Figure 24, page 106). 
 
Faria et al. (2009) reported an increase in GLUT2 gene expression in Caco-2 cells 
after a 96-hour pre-treatment with an anthocyanin-rich extract obtained from red 
grape skin.  The authors suggested that the augmented GLUT2 expression is 
involved in the enhanced absorption of the anthocyanins and hence their 
bioavailability after chronic exposure (Faria et al., 2009).  Conversely, a Canadian 
research group has demonstrated reductions in the protein expression of GLUT2 and 
SGLT1 after incubation of Caco-2 cells with extracts of native anti-diabetic 
medicinal plants (Nistor Baldea et al., 2010).  Phytochemical characterisations have 
shown that these extracts are rich in flavonoids such as quercetin glycosides (Spoor 
et al., 2006, Harbilas et al., 2009).  It has also been shown that feeding 
streptozotocin-induced diabetic mice with the apple flavonoid, phloridzin, reversed 
the streptozotocin-stimulated expression of SGLT1 in the small intestine (Masumoto 
et al., 2009). 
 
The discrepancies in the effect of flavonoids on the gene expression of intestinal 
glucose transporters are not fully understood.  One possible explanation is that 
multiple mechanisms are involved in these modulatory effects and different 
concentrations of flavonoids are required to reach the thresholds to activate 
individual pathways.  In fact, we observed biphasic dose responses in the gene 
expression of glucose transporters in Caco-2 cells exposed to berry extract or 
quercetin.  This is not unusual, since similar biphasic cellular changes have also been 
reported in various in vitro cell systems in response to a range of quercetin 
concentrations (Van Der Woude et al., 2005, Santini et al., 2009). 
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Elevated protein levels of GLUT2 and SGLT1 have been observed in the duodenum 
of type 2 diabetic patients (Dyer et al., 2002).  Also, in about 75% of morbidly obese 
human subjects, GLUT2 was detected at the apical membrane in jejunal enterocytes 
in the fasting state, in contrast to its basolateral-only location in lean subjects (Ait-
Omar et al., 2011).  Together, these aberrations lead to enhanced intestinal glucose 
absorption, hence provoking increased postprandial glycaemic excursions.  Our 
chronic studies demonstrated that high doses of berry extract down-regulated the 
gene expression of the two major intestinal glucose transporters, GLUT2 and 
SGLT1.  These findings suggested that consumption of anthocyanin-enriched berry 
extract might help ameliorate the impairment of glycaemic control in diabetic 
conditions by reversing the up-regulated expressions of GLUT2 and SGLT1. 
 
4.3 Chronic effects of berry extract and polyphenols on 
glucose uptake in the intestinal Caco-2 cells 
Given the dramatic down-regulation of GLUT2 and SGLT1 gene expression by the 
highest concentrations of berry extract and quercetin, we would expect a reduction in 
glucose uptake under the same treatment conditions.  However, surprisingly, we did 
not observe any changes in glucose uptake into Caco-2 cells after prolonged pre-
incubation with berry extract or quercetin, nor with the well-established glucose 
transporter inhibitors, phloretin and phloridzin (see Figure 25, page 107 and Figure 
26, page 108). 
 
The lack of changes at the functional level could be due to the high abundance of 
GLUT1 and GLUT3 transporters in our Caco-2 subclone.  In normal tissue, mRNA 
levels of GLUT1 and GLUT3 are negligible in the small intestine (Yano et al., 1991, 
Yoshikawa et al., 2011).  However, up-regulation of GLUT1 and GLUT3 expression 
occurs in the transformation process, thus, elevation of GLUT1 and GLUT3 proteins 
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has been observed in many cancers (Macheda et al., 2005).  Due to the carcinoma 
origin of Caco-2 cells, constituent and measurable levels of GLUT1 and GLUT3 
mRNAs are expected.  Mahraoui et al. (1994a) have reported a decline in the mRNA 
levels of GLUT1 and GLUT3 but an increase for GLUT2 and SGLT1 in the Caco-
2/TC7 subclone during differentiation.  Nevertheless, several groups (as well as the 
present studies for this thesis, see Table 17, page 92) have reported low or negligible 
expressions of GLUT2 and SGLT1 compared to that of GLUT1 and GLUT3 in 
differentiated Caco-2 cells (Sun et al., 2002, Landowski et al., 2004, Dihal et al., 
2007, Hayeshi et al., 2008). 
 
We showed that the gene expression of GLUT1 was not altered by any of the 
concentrations of berry extract tested, whereas that of GLUT3 was reduced only at 
the highest concentration of 0.125% (w/v) (see Figure 21, page 103).  GLUT3 is a 
glucose transporter with a particular high substrate affinity, as reflected by the 
distinct kinetics compared to GLUT2 (Km values for deoxyglucose transport of 
around 1.4 and 11.2 mM, respectively) (Arbuckle et al., 1996).  The high abundance 
and affinity of GLUT3 could therefore mask any changes in glucose uptake 
attributed to perturbations in the expression of GLUT2 or SGLT1.  Furthermore, the 
rate of carrier-mediated glucose transport into the enterocytes also depends on the 
level of glucose transporters located at the apical membrane.  The distribution of 
glucose transporters between intracellular compartments and the apical membrane is 
tightly regulated post-translationally (Kipp et al., 2003, Kellett and Brot-Laroche, 
2005). Therefore, glucose uptake might not directly reflect the changes in the gene 




4.4 Global miRNA expression in response to berry extract 
in the intestinal Caco-2 cells 
As mentioned in the Introduction, miRNAs are believed to control the expression of 
over half to two-thirds of all protein-coding genes (Fabian et al., 2010) and thus have 
arisen to become important cellular molecules that are involved in numerous integral 
biological processes. In fact, they have been implicated in the control of glucose 
homeostasis and the pathogenesis of diabetes (Tang et al., 2008, Frost and Olson, 
2011). 
 
Microarrays offer a convenient tool for miRNA expression profiling to quickly and 
simultaneously determine aberration in the relative expression levels of large 
numbers of miRNAs in normal cellular and pathophysiological processes.  However, 
due to the short length of miRNAs (~22 nucleotides) and the high similarity in 
sequences between different miRNA species, the sensitivity and specificity of such 
hybridisation-based profiling approach have faced technical and practical challenges. 
 
In light of these technical challenges, several studies have evaluated the reliability 
and reproducibility of the use of microarrays for miRNA expression measurements.  
Git et al. (2010) reported a high variability in the reproducibility of hybridisation and 
consistency of present/ absent calls between several miRNA microarray platforms.  
Comparisons between the performances of microarray and PCR (the latter widely 
regarded as the “gold standard” in the detection and quantitation of gene expression) 
showed generally good correlations (Ach et al., 2008, Git et al., 2010).  However, 
both of the abovementioned groups demonstrated that a small number of miRNAs 
showed particular poor correlations between the two approaches (Ach et al., 2008, 
Git et al., 2010).  A review on miRNA profiling methodologies by Pritchard et al. 
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(2012) warned that microarrays have a restricted linear range of quantification and 
poor specificity for miRNAs closely related in sequence. 
 
In the present study for this thesis, the qRT-PCR results validated only three out of 
the five selected miRNAs, while the changes in the expression of let-7f and miR-
106b showed opposite directions in qRT-PCR and microarray (see Figure 27, page 
112).  This was likely attributed to the high similarity in the sequences between 
several miRNA species.  For example, let-7d and let-7f differ from let-7a by only 
one single nucleotide (all of which are encoded by a single genomic cluster on 
chromosome 13) (see Figure 43). 
 
 
Figure 43. Sequences of the miRNAs, let-7a, let-7d and let-7f 
Sequences of the let-7 family showed high similarity.  Differences in the nucleotide 
are highlighted in grey.  miRNA sequences were obtained from the miRNA database, 
miRBase (http://www.mirbase.org/). 
 
We reported an up-regulation of the miRNA let-7a in Caco-2 cells upon treatment 
with berry extract.  Numerous studies have demonstrated the important role of the 
let-7 miRNA family in growth and development and have shown that the aberration 
of let-7a expression is implicated in the development of cancers (Johnson et al., 
2005, Akao et al., 2006, Johnson et al., 2007, He et al., 2009, Yang et al., 2011).  
More recently, it was revealed that let-7 miRNAs are also involved in glucose 
metabolism and insulin sensitivity (Frost and Olson, 2011, Zhu et al., 2011).  Using 
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the miRNA target prediction algorithm (TargetScanHuman version 6.2; 
http://www.targetscan.org/), we found that let-7a is predicted to target the mRNA of 
GLUT2.  Our findings proposed a role of let-7a in the down-regulation of GLUT2 
gene expression by berry extract but further studies using miRNA transfection 
techniques will be required to substantiate this. 
 
4.5 Effects of berry extract on glucose transport in C2C12 
myotubes 
The use of natural foods and herbal medicines as an alternative to pharmacological 
agents for therapies of diabetes has recently attracted much attention.  Specifically, 
there is a large body of literature that have reported modulatory effects of 
polyphenols on glucose transport in skeletal muscles, the principal site of 
postprandial glucose disposal. 
 
In cultured muscle cells, polyphenol-rich extracts of bitter melon (Momordica 
charantia) or root of Indian shot (Canna indica L.) have been shown to stimulate 
glucose uptake (Purintrapiban et al., 2006, Kumar et al., 2009).  The increase in 
glucose uptake induced by bitter melon extracts was in parallel with an up-regulation 
of GLUT4 expression that required de novo protein synthesis (Kumar et al., 2009).  
On the other hand, extracts of root of Indian shot was demonstrated to enhance the de 
novo synthesis of GLUT1 protein, as well as to promote the levels of GLUT1 and 
GLUT4 located at the plasma membrane (Purintrapiban et al., 2006). 
 
In obese diabetic ob/ob mice, treatment with the ubiquitous flavonoid quercetin 
improved hyperglycemia and insulin resistance (Anhe et al., 2012).  These effects 
were at least in part due to an increase in GLUT4 expression in muscle (Anhe et al., 
2012).  Similar improvements in plasma glucose and glucose tolerance was also 
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observed in ob/ob mice fed with a citrus flavonoid, nobiletin (Lee et al., 2010b).  
However, in the latter study, an up-regulation of GLUT1 expression and an increase 
in the level of GLUT4 proteins on the plasma membrane in muscle were observed 
(Lee et al., 2010b). 
 
Tea extracts have also been shown to possess anti-diabetic effects in mice fed with 
high-fat or high-fructose diets (Cao et al., 2007, Nishiumi et al., 2010), both of which 
can induce hyperglycemia and insulin resistance (Luo et al., 1998).  In both models, 
restoration of the diets-induced reduction of GLUT4 expression in muscles was 
observed (Cao et al., 2007, Nishiumi et al., 2010). 
 
In the present study, the dose-response investigation of berry extract on gene 
expression of glucose transporter in C2C12 muscle cells demonstrated no changes in 
GLUT4 mRNA levels across all concentrations tested.  In contrast, while the lowest 
dose of 0.008% (w/v) suppressed GLUT1 expression, the highest dose (0.125% 
(w/v)) increased it (see Figure 35, page 120). 
 
Muscle is the insulin-sensitive tissue responsible for the majority of insulin-mediated 
glucose disposal.  It was estimated that glucose uptake into skeletal muscles 
accounted for only approximately 20% of whole body glucose uptake in the basal 
state (Baron et al., 1988).  However, during hyperinsulinemia, insulin-mediated 
glucose uptake in skeletal muscle represented 75% and 95% of whole body glucose 
disposal, at euglycemia and hyperglycemia, respectively (Baron et al., 1988).  Thus, 
defects of glucose uptake into muscle in response to insulin action represent a 




In an attempt to evaluate the effects of berry extract on glucose uptake in muscle 
cells under insulin-stimulated conditions, we chronically incubated differentiating 
C2C12 cells with 100 nM insulin, starting from 3 days before and during exposure to 
berry extract.  Chronic exposure of cultured muscle cells to insulin has been shown 
to lead to the development of insulin resistance (Kumar and Dey, 2003).  This occurs 
through prolonged insulin-induced stimulation of JNK and PI3K pathways leading to 
phosphorylation of IRS-1 at serine
318
 (Mussig et al., 2005).  Serine
318
 
phosphorylation of IRS-1 has been found to be associated with a reduction of 
IR/IRS-1 binding and IRS-1 tyrosine phosphorylation (Pederson et al., 2001).  It also 
induced proteosomal degradation of IRS-1 and a reduction in the acute insulin-
elicited translocation of GLUT4 (Sun et al., 1999, Huang et al., 2002).  Altogether, 
these changes in IRS-1 and GLUT4 lead to an impaired insulin signalling.  
 
We showed that in C2C12 myotubes, chronic incubation with insulin alone induced a 
striking 2.7-fold up-regulation of the gene expression of GLUT4.  Conversely, a 22% 
down-regulation in the gene expression of GLUT1 was observed (P= 0.005, 
Student’s t-test; not significant in one-way ANOVA) (see Figure 37, page 122).  
These changes were reflected at the functional level, as glucose uptake was only 
stimulated by acute exposure (30 minutes) to insulin in C2C12 myotubes pre-treated 
with insulin (see Figure 38, page 124).  Our observations opposed previous findings 
by other groups mentioned above, i.e. chronic insulin exposure induced insulin 
resistance in cultured muscle cells.  Instead, 3-day insulin exposure in C2C12 
myotubes led to a development of insulin sensitivity. 
 
We do not know why this occurred but interestingly, in contrast to studies reporting 
development of insulin insensitivity in muscle cells chronically incubated with 
150 
 
insulin, others suggested that insulin promotes mitogenesis and myogenesis (Mandel 
and Pearson, 1974, Ewton and Florini, 1981, Sasaoka et al., 1994, Milasincic et al., 
1996).  This is in accordance with our observations that insulin pre-treatment 
promoted differentiation in C2C12 cells, determined from histological evidence of a 
more extensive development of multinucleated myotubes (see Figure 36, page 121).  
Insulin pre-treated cells also appeared to cause changes in intermediary metabolism 
(personal observations showed that the phenol red pH indicator in culture medium 
changed colour more rapidly, presumably due to higher rate of acidic metabolites 
production).  Furthermore, both RNA and protein yields were higher in insulin pre-
treated cells (data not shown). 
 
Given that our insulin pre-treatment regimen promoted differentiation of C2C12 cells 
and sensitised the myotubes to insulin action on glucose uptake, we showed that 
berry extract did not alter glucose uptake in insulin-sensitive C2C12 cells.  Although 
berry extract elicited a 2.4-fold increase in the mRNA level GLUT1 in insulin pre-
treated C2C12 cells, the basal glucose uptake did not alter following berry extract 
treatment.  Berry extract did not have any effects on insulin-mediated glucose 
uptake. 
 
4.5.1 Possible involvement of signalling pathways in the regulation 
of glucose uptake in C2C12 myotubes 
In our studies, we aimed to evaluate the chronic effects of berry extract on glucose 
uptake in C2C12 muscle cells via the regulation of glucose transporter gene 
expression.  Thus, our glucose uptake studies in C2C12 muscle cells were carried out 
in the absence of berry extract.  Furthermore, C2C12 cells were pre-incubated in 
berry extract-free buffer at room temperature for 15 minutes prior to the uptake 
experiments.  Under these conditions, where post-translational modifications such as 
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phosphorylation might have completely or partially lost, we found that berry extract 
had no effect on either basal or insulin-stimulated glucose uptake in C2C12 cells.  
However, in vitro and in vivo studies by other research groups have shown that 
various flavonoids and flavonoid-rich food extracts modified glucose uptake in 
skeletal muscle by modulating insulin-dependent or insulin-independent signalling 
pathways.  These studies will be discussed in the following section. 
 
4.5.1.1 The insulin signalling pathways in the C2C12 myotubes 
Intravenous injection of the flavonoid myricetin improved insulin sensitivity in high-
fructose chow-fed rats (Liu et al., 2007).  This was in part attributed to an increased 
basal as well as insulin-stimulated phosphorylation of IR, IRS-1 and AKT.  
Furthermore, myricetin treatment also improved the defective action of insulin on the 
translocation of glucose transporter 4 (GLUT4) in insulin-resistant soleus muscle 
(Liu et al., 2007). 
 
Kaempferol 3-neohesperidoside was demonstrated to have a stimulatory effect on 
glucose uptake in rat soleus muscle (Zanatta et al., 2008).  Insulin did not show a 
synergistic effect with the abovementioned flavonoid, while pre-treatment with 
inhibitors of PKC or PI3K blocked its stimulatory effect.  On the other hand, 
inhibitors of MEK or protein synthesis did not have any effect (Zanatta et al., 2008).  
These results suggested that kaempferol 3-neohesperidoside increases glucose uptake 
in rat soleus muscle, at least in part, via the PKC and PI3K pathways.  Moreover, the 
same research group recently showed that another glycoside of kaempferol, 
kaempferol 3,7-dirhamnoside, also stimulated glucose uptake in rat soleus muscle, 
and was completely blocked by inhibitors of insulin receptor tyrosine kinase, PI3K 
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and atypical PKC, as well as a microtubule-depolymerising agent that prevents 
GLUT4 translocation (Cazarolli et al., 2013). 
 
4.5.1.2 The AMPK pathway in the C2C12 myotubes 
In muscle cell models, either C2C12 or L6 myotubes, treatments with either the 
citrus flavonoids, naringenin and tangeretin (Zygmunt et al., 2010, Kim et al., 2012), 
a flavonoid-rich fermented blueberry juice (Tri et al., 2007), an ethanol extract of 
lingonberris, or its constituent polyphenols, the quercetin aglycone, quercetin-3-O-
glucoside or quercetin-3-O-galactoside (Eid et al., 2010), stimulated glucose uptake.  
The increase in glucose uptake was accompanied by increased phosphorylation of 
AMPK but not AKT, suggesting the involvement of the insulin-independent AMPK 




 obese and diabetic mice, supplementation of a bilberry extract rich in 
anthocyanins ameliorated plasma glucose level and restored insulin sensitivity 
(Takikawa et al., 2010). These changes were accompanied by increases in total 
AMPKα in white adipose tissue (WAT) and phosphorylation of AMPKα at Thr-172 
in WAT as well as skeletal muscle and liver.  Protein expression of GLUT4 was also 
found to be up-regulated (Takikawa et al., 2010). 
 
Our studies focused on the chronic effects of berry extract on glucose transporter 
expression in C2C12 muscle cells and demonstrated that berry extract did not elicit 
any effect on glucose uptake in C2C12 cells following 24-hour pre-treatment (see 
Figure 38, page 124).  Based on the studies discussed above, we postulated that 
berry extract might exert an acute effect on glucose transport in skeletal muscles by 
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inducing the translocation of GLUT4 transporters to the plasma membrane.  This 
might occur via modulations of insulin-dependent or insulin-independent signalling 
pathways.  However, time limitations for the project precluded us from further 
investigating the role of signalling pathways in the effect of berry flavonoids on 
glucose uptake in muscle.  Future works will be required to test these hypotheses.  
These include the examinations of GLUT4 subcellular locations and evaluations of 
the phosphorylation states (activities) of various molecules involved in insulin-
dependent or insulin-independent signalling pathways in response to berry extract. 
 
4.6 Global gene expression profiling of C2C12 myotubes in 
response to berry extract 
Our microarray data demonstrated that berry extract at 0.125% (w/v) triggered 
differential expression of genes involved in multiple cellular functions.  In the 
following discussion, I will focus on the genes implicated in glutathione metabolism, 
transcriptional regulation, nucleic acid binding/ processing, membrane transport and 
extracellular structure/ cytoskeleton.   
 
4.6.1 Glutathione metabolism 
Glutathione-S-transferases (GSTs) are a family of phase II xenobiotic-metabolising 
enzymes that modify xenobiotic compounds allowing their subsequent excretion 
(Douglas, 2006).  Their ability to detoxify xenobiotics gives rise to their pivotal role 
in protecting cells against oxidative stress. 
 
Numerous studies have reported induction of the expressions or activities of GSTs by 
flavonoids (Moon et al., 2006).  For example, oral feeding of flavonoid-rich green tea 
leaves to rats resulted in a significant increase in the activities of GST in the liver as 
compared to the control group (Lin et al., 1998), whereas bilberry anthocyanins up-
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regulated the expression of GST-pi in cultured human retinal pigment epithelial cells 
(Milbury et al., 2007).  Nevertheless, other groups also demonstrated an inhibition of 
GST activity by flavonoids such as quercetin and kaempferol (Sahu and Gray, 1996, 
Van Zanden et al., 2004).  Our microarray data showed that berry extract induced an 
up-regulation of a handful of different GST classes.  These include the GST-alpha 1 
to 4 (GSTA1-4) and GST-mu 1 (GSTM1) from the cytosolic superfamily, and two 
microsomal isoforms (MGST1 and 2).  The MAS5.0 algorithm also identified an up-
regulation for three more isoforms, namely GST-omega 1 (GSTO1), GST-pi 2 
(GSTP2) and microsomal GST 3 (MGST3) (fold changes are 1.7, 1.6 and 1.3, 
respectively), although the changes did not reach the 2-fold threshold. 
 
The activity of GSTs depends on a steady supply of GSH within the cell.  In this 
regard, we also revealed an up-regulation of two enzymes that regulate the cellular 
level of GSH.  These are glutamate cysteine ligase (GCL), the first enzyme in the 
GSH biosynthesis pathway, and glucose-6-phosphate dehydrogenase (G6PD), a 
cytosolic enzyme that maintains the level of the co-enzyme nicotinamide adenine 
dinucleotide phosphate (NADPH), which in turn maintains the level of GSH. 
 
Perturbations in the GSH-dependent xenobiotic metabolism have been demonstrated 
in diabetes (Raza et al., 2000, Fujita et al., 2001, Yalin et al., 2007).  There is also 
clear evidence that defects in GSH metabolism is implicated in the development of 
cancers (Schipper et al., 1997, Locigno and Castronovo, 2001).  Our finding provides 
preliminary evidence that flavonoid-rich berry extract may increase cellular 
antioxidant defence and may serve as a dietary strategy for the prevention and 
treatment of diabetes and cancers. 
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4.6.2 Transcriptional regulation 
Thirty six genes differentially expressed as a result of berry extract treatment were 
grouped into the category of transcriptional regulation.  This implies that berry 
extract elicited a wide range of cellular changes through the regulation of genes at 
the transcriptional level. 
 
4.6.2.1 CCAAT/ enhancer-binding proteins 
Among the 36 genes involved in transcriptional regulation, the CCAAT/ enhancer-
binding proteins (C/EBPs) are of particular interest due to their regulation by 
antioxidants.  Three members from this family, i.e. the –alpha, -beta and –delta 
isoforms, were up-regulated by berry extract.  The C/EBP-beta transcription factor 
has been shown to mediate the modulation of gene expression of antioxidant 
enzymes by flavonoids such as genistein (Wiegand et al., 2009).  Interestingly, the 
C/EBP response elements have been found on the regulatory promoter regions of a 
few phase II enzymes (Kang et al., 2003).  These include glutamate cysteine ligase 
(GCL) and GST-alpha (GSTA) (mentioned above in the Glutathione metabolism 
section), as well as NAD(P)H dehydrogenase, quinone 1 (NQO-1) and heme 
oxygenase 1 (HMOX-1) (Kang et al., 2003).  All of these phase II enzymes were up-
regulated at the mRNA level by berry extract.  Therefore, C/EBPs may serve as 
common transcriptional factors that co-ordinate the induction of antioxidant genes by 
berry extract. 
 
4.6.2.2 p53 tumour suppressor protein and related genes 
The p53 protein plays an important role in the regulation of cell cycle and functions 
as a tumour suppressor (Braithwaite et al., 1987, Finlay et al., 1989).  Studies have 
demonstrated that flavonoids can induce G2/M cell cycle arrest and apoptosis in both 
non-tumour and cancer cell lines via a p53-dependent mechanism (Plaumann et al., 
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1996, Kook et al., 2007, Vidya Priyadarsini et al., 2010).  In this study, berry extract 
elevated the gene expression of p53.  In addition to the changes in the expression of 
p53 itself, we also observed an up-regulation of activating transcription factor 3 
(ATF3), which encodes for a protein involved in stabilisation of p53 (Yan and Boyd, 
2006).  ATF3 and fos-like antigen 2 (FOSL2), the latter which was also up-regulated 
following berry treatment, are components of the heterodimeric transcription factor, 
activator protein 1 (AP-1) (Hai and Curran, 1991).  It is proposed that there is a 
functional link between AP-1 and p53 as both molecules are involved in the control 
of cell survival in response to extracellular stimuli (Kirch et al., 1999, Ameyar et al., 
2003, Hess et al., 2004). The authors suggested that interactions between these two 
proteins play an essential role in cell fate decisions (Kirch et al., 1999, Ameyar et al., 
2003, Hess et al., 2004). 
 
Altogether, the changes in the expression of p53 and p53-related genes showed that 
berry extract seemed to favour an activation of the p53 pathway, which would likely 
initiate cellular changes that ultimately lead to cell cycle arrest or cell death.  
However, it is worth mentioning that p53 is also subjected to complex regulation by 
undergoing numerous post-translational modifications such as phosphorylation and 
ubiquitination (Laptenko and Prives, 2006). 
 
4.6.3 Nucleic acid binding/ processing 
Remarkably, berry extract elicited a down-regulation of the expression of all genes 
involved in nucleic acid binding/ processing, except one, namely the RNA binding 




4.6.3.1 RNA binding motif proteins 
RNA binding motif proteins (RBPs) are a large family of proteins that associate with 
RNAs to form ribonucleoprotein (RNP) complexes.  Formation of RNP complexes 
allows extensive post-transcriptional regulation of gene expression by alternative 
splicing, RNA modification, polyadenylation, mRNA localisation, etc (Glisovic et 
al., 2008).  Our data showed down-regulation of 8 genes from this family but up-
regulation of RBPMS in cells treated with berry extract.  Since RBPs possess 
different modes of action and diverse RNA-sequence specificities and affinities, the 
down-regulation of multiple RBPs by berry extract might represent an inhibition of 
the processing of a variety of pre-mRNAs/ mRNAs. 
 
4.6.4 Membrane transport 
Differentially expressed genes involved in membrane transport include four genes 
encoding ATP-binding cassette transporters. 
 
4.6.4.1 ATP-binding cassette transporters 
Among the four ATP-binding cassette (ABC) transporters differentially expressed by 
berry extract, sub-family B (MDR/TAP) member 1A (ABCB1A) and sub-family C 
(CFTR/MRP) member 4 (ABCC4) were up-regulated, whilst sub-family A (ABC1) 
member 8A (ABCA8A) and sub-family C (CFTR/MRP) member 9 (ABCC9) were 
down-regulated.  ABCB1 is a transmembrane active efflux pump for xenobiotic 
compounds with a broad substrate specificity (Leschziner et al., 2006).  The gene 
sequence of ABCB1 contains putative binding sites for stress-induced transcription 
factors, such as AP-1 and C/EBPs (Sukhai and Piquette-Miller, 2000).  ABCC4 is 
implicated in pumping a wide variety of endogenous and xenobiotic organic anionic 
compounds out of the cell (Russel et al., 2008).  On the other hand, ABCA8 
transports certain lipophilic drugs (Tsuruoka et al., 2002) and ABCC9 is an ATP-
158 
 
sensitive potassium channel (Dean et al., 2001).  These findings indicated that berry 
extract specifically enhanced the expression of ABC transporters that remove 
xenobiotics from cells. 
 
4.6.5 Extracellular structure/ cytoskeleton 
Following exposure to berry extract, 14 genes involved in the regulation of 
extracellular/cytoskeleton were differentially expressed in C2C12 myotubes.  In 
particular, four genes from a sub-family of leucine-rich repeats (LRRs), namely the 
small leucine-rich proteoglycans (SLRPs), are implicated in modulating extracellular 
matrix via regulation of collagen fibrillogenesis. 
 
4.6.5.1 Small leucine-rich proteoglycans and collagen 
Among the differentially expressed genes encoding LRRs, 4 of them are sub-
characterised as SLRPs.  These genes are asporin, fibromodulin, lumican and 
osteomodulin.  Use of the MAS5.0 algorithm further identified a 1.7-fold down-
regulation of the gene of another SLRP, namely decorin. 
 
Various SLRPs can bind fibrillar collagens (Vogel et al., 1984, Hedbom and 
Heinegård, 1993, Rada et al., 1993).  The interactions between SLRPs and collagens 
play an important role in proper collagen fibril assembly and formation of a 
functional extracellular matrix (ECM) (Kalamajski and Oldberg, 2010).  In skeletal 
muscle, collagens provide external structural support for muscle cells, where they are 
found predominantly in three structures, namely epimysium, perimysium and 
endomysium (Borg and Caulfield, 1980).  However, over-accumulation of collagen 





In addition to their role as structural proteins, SLRPs have also been identified as 
modulators of signalling pathways, which include those mediated by transforming 
growth factor-beta (TGF-beta) (Hildebrand et al., 1994, Droguett et al., 2006), 
insulin-like growth factor-1 (IGF-1) (Schönherr et al., 2005) and Toll-like receptor 
(Wu et al., 2007). 
 
We reported here that exposure of C2C12 myotubes to berry extract negatively 
modulated the expression of not only several SLRPs, but also 7 genes that encode 
different types of collagen.  These changes suggested there is some potency of berry 
extract in the regulation of collagen fibrillogenesis as well as in multiple signalling 
pathways that are involved in muscle cell growth and repair. 
 
4.7 Effects of ethanol on gene expression of glucose 
transporters in C2C12 myotubes 
Spolarics et al. (1994) demonstrated that acute alcohol administration (3 hours) to 
rats markedly attenuated basal as well as insulin-stimulated glucose use in skeletal 
muscles.  We found, in the present study, that incubation of C2C12 myotubes with 
ethanol at 30-300 mM for 24 hours triggered significant down-regulation of the gene 
expression of the insulin-responsive GLUT4 transporter (see Figure 39, page 125).  
This finding suggested a possible mechanism by which alcohol inhibits glucose 
utilisation in the skeletal muscles.  However, in terms of muscle or any other tissues, 
it is difficult to ascribe mechanisms to a particular pathology if only one or two genes 
are examined.  Ideally, several genes or the entire gene network should be 




4.8 Global gene expression profiling of C2C12 myotubes in 
response to ethanol 
Chronic alcoholism has been shown to cause muscle damage (Song and Rubin, 1972, 
Rubin et al., 1976).  In the C2C12 muscle cell model, we demonstrated that 24-hour 
ethanol treatment induced changes in the expression of genes involved in multiple 
cellular functions.  These include insulin signalling/ glucose metabolism, muscle 
metabolism and contraction, cell cycle and protein synthesis. 
 
4.8.1 Insulin signalling/ glucose metabolism 
4.8.1.1 PI3K-mediated signalling pathway 
Phosphatidylinositide 3-kinase (PI3K) is a key component of the insulin signalling 
pathway (Tsakiridis et al., 1995).  Downstream targets of the PI3K-mediated 
signalling pathway include the tre-2/USP6, BUB2, cdc16 domain family member 1 
(TBC1D1), a Rab GTPase-activating protein which regulates GLUT4 translocation 
(Roach et al., 2007, Peck et al., 2009).  Insulin receptor substrate-2 (IRS-2) 
represents one of the cytoplasmic signalling molecules that mediate signals between 
the transmembrane insulin receptor tyrosine kinase and its downstream effectors 
such as PI3K (Sun et al., 1995).  In the present study, the expressions of genes 
encoding the beta catalytic subunit of PI3K and TBC1D1 in C2C12 cells were both 
down-regulated by ethanol.  In contrast, a significant 30% up-regulation of the IRS-2 
expression was observed in our qRT-PCR validation (although it was not altered in 
the microarray, possibly due to its lower detection sensitivity).  Perturbations in the 
PI3K-mediated signalling have been reported in skeletal muscles exposed to ethanol 
(Qu et al., 2011, Nguyen et al., 2012).  Our data confirmed that ethanol altered the 
PI3K-dependent insulin signalling pathway in C2C12 myotubes.  The up-regulation 
of IRS2 might indicate a feedback mechanism in response to the defects in the 
downstream insulin signalling. 
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4.8.1.2 Insulin-like growth factor 
Insulin-like growth factor 1 (IGF-1) is known to promote both cell proliferation and 
differentiation in muscle (Florini et al., 1991, Coolican et al., 1997).  Chronic alcohol 
feeding to rats decreases muscle protein (i.e. a catabolic event) and IGF-1 levels in 
the circulation and skeletal muscle, with a concomitant increase in IGF binding 
protein 1 (Lang et al., 1998).  Resnicoff et al. (1993) also demonstrated that alcohol 
markedly inhibited auto-phosphorylation of IGF-1 receptor and IGF-1-mediated cell 
growth in adipocytes.  In contrast, increased IGF-1 mRNA expression occurred 
during stretch-induced muscle hypertrophy (i.e. an anabolic event) (Czerwinski et al., 
1994, Yang et al., 1997).  Intriguingly, we reported an up-regulation of the 
expression of IGF-1 in C2C12 myotubes upon ethanol treatment but a decline in 
IGF-binding protein 3 (IGFBP3), the latter which has been found to bind to IGF-1 
and inhibit IGF-1-stimulated protein synthesis in cardiomyocytes (Ito et al., 1993).  
IGF-1 is primarily produced in the liver but also in target tissues acting in a 
paracrine/ autocrine fashion (Zapf and Froesch, 1986).  The length of ethanol 
treatment (24 hours) in the present study was relatively short compared to chronic 
alcohol feeding in animal models (usually for several weeks).  Thus, the changes in 
the levels of IGF-1 and IGFBP3 we observed in this study might reflect an initial 
response of skeletal muscle, as an extra-hepatic tissue, to compensate for a general 
perturbation in IGF-1-mediated signalling. 
 
4.8.2 Muscle metabolism and contraction 
4.8.2.1 Myosin heavy chains 
Myosin heavy chains comprise the force-generating proteins in skeletal muscle.  Our 
microarray data showed that ethanol down-regulated genes expressing two myosin 
heavy chain (MyHC) isoforms, myosin heavy chain IIa (MyHC-IIa) fast-twitch 
(MYH2) and myosin heavy chain β (MyHC-β) cardiac muscle, slow-twitch (MYH7).  
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However, qRT-PCR validation only confirmed the down-regulation of MyHC-β, 
whereas the reduction of MyHC-IIa expression was not significant.  Our 
observations were consistent with the findings reported by Reilly et al. (2000).  
These authors demonstrated that in chronically ethanol-fed rats, only the MyHC-β 
isoform showed significant reduction at the mRNA level among all muscle MyHC 
types (Reilly et al., 2000).  This down-regulation was observed in both type I-
predominant soleus muscle and type II-predominant plantaris muscle (Reilly et al., 
2000).  Thus, our results appeared to resemble the in vivo ethanol-fed animal model 
in terms of changes in myosin heavy chains gene expression. 
 
4.8.2.2 Troponin and tropomyosin 
The expression of troponin I, cardiac 3 (TNNI3) and tropomyosin 1, alpha (TPM1A) 
were up-regulated in C2C12 myotubes exposed to ethanol as shown in the 
microarray.  However, the change of TNNI3 did not reach statistical significance in 
the qRT-PCR validation.  In fact, the signal intensities from the probes detecting 
TNNI3 were low.  This is consistent with the findings that this troponin isoform is 
not expressed in fetal and healthy or diseased adult human skeletal muscle tissue 
(Bodor et al., 1995).  Tropomyosin is an elongated alpha-helical coiled-coil protein 
that regulates muscle contraction by modulating the actin-myosin interaction (Zot 
and Potter, 1987).  It does so by sterically hindering the myosin binding sites on actin 
filaments in the relaxed state.  On activation triggered by an elevated Ca
2+
 
concentration, tropomyosin undergoes a conformational change, exposing the 
binding sites on actin for myosin cross-bridge, which drives force generation and 
muscle contraction (Lehman et al., 2000, Gordon et al., 2001).  TPM1A, the fast-
twitch muscle isoform of tropomyosin, was up-regulated in response to ethanol in 
this study.  This change might be relevant to the prevalence of muscle weakness in 
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chronic alcoholic misusers, which was observed in approximately half of the patients 
with chronic alcoholic myopathy (Urbano-Marquez et al., 1995). 
 
4.8.2.3 Ankyrin repeat domain-containing protein 2 
Ankyrin repeat domain-containing protein 2 (ANKRD2) is a stretch-responsive 
protein present in striated muscles (Kemp et al., 2000).  Studies by Miller et al. 
(2003) suggested that ANKRD2 elicited stretch-induced responses by linking strain 
signals from titin, a myofibrillar elastic protein, to the induction of muscle-specific 
gene expression.  Later investigations, which demonstrated the ability of ANKRD2 
to translocate between the sarcomere and the nucleus in response to muscle damage, 
supported this notion (Kojic et al., 2004, Tsukamoto et al., 2008).  Interestingly, 
expression of ANKRD2 is associated with slow-twitch muscles (Tsukamoto et al., 
2002, Mckoy et al., 2005, Barash et al., 2007).  Stretching of fast-twitch muscles up-
regulated the expression of ANKRD2 and this change was in parallel with a 
transition towards a slow muscle phenotype (Mckoy et al., 2005).  ANKRD2 was 
also involved in the coordination of proliferation and apoptosis during muscle 
differentiation (Bean et al., 2008). 
 
In alcoholic myopathy, atrophy mainly occurs in the fast type II muscle fibres 
(Martin et al., 1985), whereas the slow type I fibres are relatively protected (Hanid et 
al., 1981, Slavin et al., 1983).  The up-regulation of ANKRD2, which is mainly 
associated with the slow type I muscle, in C2C12 myotubes in response to ethanol 
we reported here led us to speculate a possible role of ANKRD2 in protecting this 




4.8.3 Cell cycle 
Alcohol increased the expression of the proto-oncogene, c-MYC, in rat skeletal and 
cardiac muscles, especially in the type II ﬁbre-predominant muscles (Paice et al., 
2002, Nakahara et al., 2003).  The authors postulated it was a cellular adaptation to 
the stress provoked by ethanol (Paice et al., 2002, Nakahara et al., 2003).  c-MYC is 
a transcriptional activator that induces a number of positive regulators of cell cycle 
progression (Morrish et al., 2008), as well as genes involved in glucose metabolism, 
biogenesis of mitochondria, tRNAs, ribosomes and protein synthesis (Leon et al., 
2009).  This protein appears to function through hetero-dimerisation with the 
constitutively expressed bHLH-Zip protein, MAX (Ayer et al., 1993).  In this study, 
although ethanol did not cause any changes in the expression of c-MYC, we reported 
a decline in the expression of MAX dimerisation protein 1 (MXD1).  MXD1 
competes with c-MYC for binding MAX to form a hetero-dimeric complex and 
antagonises the transcriptional activity of c-MYC.  Thus, in our C2C12 cell model, 
alcohol appeared to promote the function of c-MYC by suppressing MXD1 
expression. 
 
Cyclin D1 (CCND1) is a nuclear protein required for cell cycle progression in G1 
(Baldin et al., 1993), whereas NIMA (never in mitosis gene a)-related expressed 
kinase 8 (NEK8) is implicated in G2/M progression (Bowers and Boylan, 2004).  In 
contrast, growth arrest-specific 1 (GAS1) plays a role in growth suppression by 
blocking entry to S phase (Del Sal et al., 1992).  The observations that the 
expressions of CCND1 and NEK8 were down-regulated and that of GAS1 was up-
regulated by ethanol suggested that ethanol is likely to induce cell cycle arrest.  
Intriguingly, c-MYC was found to suppress the expression of GAS1 (Gartel and 
Shchors, 2003).  Taken together, the changes in the expression of genes related to 
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cell cycle control suggested an intricate interplay of various molecules in muscle 
cells to determine cell fate in response to cytotoxic agents, as represented by ethanol 
here.  
 
4.8.4 Protein synthesis 
Cellular mRNA translation involves the binding of the 5′-end of mRNA to the pre-
initiation complex, eIF4F (Sonenberg and Dever, 2003).  The activity of eIF4F 
depends on the formation of an active heterotrimeric complex composed of the 
eukaryotic initiation factors, eIF4E, eIF4A and eIF4G (Clemens, 2001).  We showed 
that ethanol reduced the expression of eIF4E, the least abundant and presumably the 
most rate-limiting constituent of the active eIF4F complex in skeletal muscle (Lang 
et al., 2004).  In addition, the MAS5.0 algorithm also indicated a 20% down-
regulation of mTOR, a serine/ threonine protein kinase that phosphorylates eIF4E-
binding protein and liberates eIF4E to enter the eIF4F complex (Wang et al., 2000).  
It has been reported that chronic alcohol consumption led to reduced muscle protein 
synthesis (Pacy et al., 1991) and this inhibition was associated with reduced 
availability of eIF4E (Lang et al., 1999).  The changes we reported in this study were 
in agreement with the above mentioned studies, indicating that ethanol suppressed 
genes responsible for the initiation of protein synthesis.  Interestingly, stresses that 
reduced eIF4E availability were also found to regulate cell cycle progression, for 
example, by inhibiting the synthesis of cyclin D1, which was also reduced in our 
study (mentioned above in the “Cell cycle” section). 
 
4.8.5 Ethanol-treated C2C12 myotubes as an in vitro cell model of 
alcoholic myopathy 
Alcoholic myopathy is one of the most common alcohol-related diseases (Martin et 
al., 1985, Urbano-Marquez et al., 1989, Urbano-Marquez et al., 1995).  Animal 
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models have been developed to dissect out the pathogenic mechanisms of alcohol-
induced muscle diseases (Ward et al., 1987, Preedy and Peters, 1988b, Preedy and 
Peters, 1988a) but the use of cell culture models is scarce (Hong-Brown et al., 2001, 
Qu et al., 2011).  In this study, using the C2C12 muscle cell model, which expresses 
the alcohol dehydrogenase 1B mRNA, we evaluated the cellular consequences of 
ethanol treatment on muscle by measuring the changes in global gene expression 
with a microarray approach. 
 
We demonstrated that exposure of differentiated C2C12 myotubes to ethanol led to 
the differential expression of genes that encode proteins involved in the PI3K-
mediated insulin signalling pathway.  These are the PI3K beta catalytic subunit, 
TBC1D1 and IRS2.  Alterations in genes related to IGF-1 signalling and glucose 
metabolism were also detected.  These findings are in line with impairment in muscle 
glucose utilisation and development of insulin insensitivity after alcohol 
administration (Spolarics et al., 1994, Onishi et al., 2003, Wan et al., 2005). 
 
Furthermore, we showed that ethanol incubation suppressed the expression of 
eukaryotic initiation factors (eIFs) in C2C12 cells, potentially inhibiting initiation of 
translation and subsequently leading to reduced protein synthesis.  Considering that 
myofibrillar proteins are responsible for force generation and its regulation during 
muscle contraction, we reported changes in the mRNA levels of myofibrillar 
proteins, including myosin heavy chains, troponin and tropomyosin.  Several genes 
implicated in the regulation of muscle metabolism and differentiation, namely the 
ankyrin repeat domain-containing protein 2 (ANKRD2), carbonic anhydrase 
(CAR3), mitochondrial creatine kinase (CKMT) and four-and-a-half LIM protein 1 
(FHL1), were also differentially expressed in response to ethanol.  These findings 
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suggested that ethanol-treated C2C12 myotubes partly resembled skeletal muscles of 
alcohol-fed animals in terms of a reduction in protein synthesis and myofibrillar 
changes, at least at the mRNA level (Preedy and Peters, 1988a, Pacy et al., 1991, 
Reilly et al., 2000). 
 
Based on the alterations in global gene expression of C2C12 myotubes we observed 
in response to ethanol, we propose that ethanol-treated C2C12 myotubes might serve 
as a potential cell model for the studying of pathogenic mechanisms of alcoholic 
myopathy. 
 
4.9 Putative protective effects of berry extract against 
ethanol-induced cellular damage in skeletal muscle 
Chronic alcoholism can lead to tissue damage not only in the skeletal muscle, but 
also in cardiac muscle, liver, brain, etc. (Brewer and Perrett, 1971, Rubin et al., 1976, 
Lee et al., 1979).  Oxidative stress as a result of generation of reactive oxygen 
species and depletion of antioxidant enzymes, as well as acetaldehyde-protein adduct 
formation, during cellular ethanol metabolism, are known to contribute to the 
alcohol-induced cellular damage (Polavarapu et al., 1998, Meagher et al., 1999, 
Worrall et al., 2001).  Although alcohol consumption has been shown to increase the 
generation of lipid peroxidation products in both humans and animals (Polavarapu et 
al., 1998, Meagher et al., 1999), Pignatelli et al. (2006) showed that consumption of 
either red or white wine in healthy subjects suppressed oxidative stress, as evident in 
a reduction in urinary isoprostanes, compared to participants refrained from alcoholic 
beverages.  The authors suggested that the wine exerted its antioxidant effects in 
humans via its polyphenolic content (Pignatelli et al., 2006).  In fact, quercetin, the 
most abundant flavonoid in foods, has been found to reduce ethanol-induced 
oxidative stress and cytotoxicity in human hepatocytes (Yao et al., 2007). 
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In the present study, our microarray data provided strong evidence that the flavonoid-
rich berry extract is a potent inducer of the expression of genes involved in the 
cellular antioxidant defence system in C2C12 muscle cells.  The enhancement of 
endogenous antioxidant defence appeared to occur by an up-regulation of anti-
oxidative stress enzymes such as GSTs, NQO-1 and HMOX-1, as well as the ABC 
transporter, ABCB1 (also known as MDR1) (see Figure 44). These changes were in 
turn regulated by an elevated level of the antioxidant/stress-responsive transcription 
factors, C/EBPs and AP-1.  Thus, our findings indicate that ingestion of flavonoid-
rich berry extract might increase the capacity of cells to acquire an enhanced cellular 
antioxidant system.  This potentially ameliorates the oxidative stress provoked by 
ethanol consumption and protects body tissue against ethanol-induced damage.  
However, due to time limitations within the context of this thesis, it was not possible 
to test the above assumption by simultaneous exposure of C2C12 muscle cells to the 





Figure 44. A schematic representation of the mechanism by which berry 
flavonoids enhance cellular antioxidant defence 
1) Berry flavonoids activate signalling pathways that stimulate the expression of 
transcription factors, such as C/EBPs and AP-1; 2) binding of C/EBPs and/or AP-1 
to specific DNA sequences transactivates the transcription of target genes including 
the phase II enzymes, GSTs, NQO-1 and HMOX-1, as well as the phase III 
transporter, MDR1; 3) phase II enzymes facilitate the conjugation of xenobiotics and 
endobiotics to glutathione; 4) conjugated metabolites are then excreted out of the cell 





Using the intestinal epithelial Caco-2 cell model, we demonstrated that acute 
exposure to flavonoid-rich berry extract inhibited glucose uptake, whereas chronic 
incubation down-regulated the gene expression of GLUT2 and SGLT1.  The 
concomitant up-regulation of the miRNA, let-7a, following berry treatment, 
suggested that miRNA might be involved in the down-regulation of glucose 
transporter expression. 
 
However, in C2C12 myotubes, chronic incubation with berry extract did not have 
any effects on either basal or insulin-stimulated glucose uptake.  These findings 
suggested that the flavonoid-rich berry extract may be useful for regulating the rate 
of glucose absorption from the diet; however, it is less effective in modulating 
peripheral glucose transport. 
 
Microarray studies showed that ethanol altered genes involved in multiple cellular 
functions in C2C12 muscle cells, including insulin signalling, muscle contraction and 
protein synthesis.  These alterations are in line with cellular changes that occur in 
alcoholic myopathy.  Thus, we proposed that ethanol-treated C2C12 myotubes might 
act as a cell model for alcoholic myopathy. 
 
Microarray studies also revealed that flavonoid-rich berry extract enhanced the 
endogenous antioxidant defence system in C2C12 myotubes.  This occurred via up-
regulation of oxidative stress defence enzymes such as GSTs, NQO-1 and HMOX-1, 
which were in turn regulated by the antioxidant-responsive transcription factors, 
C/EBPs and AP-1.  Thus, we postulated that berry extract might be beneficial to 




6 Future investigations 
Based on the studies performed and presented in this thesis, a few further 
investigations are proposed to substantiate our initial findings and to take the work 
into a forward trajectory, as discussed in the following section.  Rather than 
providing lengthy text on all areas, a more detailed discourse is provided for the 
miRNA transfection studies and alcohol studies. 
 
6.1 Identification of chemical constituents of berry extract 
The OptiBerry
®
 berry extract used in the present study was a commercialised 
flavonoid-rich extract of wild blueberry, strawberry, cranberry, wild bilberry, 
elderberry and raspberry.  The analysis report given by the manufacturer provided 
limited information on its phytochemical components- it only specifies the 
approximate content of a few anthocyanidins, namely cyanidin, delphinidin, 
malvidin and petunidin. 
 
However, in the literature, a much wider range of polyphenolic components has been 
identified and characterised in the abovementioned berries.  These include flavonols, 
e.g. quercetin, myricetin, kaempferol; and phenolic acids, e.g. ellagic acid, p-
coumaric acid and caffeic acid (Zheng et al., 2007, Latti et al., 2010, Gavrilova et al., 
2011, Vrhovsek et al., 2012).  Since these polyphenolic compounds also have 
modulatory effects on glucose uptake, it would be useful to perform an extensive 
phytochemical profiling of the commercial OptiBerry
®
 berry extract.  This can be 
achieved by carrying out high performance liquid chromatography (HPLC) or 




6.2 Regulation of GLUT2 expression by let-7a miRNA 
In our Caco-2 studies, we reported an up-regulation of the miRNA, let-7a, along with 
a down-regulation of GLUT2 and SGLT1 expression in response to chronic 
treatment with berry extract (16 hours).  Bioinformatics analysis showed that the 3’-
untranslated regulatory region of GLUT2 mRNA is a predicted target of let-7a.  This 
suggested a possible role for let-7a as a negative post-transcriptional regulator of 
GLUT2 expression.  Further studies using miRNA transfection techniques will be 
required to test this hypothesis. 
 
Briefly, expression of GLUT2 mRNA will be measured in two experimental 
conditions with or without berry extract, as described below: 
1) Transfection of let-7a miRNA precursor; 
2) Transfection of anti-let-7a oligonucleotide that blocks the binding activity of 
let-7a. 
 
In addition, to determine whether let-7a regulates GLUT2 expression through the 
predicted let-7a binding site on the 3’-UTR of GLUT2, luciferase activity will also 
be measured in the following conditions, with or without berry extract: 
1) Co-transfection of let-7a precursor and the predicted let-7a binding site on 
the 3’-UTR of GLUT2, cloned upstream of a luciferase reporter plasmid; 
2) Co-transfection of let-7a precursor and a mutated let-7a binding site on the 
3’-UTR of GLUT2, cloned upstream of a luciferase reporter plasmid. 
 
6.3 Involvement of signalling pathways in the acute 
regulation of glucose uptake in muscle by berry extract 
In C2C12 cells, berry extract did not exert any effects on glucose transport at the 
transcriptional level after chronic pre-incubation (24 hours).  However, it is worth 
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noting that glucose transport in muscle is also under intricate and rapid regulation at 
the translational as well as post-translational levels.  This is evident in the 
observations that insulin and muscle contraction can stimulate glucose uptake within 
minutes (Lund et al., 1995, Sun et al., 2010). Therefore, future work will include 
investigations to identify whether berry extract exert acute effects on glucose uptake 
and to elucidate the putative involvement of signalling pathways in the acute 
regulation of glucose uptake in muscle.  Translocation of glucose transporters in 
response to berry extract treatment should also be studied. 
 
6.4 Validation of ethanol-induced cellular changes in 
C2C12 muscle cells 
We characterised the changes in global gene expression in C2C12 myotubes in 
response to ethanol.  Alterations in the expression of genes involved in insulin 
signalling, muscle contraction and protein synthesis were observed.  These changes 
were generally in agreement with in vivo findings reported in alcoholic myopathy or 
its corresponding animal models.  However, further investigations are needed to 
verify the cellular changes at the protein and functional levels.  These include the 
measurements of specific myosin heavy chain proteins and the activities of kinases 
along the PI3K-mediated insulin signalling cascade. 
 
6.5 Putative protective effects of berry extract against 
ethanol-induced cellular damage in muscle 
In the microarray studies, we reported the changes in global gene expression in 
C2C12 myotubes in response to berry extract or ethanol.  Our results presented 
preliminary evidence that the flavonoid-rich berry extract increased the capacity of 
muscle cells to acquire an enhanced endogenous antioxidant defence system.  This 
occurred in part by elevating the levels of antioxidant-responsive transcription 
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factors which in turn was associated with an increase in the expression of genes 
encoding oxidative stress defence enzymes, such as glutathione-s-transferase and 
heme oxygenase 1.  Since oxidative stress has been shown to contribute to the 
perturbations in cellular integrity as a consequence of ethanol ingestion (Mantle and 
Preedy, 1999, Wu and Cederbaum, 2003), berry extract might serve as a dietary 
strategy to ameliorate ethanol-induced cellular damage.  Due to time limitations, we 
were not able to test this aforementioned hypothesis directly.  It is proposed that 
future work to investigate the cellular consequences of simultaneous incubation with 
berry extract and ethanol in C2C12 muscle cells should be undertaken for this 
purpose.  Parameters to be measured will include cellular antioxidant status (changes 
in the level of lipid peroxidation products such as malondialdehyde, and changes in 
glutathione content and glutathione peroxidase activity) and formation of aldehyde-
protein adducts. 
 
For example, malondialdehyde-acetaldehyde adducts are produced when there is 
simultaneous oxidative stress and acetaldehyde formation (Niemelä et al., 2002).  
Hydroxyethyl radical adducts are produced as a consequence of free radical 
formation, albeit as a result of ethanol metabolism, i.e. hydroxyethyl radicals are 
only produced produced as a result of ethanol metabolism (Patel et al., 2005).  
Immunohistochemistry will determine their locations, while ELISA the relative 
abundance of the aforementioned protein adducts. 
 
However, the studies prosposed above do not ascribe changes to either ethanol or 
acetaldehyde.  In order to identify which analyte contributes to specific cellular 
changes, experiments can be carried out with the simultaneous addition of ethanol 
and 4-methylpyrazole.  4-methylpyrazole is an inhibitor of alcohol dehydrogenase 
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which blocks ethanol metabolism and diminishes the level of acetaldehyde.  Thus, 
observations may potentially be ascribed to ethanol per se rather than acetaldehyde.  
The addition of cyanamide, an inhibitor of aldehyde dehydrogenase, will increase 
acetaldehyde concentration.  Thus, the use of cyanamide will show if raising 
endogenous acetaldehyde will exacerbate any effects (Niemelä et al., 2002).  The use 
of acetaldehyde alone will also substantiate these findings, though acetaldehyde is 
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Table 26. List of up-regulated genes in C2C12 myotubes upon treatment with 
0.125% (w/v) berry extract 




1456718_at TMEM56 Transmembrane protein 56 6.0 64.00 
1450826_a_at SAA3 Serum amyloid A 3 5.0 32.00 
1423436_at GSTA3 Glutathione S-transferase, alpha 3 4.7 25.99 
1419209_at CXCL1 Chemokine (C-X-C motif) ligand 1 4.4 21.11 
1419728_at CXCL5 Chemokine (C-X-C motif) ligand 5 4.3 19.70 
1421040_a_at GSTA2 Glutathione S-transferase, alpha 2 (Yc2) 3.7 13.00 
1420380_at CCL2 Chemokine (C-C motif) ligand 2 3.6 12.13 
1451054_at ORM1 Orosomucoid 1 3.4 10.56 
1449824_at PRG4 Proteoglycan 4 (megakaryocyte 
stimulating factor, articular superficial 
zone protein) 
3.2 9.19 
1456225_x_at TRIB3 Tribbles homolog 3 (Drosophila) 3.0 8.00 
1427747_a_at LCN2 Lipocalin 2 2.9 7.46 
1443536_at SLC7A11 Solute carrier family 7 (cationic amino 
acid transporter, y+ system), member 11 
2.9 7.46 
1421001_a_at CAR6 Carbonic anhydrase 6 2.8 6.96 
1449195_s_at CXCL16 Chemokine (C-X-C motif) ligand 16 2.5 5.66 
1421041_s_at GSTA1 Glutathione S-transferase, alpha 1 (Ya) 2.5 5.66 
1418752_at ALDH3A1 Aldehyde dehydrogenase family 3, 
subfamily A1 
2.4 5.28 
1426243_at CTH Cystathionase (cystathionine gamma-
lyase) 
2.3 4.92 
1421471_at NPY1R Neuropeptide Y receptor Y1 2.3 4.92 
1417130_s_at ANGPTL4 Angiopoietin-like 4 2.2 4.59 
1421228_at CCL7 Chemokine (C-C motif) ligand 7 2.2 4.59 
1450882_s_at GPR137B G protein-coupled receptor 137B 2.1 4.29 
1450075_at POLH Polymerase (DNA directed), eta (RAD 
30 related) 
2.1 4.29 
1438488_at ESD Esterase D/formylglutathione hydrolase 2.0 4.00 
1458245_at SUSD1 Sushi domain containing 1 1.9 3.73 
1443870_at ABCC4 ATP-binding cassette, sub-family C 
(CFTR/MRP), member 4 
1.8 3.48 
1423233_at CEBPD CCAAT/enhancer binding protein 
(C/EBP), delta 
1.8 3.48 
1416368_at GSTA4 Glutathione S-transferase, alpha 4 1.8 3.48 
1448239_at HMOX1 Heme oxygenase (decycling) 1 1.8 3.48 
1448377_at SLPI Secretory leukocyte peptidase inhibitor 1.8 3.48 
1451006_at XDH Xanthine dehydrogenase 1.8 3.48 
1436990_s_at CHCHD10 Coiled-coil-helix-coiled-coil-helix 
domain containing 10 
1.7 3.25 




1448469_at NID1 Nidogen 1 1.7 3.25 
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1418666_at PTX3 Pentraxin related gene 1.7 3.25 
1441315_s_at SLC19A2 Solute carrier family 19 (thiamine 
transporter), member 2 
1.7 3.25 
1419456_at DCXR Dicarbonyl L-xylulose reductase 1.6 3.03 
1418627_at GCLM Glutamate-cysteine ligase, modifier 
subunit 
1.6 3.03 
1423627_at NQO1 NAD(P)H dehydrogenase, quinone 1 1.6 3.03 
1420664_s_at PROCR Protein C receptor, endothelial 1.6 3.03 
1417263_at PTGS2 Prostaglandin-endoperoxide synthase 2 1.6 3.03 
1424938_at STEAP1 Six transmembrane epithelial antigen of 
the prostate 1 
1.6 3.03 
1421058_at ADH7 Alcohol dehydrogenase 7 (class IV), mu 
or sigma polypeptide 
1.5 2.83 
1454822_x_at APCDD1 Adenomatosis polyposis coli down-
regulated 1 
1.5 2.83 
1434866_x_at CPT1A Carnitine palmitoyltransferase 1a, liver 1.5 2.83 
1419029_at ERO1L ERO1-like (S. Cerevisiae) 1.5 2.83 
1435748_at GDA Guanine deaminase 1.5 2.83 
1418248_at GLA Galactosidase, alpha 1.5 2.83 
1423706_a_at PGD Phosphogluconate dehydrogenase 1.5 2.83 
1419758_at ABCB1A ATP-binding cassette, sub-family B 
(MDR/TAP), member 1A 
1.4 2.64 
1427844_a_at CEBPB CCAAT/enhancer binding protein 
(C/EBP), beta 
1.4 2.64 
1427302_at ENPP3 Ectonucleotide 
pyrophosphatase/phosphodiesterase 3 
1.4 2.64 
1416416_x_at GSTM1 Glutathione S-transferase, mu 1 1.4 2.64 
1421034_a_at IL4RA Interleukin 4 receptor, alpha 1.4 2.64 
1418400_at LARP6 La ribonucleoprotein domain family, 
member 6 
1.4 2.64 
1434322_at MICALL2 MICAL-like 2 1.4 2.64 
1453924_a_at PTGFR Prostaglandin F receptor 1.4 2.64 
1455936_a_at RBPMS RNA binding protein gene with multiple 
splicing 
1.4 2.64 
1450387_s_at AK4 Adenylate kinase 4 1.3 2.46 
1452365_at CSGALNACT1 Chondroitin sulfate N-
acetylgalactosaminyltransferase 1 
1.3 2.46 
1423488_at MMD Monocyte to macrophage differentiation-
associated 
1.3 2.46 
1437250_at MREG Melanoregulin 1.3 2.46 
1456653_a_at MTHFD1L Methylenetetrahydrofolate 
dehydrogenase (NADP+ dependent) 1-
like 
1.3 2.46 
1450976_at NDRG1 N-myc downstream regulated gene 1 1.3 2.46 
1449005_at SLC16A3 Solute carrier family 16 (monocarboxylic 
acid transporters), member 3 
1.3 2.46 
1455899_x_at SOCS3 Suppressor of cytokine signaling 3 1.3 2.46 
1415997_at TXNIP Thioredoxin interacting protein 1.3 2.46 
1449363_at ATF3 Activating transcription factor 3 1.2 2.30 
1451386_at BLVRB Biliverdin reductase B (flavin reductase 
(NADPH)) 
1.2 2.30 
1417574_at CXCL12 Chemokine (C-X-C motif) ligand 12 1.2 2.30 
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1422438_at EPHX1 Epoxide hydrolase 1, microsomal 1.2 2.30 
1420654_a_at GBE1 Glucan (1,4-alpha-), branching enzyme 1 1.2 2.30 
1418949_at GDF15 Growth differentiation factor 15 1.2 2.30 
1421973_at GFRA1 Glial cell line derived neurotrophic factor 
family receptor alpha 1 
1.2 2.30 
1415897_a_at MGST1 Microsomal glutathione S-transferase 1 1.2 2.30 
1452592_at MGST2 Microsomal glutathione S-transferase 2 1.2 2.30 
1452620_at PCK2 Phosphoenolpyruvate carboxykinase 2 
(mitochondrial) 
1.2 2.30 
1434773_a_at SLC2A1 Solute carrier family 2 (facilitated 
glucose transporter), member 1 
1.2 2.30 
1450409_a_at SLC48A1 Solute carrier family 48 (heme 
transporter), member 1 
1.2 2.30 
1460243_at SPTLC2 Serine palmitoyltransferase, long chain 
base subunit 2 
1.2 2.30 
1417172_at UBE2L6 Ubiquitin-conjugating enzyme E2L 6 1.2 2.30 
1438165_x_at VAT1 Vesicle amine transport protein 1 
homolog (T californica) 
1.2 2.30 
1454617_at ARRDC3 Arrestin domain containing 3 1.1 2.14 
1426334_a_at BCL2L11 BCL2-like 11 (apoptosis facilitator) 1.1 2.14 
1451382_at CHAC1 Chac, cation transport regulator 1 1.1 2.14 
1426893_at FAM102A Family with sequence similarity 102, 
member A 
1.1 2.14 
1438953_at FIGF C-fos induced growth factor 1.1 2.14 
1437247_at FOSL2 Fos-like antigen 2 1.1 2.14 
1418364_a_at FTL1 Ferritin light chain 1 1.1 2.14 
1448354_at G6PDX Glucose-6-phosphate dehydrogenase X-
linked 
1.1 2.14 
1438009_at HIST1H2AP Histone cluster 1, h2ap 1.1 2.14 
1419647_a_at IER3 Immediate early response 3 1.1 2.14 
1450161_at IKBKG Inhibitor of kappab kinase gamma 1.1 2.14 
1420961_a_at IVNS1ABP Influenza virus NS1A binding protein 1.1 2.14 
1453304_s_at LY6E Lymphocyte antigen 6 complex, locus E 1.1 2.14 
1429274_at LYPD6B LY6/PLAUR domain containing 6B 1.1 2.14 
1418936_at MAFF V-maf musculoaponeurotic fibrosarcoma 
oncogene family, protein F (avian) 
1.1 2.14 
1417234_at MMP11 Matrix metallopeptidase 11 1.1 2.14 
1438157_s_at NFKBIA Nuclear factor of kappa light polypeptide 
gene enhancer in B cells inhibitor, alpha 
1.1 2.14 
1440263_at NRP Neural regeneration protein 1.1 2.14 
1427977_x_at OOG1 Oogenesin 1 1.1 2.14 
1439148_a_at PFKL Phosphofructokinase, liver, B-type 1.1 2.14 
1448318_at PLIN2 Perilipin 2 1.1 2.14 
1452226_at RCC2 Regulator of chromosome condensation 
2 
1.1 2.14 
1426792_s_at RUSC2 RUN and SH3 domain containing 2 1.1 2.14 
1415802_at SLC16A1 Solute carrier family 16 (monocarboxylic 
acid transporters), member 1 
1.1 2.14 
1417639_at SLC22A4 Solute carrier family 22 (organic cation 
transporter), member 4 
1.1 2.14 
1420641_a_at SQRDL Sulfide quinone reductase-like (yeast) 1.1 2.14 
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1416077_at ADM Adrenomedullin 1.0 2.00 
1437333_x_at ALDH18A1 Aldehyde dehydrogenase 18 family, 
member A1 
1.0 2.00 
1422573_at AMPD3 Adenosine monophosphate deaminase 3 1.0 2.00 
1433966_x_at ASNS Asparagine synthetase 1.0 2.00 
1425814_a_at CALCRL Calcitonin receptor-like 1.0 2.00 
1448205_at CCNB1 Cyclin B1 1.0 2.00 
1418982_at CEBPA CCAAT/enhancer binding protein 
(C/EBP), alpha 
1.0 2.00 
1434976_x_at EIF4EBP1 Eukaryotic translation initiation factor 4E 
binding protein 1 
1.0 2.00 
1427578_a_at EIF6 Eukaryotic translation initiation factor 6 1.0 2.00 
1426655_a_at FAM63A Family with sequence similarity 63, 
member A 
1.0 2.00 
1419486_at FOXC1 Forkhead box C1 1.0 2.00 
1438169_a_at FRMD4B FERM domain containing 4B 1.0 2.00 
1419080_at GDNF Glial cell line derived neurotrophic factor 1.0 2.00 
1448183_a_at HIF1A Hypoxia inducible factor 1, alpha subunit 1.0 2.00 
1421992_a_at IGFBP4 Insulin-like growth factor binding protein 
4 
1.0 2.00 
1428948_at KCNMA1 Potassium large conductance calcium-
activated channel, subfamily M, alpha 
member 1 
1.0 2.00 
1438908_at MAP3K12 Mitogen-activated protein kinase kinase 
kinase 12 
1.0 2.00 
1428942_at MT2 Metallothionein 2 1.0 2.00 
1449043_at NAGA N-acetyl galactosaminidase, alpha 1.0 2.00 
1437621_x_at PHGDH 3-phosphoglycerate dehydrogenase 1.0 2.00 
1456003_a_at SLC1A4 Solute carrier family 1 (glutamate/neutral 
amino acid transporter), member 4 
1.0 2.00 
1425364_a_at SLC3A2 Solute carrier family 3 (activators of 
dibasic and neutral amino acid transport), 
member 2 
1.0 2.00 
1417695_a_at SOAT1 Sterol O-acyltransferase 1 1.0 2.00 
1448123_s_at TGFBI Transforming growth factor, beta 
induced 
1.0 2.00 
1422587_at TMEM45A Transmembrane protein 45a 1.0 2.00 
1426538_a_at TRP53 Transformation related protein 53 1.0 2.00 
1416926_at TRP53INP1 Transformation related protein 53 
inducible nuclear protein 1 
1.0 2.00 
1426472_at ZFP52 Zinc finger protein 52 1.0 2.00 






Table 27. List of down-regulated genes in C2C12 myotubes upon treatment with 
0.125% (w/v) berry extract 




1437433_at B3GALT2 UDP-Gal:betaglcnac beta 1,3-
galactosyltransferase, polypeptide 2 
-5.6 0.02 
1424963_at RP1 Retinitis pigmentosa 1 (human) -4.9 0.03 
1437752_at LIN28A Lin-28 homolog A (C. Elegans) -4.6 0.04 
1425298_a_at NAIP1 NLR family, apoptosis inhibitory protein 
1 
-3.7 0.08 
1456629_at KANK3 KN motif and ankyrin repeat domains 3 -3.4 0.09 
1455086_at UCHL5 Ubiquitin carboxyl-terminal esterase L5 -3.4 0.09 
1422051_a_at GABBR1 Gamma-aminobutyric acid (GABA) B 
receptor, 1 
-3.3 0.10 
1418471_at PGF Placental growth factor -3.3 0.10 
1437602_at FAM71B Family with sequence similarity 71, 
member B 
-3.1 0.12 
1438700_at FNBP4 Formin binding protein 4 -3.1 0.12 
1457922_at UNG Uracil DNA glycosylase -3.0 0.13 
1418745_at OMD Osteomodulin -2.9 0.13 
1426851_a_at NOV Nephroblastoma overexpressed gene -2.8 0.14 
1448254_at PTN Pleiotrophin -2.8 0.14 
1452195_s_at SFI1 Sfi1 homolog, spindle assembly 
associated (yeast) 
-2.8 0.14 
1448421_s_at ASPN Asporin -2.6 0.16 
1436932_at GRHL3 Grainyhead-like 3 (Drosophila) -2.6 0.16 
1421589_at KRT31 Keratin 31 -2.6 0.16 
1425712_at BC025446 Cdna sequence BC025446 -2.5 0.18 
1430370_at EPRS Glutamyl-prolyl-trna synthetase -2.5 0.18 
1456344_at TNC Tenascin C -2.5 0.18 
1450004_at TSLP Thymic stromal lymphopoietin -2.5 0.18 
1427496_at CEP152 Centrosomal protein 152 -2.4 0.19 
1456145_at DLEU2 Deleted in lymphocytic leukemia, 2 -2.4 0.19 
1418152_at HMGN5 High-mobility group nucleosome binding 
domain 5 
-2.4 0.19 
1452465_at MYH1 Myosin, heavy polypeptide 1, skeletal 
muscle, adult 
-2.3 0.20 
1450961_a_at TCEAL3 Transcription elongation factor A (SII)-
like 3 
-2.3 0.20 
1426142_a_at TRDN Triadin -2.3 0.20 
1441161_at B230216G23RIK RIKEN cdna B230216G23 gene -2.2 0.22 
1423607_at LUM Lumican -2.2 0.22 
1425087_at 2310003F16RIK RIKEN cdna 2310003F16 gene -2.1 0.23 
1428083_at NEAT1 Nuclear paraspeckle assembly transcript 
1 (non-protein coding) 
-2.1 0.23 
1455087_at D7ERTD715E DNA segment, Chr 7, ERATO Doi 715, 
expressed 
-2.0 0.25 
1436222_at GAS5 Growth arrest specific 5 -2.0 0.25 
1427417_at SCML4 Sex comb on midleg-like 4 (Drosophila) -2.0 0.25 
1426633_s_at KCTD14 Potassium channel tetramerisation 
domain containing 14 
-1.9 0.27 
1438080_at MRPL11 Mitochondrial ribosomal protein L11 -1.9 0.27 
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1427026_at MYH4 Myosin, heavy polypeptide 4, skeletal 
muscle 
-1.9 0.27 
1438193_at NRXN3 Neurexin III -1.9 0.27 
1429504_at RNPC3 RNA-binding region (RNP1, RRM) 
containing 3 
-1.9 0.27 
1436429_at ZFP606 Zinc finger protein 606 -1.9 0.27 
1435752_s_at ABCC9 ATP-binding cassette, sub-family C 
(CFTR/MRP), member 9 
-1.8 0.29 
1424608_a_at BZW2 Basic leucine zipper and W2 domains 2 -1.8 0.29 
1435760_at CSTA Cystatin A -1.8 0.29 
1422850_at PABPN1 Poly(A) binding protein, nuclear 1 -1.8 0.29 
1426863_at RBMX RNA binding motif protein, X 
chromosome 
-1.8 0.29 
1438501_at RPS17 Ribosomal protein S17 -1.8 0.29 
1435744_at 6720401G13RIK RIKEN cdna 6720401G13 gene -1.7 0.31 
1431754_at CCDC173 Coiled-coil domain containing 173 -1.7 0.31 
1437512_x_at EBNA1BP2 EBNA1 binding protein 2 -1.7 0.31 
1455872_at FAM167A Family with sequence similarity 167, 
member A 
-1.7 0.31 
1429637_at FAM198B Family with sequence similarity 198, 
member B 
-1.7 0.31 
1437685_x_at FMOD Fibromodulin -1.7 0.31 
1416630_at ID3 Inhibitor of DNA binding 3 -1.7 0.31 
1418697_at INMT Indolethylamine N-methyltransferase -1.7 0.31 
1441317_x_at JAKMIP1 Janus kinase and microtubule interacting 
protein 1 
-1.7 0.31 
1436218_at LGR6 Leucine-rich repeat-containing G 
protein-coupled receptor 6 
-1.7 0.31 
1436540_at MIRLET7D Microrna let7d -1.7 0.31 
1442769_at MYBPC1 Myosin binding protein C, slow-type -1.7 0.31 
1427470_s_at NAPB N-ethylmaleimide sensitive fusion 
protein attachment protein beta 
-1.7 0.31 
1444480_at PRKAG3 Protein kinase, AMP-activated, gamma 3 
non-catatlytic subunit 
-1.7 0.31 
1449500_at SERPINB7 Serine (or cysteine) peptidase inhibitor, 
clade B, member 7 
-1.7 0.31 
1417860_a_at SPON2 Spondin 2, extracellular matrix protein -1.7 0.31 
1458087_at STAC3 SH3 and cysteine rich domain 3 -1.7 0.31 
1422231_a_at TNFRSF25 Tumor necrosis factor receptor 
superfamily, member 25 
-1.7 0.31 
1434493_at 1810022K09RIK RIKEN cdna 1810022K09 gene -1.6 0.33 
1425274_at ASPH Aspartate-beta-hydroxylase -1.6 0.33 
1418440_at COL8A1 Collagen, type VIII, alpha 1 -1.6 0.33 
1417403_at ELOVL6 ELOVL family member 6, elongation of 
long chain fatty acids (yeast) 
-1.6 0.33 
1437184_at GUF1 GUF1 gtpase homolog (S. Cerevisiae) -1.6 0.33 
1439251_at IDUA Alpha-L-iduronidase -1.6 0.33 
1454966_at ITGA8 Integrin alpha 8 -1.6 0.33 
1439847_s_at KLF12 Kruppel-like factor 12 -1.6 0.33 
1417686_at LGALS12 Lectin, galactose binding, soluble 12 -1.6 0.33 








1434709_at NRCAM Neuron-glia-CAM-related cell adhesion 
molecule 
-1.6 0.33 
1435341_at PPIG Peptidyl-prolyl isomerase G (cyclophilin 
G) 
-1.6 0.33 
1455195_at RPS24 Ribosomal protein S24 -1.6 0.33 
1423280_at STMN2 Stathmin-like 2 -1.6 0.33 
1439937_at TM9SF1 Transmembrane 9 superfamily member 1 -1.6 0.33 
1436294_at ANKRD29 Ankyrin repeat domain 29 -1.5 0.35 
1452732_at ASPRV1 Aspartic peptidase, retroviral-like 1 -1.5 0.35 
1428397_at B3GALT5 UDP-Gal:betaglcnac beta 1,3-
galactosyltransferase, polypeptide 5 
-1.5 0.35 
1455771_at BZRAP1 Benzodiazepine receptor associated 
protein 1 
-1.5 0.35 
1430584_s_at CAR3 Carbonic anhydrase 3 -1.5 0.35 
1437025_at CD28 CD28 antigen -1.5 0.35 
1419477_at CLEC2D C-type lectin domain family 2, member d -1.5 0.35 
1456887_at CMKLR1 Chemokine-like receptor 1 -1.5 0.35 
1440911_at COL23A1 Collagen, type XXIII, alpha 1 -1.5 0.35 
1419959_s_at CPHX Cytoplasmic polyadenylated homeobox -1.5 0.35 
1435343_at DOCK10 Dedicator of cytokinesis 10 -1.5 0.35 
1418511_at DPT Dermatopontin -1.5 0.35 
1434202_a_at FAM107A Family with sequence similarity 107, 
member A 
-1.5 0.35 
1456784_at GM14137 Predicted gene 14137 -1.5 0.35 
1424252_at HNRPDL Heterogeneous nuclear ribonucleoprotein 
D-like 
-1.5 0.35 
1455180_at MYZAP Myocardial zonula adherens protein -1.5 0.35 
1421566_at PET2 Plasmacytoma expressed transcript 2 -1.5 0.35 
1419820_at PKHD1 Polycystic kidney and hepatic disease 1 -1.5 0.35 
1455696_a_at PRPF4B PRP4 pre-mrna processing factor 4 
homolog B (yeast) 
-1.5 0.35 
1443921_at RANBP3L RAN binding protein 3-like -1.5 0.35 
1425523_at RBM25 RNA binding motif protein 25 -1.5 0.35 
1448754_at RBP1 Retinol binding protein 1, cellular -1.5 0.35 
1450734_at SEC16B SEC16 homolog B (S. Cerevisiae) -1.5 0.35 
1417305_at SPEG SPEG complex locus -1.5 0.35 
1436602_x_at CACNA1B Calcium channel, voltage-dependent, N 
type, alpha 1B subunit 
-1.4 0.38 
1424131_at COL6A3 Collagen, type VI, alpha 3 -1.4 0.38 
1459885_s_at COX7C Cytochrome c oxidase, subunit viic -1.4 0.38 
1417307_at DMD Dystrophin, muscular dystrophy -1.4 0.38 
1443745_s_at DMP1 Dentin matrix protein 1 -1.4 0.38 
1427298_at DNM3OS Dynamin 3, opposite strand -1.4 0.38 
1436434_at E2F2 E2F transcription factor 2 -1.4 0.38 
1425589_at HSD17B13 Hydroxysteroid (17-beta) dehydrogenase 
13 
-1.4 0.38 
1423804_a_at IDI1 Isopentenyl-diphosphate delta isomerase -1.4 0.38 
1436037_at ITGA4 Integrin alpha 4 -1.4 0.38 
1430447_a_at LAIR1 Leukocyte-associated Ig-like receptor 1 -1.4 0.38 
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1431071_at MTX3 Metaxin 3 -1.4 0.38 
1435934_at NDUFAB1 NADH dehydrogenase (ubiquinone) 1, 
alpha/beta subcomplex, 1 
-1.4 0.38 
1426003_at NTRK3 Neurotrophic tyrosine kinase, receptor, 
type 3 
-1.4 0.38 
1418252_at PADI2 Peptidyl arginine deiminase, type II -1.4 0.38 
1423325_at PNN Pinin -1.4 0.38 
1429052_at PTPRD Protein tyrosine phosphatase, receptor 
type, D 
-1.4 0.38 
1417214_at RAB27B RAB27b, member RAS oncogene family -1.4 0.38 
1435080_x_at SFRS18 Serine/arginine-rich splicing factor 18 -1.4 0.38 
1422644_at SH3BGR SH3-binding domain glutamic acid-rich 
protein 
-1.4 0.38 
1436698_x_at TMEM204 Transmembrane protein 204 -1.4 0.38 
1447100_s_at 5730508B09RIK RIKEN cdna 5730508B09 gene -1.3 0.41 
1433801_at 9930012K11RIK RIKEN cdna 9930012K11 gene -1.3 0.41 
1441054_at APOL8 Apolipoprotein L 8 -1.3 0.41 
1417704_a_at ARHGAP6 Rho gtpase activating protein 6 -1.3 0.41 
1454149_a_at CCNL2 Cyclin L2 -1.3 0.41 
1438540_at COL25A1 Collagen, type XXV, alpha 1 -1.3 0.41 
1425476_at COL4A5 Collagen, type IV, alpha 5 -1.3 0.41 
1425698_a_at CREBZF CREB/ATF bzip transcription factor -1.3 0.41 
1422812_at CXCR6 Chemokine (C-X-C motif) receptor 6 -1.3 0.41 
1437256_at DCUN1D5 DCN1, defective in cullin neddylation 1, 
domain containing 5 (S. Cerevisiae) 
-1.3 0.41 
1429299_at DDAH1 Dimethylarginine 
dimethylaminohydrolase 1 
-1.3 0.41 
1428960_at ENKUR Enkurin, TRPC channel interacting 
protein 
-1.3 0.41 
1438718_at FGF9 Fibroblast growth factor 9 -1.3 0.41 
1435459_at FMO2 Flavin containing monooxygenase 2 -1.3 0.41 
1451776_s_at HOPX HOP homeobox -1.3 0.41 
1439885_at HOXC5 Homeobox C5 -1.3 0.41 
1449872_at HSPB3 Heat shock protein 3 -1.3 0.41 
1440235_at ITGA10 Integrin, alpha 10 -1.3 0.41 
1445841_at LRRC39 Leucine rich repeat containing 39 -1.3 0.41 
1424802_a_at LUC7L3 LUC7-like 3 (S. Cerevisiae) -1.3 0.41 
1433758_at NISCH Nischarin -1.3 0.41 
1419392_at PCLO Piccolo (presynaptic cytomatrix protein) -1.3 0.41 
1416321_s_at PRELP Proline arginine-rich end leucine-rich 
repeat 
-1.3 0.41 
1452869_at PRPF38B PRP38 pre-mrna processing factor 38 
(yeast) domain containing B 
-1.3 0.41 
1429169_at RBM3 RNA binding motif protein 3 -1.3 0.41 
1435933_at SCN2A1 Sodium channel, voltage-gated, type II, 
alpha 1 
-1.3 0.41 
1432798_at SLC12A6 Solute carrier family 12, member 6 -1.3 0.41 
1429662_at SPATA1 Spermatogenesis associated 1 -1.3 0.41 
1441024_at STIM2 Stromal interaction molecule 2 -1.3 0.41 
1419088_at TIMP3 Tissue inhibitor of metalloproteinase 3 -1.3 0.41 
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1455162_at TTC39A Tetratricopeptide repeat domain 39A -1.3 0.41 
1434842_s_at UPF3B UPF3 regulator of nonsense transcripts 
homolog B (yeast) 
-1.3 0.41 
1460657_at WNT10A Wingless related MMTV integration site 
10a 
-1.3 0.41 
1439073_at ZFP160 Zinc finger protein 160 -1.3 0.41 
1438343_at 0610037L13RIK RIKEN cdna 0610037L13 gene -1.2 0.44 
1431818_at 1700012B15RIK RIKEN cdna 1700012B15 gene -1.2 0.44 
1451415_at 1810011O10RIK RIKEN cdna 1810011O10 gene -1.2 0.44 
1439495_at 4933407H18RIK RIKEN cdna 4933407H18 gene -1.2 0.44 
1427371_at ABCA8A ATP-binding cassette, sub-family A 
(ABC1), member 8a 
-1.2 0.44 
1433598_at ARGLU1 Arginine and glutamate rich 1 -1.2 0.44 
1460736_at BOD1L Biorientation of chromosomes in cell 
division 1-like 
-1.2 0.44 
1455738_at CCDC55 Coiled-coil domain containing 55 -1.2 0.44 
1427138_at CCDC88C Coiled-coil domain containing 88C -1.2 0.44 
1435779_at CEP110 Centrosomal protein 110 -1.2 0.44 
1438109_at CLCA5 Chloride channel calcium activated 5 -1.2 0.44 
1460372_at DUOXA1 Dual oxidase maturation factor 1 -1.2 0.44 
1436329_at EGR3 Early growth response 3 -1.2 0.44 
1434605_at EIF5B Eukaryotic translation initiation factor 
5B 
-1.2 0.44 
1439757_s_at EPHA4 Eph receptor A4 -1.2 0.44 
1428427_at FBXL2 F-box and leucine-rich repeat protein 2 -1.2 0.44 
1455337_at FGD4 FYVE, rhogef and PH domain containing 
4 
-1.2 0.44 
1453851_a_at GADD45G Growth arrest and DNA-damage-
inducible 45 gamma 
-1.2 0.44 
1443939_at GM12824 Predicted gene 12824 -1.2 0.44 
1418301_at IRF6 Interferon regulatory factor 6 -1.2 0.44 
1425039_at ITGBL1 Integrin, beta-like 1 -1.2 0.44 
1427285_s_at MALAT1 Metastasis associated lung 
adenocarcinoma transcript 1 (non-coding 
RNA) 
-1.2 0.44 
1436796_at MATR3 Matrin 3 -1.2 0.44 
1424123_at MFSD7C Major facilitator superfamily domain 
containing 7C 
-1.2 0.44 
1455238_at MUM1L1 Melanoma associated antigen (mutated) 
1-like 1 
-1.2 0.44 
1425153_at MYH2 Myosin, heavy polypeptide 2, skeletal 
muscle, adult 
-1.2 0.44 
1435041_at MYL6 Myosin, light polypeptide 6, alkali, 
smooth muscle and non-muscle 
-1.2 0.44 
1444980_at ONECUT2 One cut domain, family member 2 -1.2 0.44 
1453145_at PISD-PS3 Phosphatidylserine decarboxylase, 
pseudogene 3 
-1.2 0.44 
1431110_at PLXDC2 Plexin domain containing 2 -1.2 0.44 
1426622_a_at QPCT Glutaminyl-peptide cyclotransferase 
(glutaminyl cyclase) 
-1.2 0.44 
1443715_at RBM24 RNA binding motif protein 24 -1.2 0.44 
1448201_at SFRP2 Secreted frizzled-related protein 2 -1.2 0.44 
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1415874_at SPRY1 Sprouty homolog 1 (Drosophila) -1.2 0.44 
1420018_s_at TSPAN8 Tetraspanin 8 -1.2 0.44 
1455807_at TSPYL5 Testis-specific protein, Y-encoded-like 5 -1.2 0.44 
1460448_s_at TTC14 Tetratricopeptide repeat domain 14 -1.2 0.44 
1427263_at XIST Inactive X specific transcripts -1.2 0.44 
1454975_at ZFC3H1 Zinc finger, C3H1-type containing -1.2 0.44 
1421139_a_at ZFP386 Zinc finger protein 386 (Kruppel-like) -1.2 0.44 
1430886_at 1700112E06RIK RIKEN cdna 1700112E06 gene -1.1 0.47 
1429953_at 2210011C24RIK RIKEN cdna 2210011C24 gene -1.1 0.47 
1435794_at 5031425E22RIK RIKEN cdna 5031425E22 gene -1.1 0.47 
1428220_at 5730419I09RIK RIKEN cdna 5730419I09 gene -1.1 0.47 
1453658_at 5830477G23RIK RIKEN cdna 5830477G23 gene -1.1 0.47 
1457987_at 6030458C11RIK RIKEN cdna 6030458C11 gene -1.1 0.47 
1438720_at 9330159F19RIK RIKEN cdna 9330159F19 gene -1.1 0.47 
1428387_at ACSL3 Acyl-coa synthetase long-chain family 
member 3 
-1.1 0.47 
1448789_at ALDH1A3 Aldehyde dehydrogenase family 1, 
subfamily A3 
-1.1 0.47 
1425677_a_at ANK1 Ankyrin 1, erythroid -1.1 0.47 
1440193_at ANKRD12 Ankyrin repeat domain 12 -1.1 0.47 
1429247_at ANXA6 Annexin A6 -1.1 0.47 
1455396_at ATP8B1 Atpase, class I, type 8B, member 1 -1.1 0.47 
1450051_at ATRX Alpha thalassemia/mental retardation 
syndrome X-linked homolog (human) 
-1.1 0.47 
1437122_at BCL2 B cell leukemia/lymphoma 2 -1.1 0.47 
1448595_a_at BEX1 Brain expressed gene 1 -1.1 0.47 
1422912_at BMP4 Bone morphogenetic protein 4 -1.1 0.47 
1449345_at CCDC34 Coiled-coil domain containing 34 -1.1 0.47 
1453045_at CCDC41 Coiled-coil domain containing 41 -1.1 0.47 
1436572_at CCDC45 Coiled-coil domain containing 45 -1.1 0.47 
1443906_at CD55 CD55 antigen -1.1 0.47 
1435005_at CENPE Centromere protein E -1.1 0.47 
1457823_at CYR61 Cysteine rich protein 61 -1.1 0.47 
1435357_at D4WSU53E DNA segment, Chr 4, Wayne State 
University 53, expressed 
-1.1 0.47 
1455361_at DGKB Diacylglycerol kinase, beta -1.1 0.47 
1436650_at FILIP1 Filamin A interacting protein 1 -1.1 0.47 
1437820_at FOXS1 Forkhead box S1 -1.1 0.47 
1451285_at FUS Fusion, derived from t(12;16) malignant 
liposarcoma (human) 
-1.1 0.47 
1440342_at G530011O06RIK RIKEN cdna G530011O06 gene -1.1 0.47 
1431687_at GMFB Glia maturation factor, beta -1.1 0.47 
1452239_at GT(ROSA)26SOR Gene trap ROSA 26, Philippe Soriano -1.1 0.47 
1418102_at HES1 Hairy and enhancer of split 1 
(Drosophila) 
-1.1 0.47 
1419302_at HEYL Hairy/enhancer-of-split related with 
YRPW motif-like 
-1.1 0.47 
1419519_at IGF1 Insulin-like growth factor 1 -1.1 0.47 
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1425454_a_at IL12A Interleukin 12a -1.1 0.47 
1454768_at KCNF1 Potassium voltage-gated channel, 
subfamily F, member 1 
-1.1 0.47 
1447551_x_at LPHN3 Latrophilin 3 -1.1 0.47 
1429679_at LRRC17 Leucine rich repeat containing 17 -1.1 0.47 
1451498_at LRRC26 Leucine rich repeat containing 26 -1.1 0.47 
1453836_a_at MGLL Monoglyceride lipase -1.1 0.47 
1422597_at MMP15 Matrix metallopeptidase 15 -1.1 0.47 
1418388_s_at MPHOSPH8 M-phase phosphoprotein 8 -1.1 0.47 
1434830_at MXD1 MAX dimerization protein 1 -1.1 0.47 
1449586_at PKP1 Plakophilin 1 -1.1 0.47 
1430636_at PPP4R1L-PS Protein phosphatase 4, regulatory subunit 
1-like, pseudogene 
-1.1 0.47 
1421354_at PRKG2 Protein kinase, cgmp-dependent, type II -1.1 0.47 
1428172_at PRPF39 PRP39 pre-mrna processing factor 39 
homolog (yeast) 
-1.1 0.47 
1442148_at PSIP1 PC4 and SFRS1 interacting protein 1 -1.1 0.47 
1455358_at RBFOX1 RNA binding protein, fox-1 homolog (C. 
Elegans) 1 
-1.1 0.47 
1451041_at ROCK2 Rho-associated coiled-coil containing 
protein kinase 2 
-1.1 0.47 
1438076_at RPL30 Ribosomal protein L30 -1.1 0.47 
1420417_at SEMA3A Sema domain, immunoglobulin domain 
(Ig), short basic domain, secreted, 
(semaphorin) 3A 
-1.1 0.47 
1451031_at SFRP4 Secreted frizzled-related protein 4 -1.1 0.47 
1456914_at SLC16A4 Solute carrier family 16 (monocarboxylic 
acid transporters), member 4 
-1.1 0.47 
1443749_x_at SLC1A3 Solute carrier family 1 (glial high affinity 
glutamate transporter), member 3 
-1.1 0.47 
1424452_at SLTM SAFB-like, transcription modulator -1.1 0.47 
1437658_a_at SNHG1 Small nucleolar RNA host gene (non-
protein coding) 1 
-1.1 0.47 
1427500_at SPCS1 Signal peptidase complex subunit 1 
homolog (S. Cerevisiae) 
-1.1 0.47 
1430271_x_at TAF1D TATA box binding protein (Tbp)-
associated factor, RNA polymerase I, D 
-1.1 0.47 
1423505_at TAGLN Transgelin -1.1 0.47 
1428467_at TARDBP TAR DNA binding protein -1.1 0.47 
1435585_at TCEAL7 Transcription elongation factor A (SII)-
like 7 
-1.1 0.47 
1437634_at THOC2 THO complex 2 -1.1 0.47 
1418398_a_at TSPAN32 Tetraspanin 32 -1.1 0.47 
1453058_at WDR5B WD repeat domain 5B -1.1 0.47 
1436396_at WDR60 WD repeat domain 60 -1.1 0.47 
1431297_a_at 4933436C20RIK RIKEN cdna 4933436C20 gene -1.0 0.50 
1429987_at 9930013L23RIK RIKEN cdna 9930013L23 gene -1.0 0.50 
1429214_at ADAMTSL2 ADAMTS-like 2 -1.0 0.50 
1435160_at AHSA2 AHA1, activator of heat shock protein 
atpase 2 
-1.0 0.50 
1426301_at ALCAM Activated leukocyte cell adhesion 
molecule 
-1.0 0.50 
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1452104_at ARL16 ADP-ribosylation factor-like 16 -1.0 0.50 
1433863_at BTF3 Basic transcription factor 3 -1.0 0.50 
1456224_x_at CAGE1 Cancer antigen 1 -1.0 0.50 
1417420_at CCND1 Cyclin D1 -1.0 0.50 
1423622_a_at CCNL1 Cyclin L1 -1.0 0.50 
1433450_at CDK5R1 Cyclin-dependent kinase 5, regulatory 
subunit 1 (p35) 
-1.0 0.50 
1452991_at CHD2 Chromodomain helicase DNA binding 
protein 2 
-1.0 0.50 
1445194_at CNKSR2 Connector enhancer of kinase suppressor 
of Ras 2 
-1.0 0.50 
1446326_at COL1A2 Collagen, type I, alpha 2 -1.0 0.50 
1434667_at COL8A2 Collagen, type VIII, alpha 2 -1.0 0.50 
1437051_at DFFB DNA fragmentation factor, beta subunit -1.0 0.50 
1451912_a_at FGFRL1 Fibroblast growth factor receptor-like 1 -1.0 0.50 
1452799_at FGGY FGGY carbohydrate kinase domain 
containing 
-1.0 0.50 
1445534_at FLNB Filamin, beta -1.0 0.50 
1433640_at FUBP1 Far upstream element (FUSE) binding 
protein 1 
-1.0 0.50 
1448700_at G0S2 G0/G1 switch gene 2 -1.0 0.50 
1418007_at GCFC1 GC-rich sequence DNA-binding factor 1 -1.0 0.50 
1435695_a_at GGCT Gamma-glutamyl cyclotransferase -1.0 0.50 
1428301_at GM10128 Predicted gene 10128 -1.0 0.50 
1428250_at GPR30 G protein-coupled receptor 30 -1.0 0.50 
1418349_at HBEGF Heparin-binding EGF-like growth factor -1.0 0.50 
1431777_a_at HMGN3 High mobility group nucleosomal 
binding domain 3 
-1.0 0.50 
1455740_at HNRNPA1 Heterogeneous nuclear ribonucleoprotein 
A1 
-1.0 0.50 
1427433_s_at HOXA3 Homeobox A3 -1.0 0.50 
1435332_at HTR7 5-hydroxytryptamine (serotonin) receptor 
7 
-1.0 0.50 
1423104_at IRS1 Insulin receptor substrate 1 -1.0 0.50 
1450029_s_at ITGA9 Integrin alpha 9 -1.0 0.50 
1428615_at LPAR6 Lysophosphatidic acid receptor 6 -1.0 0.50 
1417511_at LYAR Ly1 antibody reactive clone -1.0 0.50 
1435514_at LZTFL1 Leucine zipper transcription factor-like 1 -1.0 0.50 
1434364_at MAP3K14 Mitogen-activated protein kinase kinase 
kinase 14 
-1.0 0.50 
1456927_at MAST2 Microtubule associated serine/threonine 
kinase 2 
-1.0 0.50 
1449965_at MCPT8 Mast cell protease 8 -1.0 0.50 
1421028_a_at MEF2C Myocyte enhancer factor 2C -1.0 0.50 
1452349_x_at MNDA Myeloid cell nuclear differentiation 
antigen 
-1.0 0.50 
1434194_at MTAP2 Microtubule-associated protein 2 -1.0 0.50 
1452670_at MYL9 Myosin, light polypeptide 9, regulatory -1.0 0.50 
1441111_at MYLK4 Myosin light chain kinase family, 
member 4 
-1.0 0.50 
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1424543_at NCK1 Non-catalytic region of tyrosine kinase 
adaptor protein 1 
-1.0 0.50 
1435649_at NEXN Nexilin -1.0 0.50 
1434275_at NKD2 Naked cuticle 2 homolog (Drosophila) -1.0 0.50 
1423249_at NKTR Natural killer tumor recognition 
sequence 
-1.0 0.50 
1418355_at NUCB2 Nucleobindin 2 -1.0 0.50 
1419665_a_at NUPR1 Nuclear protein 1 -1.0 0.50 
1423915_at OLFML2B Olfactomedin-like 2B -1.0 0.50 
1420797_at OTOG Otogelin -1.0 0.50 
1419767_at PADI3 Peptidyl arginine deiminase, type III -1.0 0.50 
1440635_at PALLD Palladin, cytoskeletal associated protein -1.0 0.50 
1456532_at PDGFD Platelet-derived growth factor, D 
polypeptide 
-1.0 0.50 
1421413_a_at PDLIM5 PDZ and LIM domain 5 -1.0 0.50 
1435353_a_at PISD-PS1 Phosphatidylserine decarboxylase, 
pseudogene 1 
-1.0 0.50 
1443282_at PRPF38A PRP38 pre-mrna processing factor 38 
(yeast) domain containing A 
-1.0 0.50 
1435316_at PSMA6 Proteasome (prosome, macropain) 
subunit, alpha type 6 
-1.0 0.50 
1428789_at RALGPS2 Ral GEF with PH domain and SH3 
binding motif 2 
-1.0 0.50 
1424470_a_at RAPGEF3 Rap guanine nucleotide exchange factor 
(GEF) 3 
-1.0 0.50 
1443033_at RBM14 RNA binding motif protein 14 -1.0 0.50 
1435391_at RBM33 RNA binding motif protein 33 -1.0 0.50 
1432232_at RCOR3 REST corepressor 3 -1.0 0.50 
1421565_at ROBO3 Roundabout homolog 3 (Drosophila) -1.0 0.50 
1426123_a_at RRBP1 Ribosome binding protein 1 -1.0 0.50 
1451640_a_at RSRC2 Arginine/serine-rich coiled-coil 2 -1.0 0.50 
1427988_s_at SAFB2 Scaffold attachment factor B2 -1.0 0.50 
1460603_at SAMD9L Sterile alpha motif domain containing 9-
like 
-1.0 0.50 
1458813_at SCN5A Sodium channel, voltage-gated, type V, 
alpha 
-1.0 0.50 
1416778_at SDPR Serum deprivation response -1.0 0.50 
1448415_a_at SEMA3B Sema domain, immunoglobulin domain 
(Ig), short basic domain, secreted, 
(semaphorin) 3B 
-1.0 0.50 
1459903_at SEMA7A Sema domain, immunoglobulin domain 
(Ig), and GPI membrane anchor, 
(semaphorin) 7A 
-1.0 0.50 
1457266_at SLC38A6 Solute carrier family 38, member 6 -1.0 0.50 
1427275_at SMC4 Structural maintenance of chromosomes 
4 
-1.0 0.50 
1448829_at SMC6 Structural maintenance of chromosomes 
6 
-1.0 0.50 
1427134_at SREK1 Splicing regulatory glutamine/lysine-rich 
protein 1 
-1.0 0.50 
1427430_at SUCO SUN domain containing ossification 
factor 
-1.0 0.50 
1438303_at TGFB2 Transforming growth factor, beta 2 -1.0 0.50 
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1449969_at TMOD4 Tropomodulin 4 -1.0 0.50 
1452027_a_at TRP63 Transformation related protein 63 -1.0 0.50 
1431279_s_at TTLL5 Tubulin tyrosine ligase-like family, 
member 5 
-1.0 0.50 
1449682_s_at TUBB2B Tubulin, beta 2B class IIB -1.0 0.50 
1460272_at UBL4B Ubiquitin-like 4B -1.0 0.50 
1430568_at ZC3H13 Zinc finger CCCH type containing 13 -1.0 0.50 
1455092_at ZFP207 Zinc finger protein 207 -1.0 0.50 
1437128_a_at ZFP945 Zinc finger protein 945 -1.0 0.50 
1432001_at ZMYND17 Zinc finger, MYND domain containing 
17 
-1.0 0.50 





Table 28. List of up-regulated genes in C2C12 myotubes upon treatment with 300 mM 
ethanol 




1433607_at CBLN4 Cerebellin 4 precursor protein 3.4 10.56 
1434526_at EPHX4 Epoxide hydrolase 4 1.8 3.48 
1457775_at SACS Sacsin 1.8 3.48 
1444176_at ATP6V0D2 Atpase, H+ transporting, lysosomal 
V0 subunit D2 
1.5 2.83 
1417231_at CLDN2 Claudin 2 1.4 2.64 
1419209_at CXCL1 Chemokine (C-X-C motif) ligand 1 1.2 2.30 
1419728_at CXCL5 Chemokine (C-X-C motif) ligand 5 1.2 2.30 
1419145_at SMTNL1 Smoothelin-like 1 1.2 2.30 
1436109_at AI317395 Expressed sequence AI317395 1.1 2.14 
1451280_at ARPP21 Cyclic AMP-regulated 
phosphoprotein, 21 
1.1 2.14 
1421228_at CCL7 Chemokine (C-C motif) ligand 7 1.1 2.14 
1417408_at F3 Coagulation factor III 1.1 2.14 
1416676_at KNG1 Kininogen 1 1.1 2.14 
1453898_at NMRK2 Nicotinamide riboside kinase 2 1.1 2.14 
1424443_at TM6SF1 Transmembrane 6 superfamily 
member 1 
1.0 2.00 
1428722_at CKMT2 Creatine kinase, mitochondrial 2 0.9 1.87 
1453822_at DNALC1 Dynein, axonemal, light chain 1 0.9 1.87 
1415904_at LPL Lipoprotein lipase 0.9 1.87 
1452031_at SLC1A3 Solute carrier family 1 (glial high 
affinity glutamate transporter), 
member 3 
0.9 1.87 
1417426_at SRGN Serglycin 0.9 1.87 
1416713_at TPPP3 Tubulin polymerization-promoting 
protein family member 3 
0.9 1.87 
1422153_a_at ASB11 Ankyrin repeat and SOCS box-
containing 11 
0.8 1.74 
1418174_at DBP D site albumin promoter binding 
protein 
0.8 1.74 
1438953_at FIGF C-fos induced growth factor 0.8 1.74 
1442884_at HGF Hepatocyte growth factor 0.8 1.74 
1443921_at RANBP3L RAN binding protein 3-like 0.8 1.74 
1451204_at SCARA5 Scavenger receptor class A, member 
5 (putative) 
0.8 1.74 
1429961_at TSACC TSSK6 activating co-chaperone 0.8 1.74 
1451780_at BLNK B cell linker 0.7 1.62 
1448649_at ENPEP Glutamyl aminopeptidase 0.7 1.62 
1416023_at FABP3 Fatty acid binding protein 3, muscle 
and heart 
0.7 1.62 
1422540_at FBLN1 Fibulin 1 0.7 1.62 
1450440_at GFRA1 Glial cell line derived neurotrophic 
factor family receptor alpha 1 
0.7 1.62 
1448269_a_at KLHL13 Kelch-like 13 (Drosophila) 0.7 1.62 








1428083_at NEAT1 Nuclear paraspeckle assembly 
transcript 1 (non-protein coding) 
0.7 1.62 
1418187_at RAMP2 Receptor (calcitonin) activity 
modifying protein 2 
0.7 1.62 
1448529_at THBD Thrombomodulin 0.7 1.62 
1450004_at TSLP Thymic stromal lymphopoietin 0.7 1.62 
1453024_at WDR37 WD repeat domain 37 0.7 1.62 
1427371_at ABCA8A ATP-binding cassette, sub-family A 
(ABC1), member 8a 
0.6 1.52 
1417946_at ABHD3 Abhydrolase domain containing 3 0.6 1.52 
1416203_at AQP1 Aquaporin 1 0.6 1.52 
1419684_at CCL8 Chemokine (C-C motif) ligand 8 0.6 1.52 
1449402_at CHST7 Carbohydrate (N-acetylglucosamino) 
sulfotransferase 7 
0.6 1.52 
1419477_at CLEC2D C-type lectin domain family 2, 
member d 
0.6 1.52 
1415857_at EMB Embigin 0.6 1.52 
1436536_at EXOC3L Exocyst complex component 3-like 0.6 1.52 
1430986_at FARSB Phenylalanyl-trna synthetase, beta 
subunit 
0.6 1.52 
1417872_at FHL1 Four and a half LIM domains 1 0.6 1.52 
1435749_at GDA Guanine deaminase 0.6 1.52 
1439837_at GIGYF2 GRB10 interacting GYF protein 2 0.6 1.52 
1423091_a_at GPM6B Glycoprotein m6b 0.6 1.52 
1428361_x_at HBA-A1 Hemoglobin alpha, adult chain 1 0.6 1.52 
1449038_at HSD11B1 Hydroxysteroid 11-beta 
dehydrogenase 1 
0.6 1.52 
1423608_at ITM2A Integral membrane protein 2A 0.6 1.52 
1451762_a_at KIF1B Kinesin family member 1B 0.6 1.52 
1434877_at NPTX1 Neuronal pentraxin 1 0.6 1.52 
1417653_at PVALB Parvalbumin 0.6 1.52 
1419247_at RGS2 Regulator of G-protein signaling 2 0.6 1.52 
1416523_at RNASE1 Ribonuclease, rnase A family, 1 
(pancreatic) 
0.6 1.52 
1441370_at TMCC1 Transmembrane and coiled coil 
domains 1 
0.6 1.52 
1425098_at ZFP106 Zinc finger protein 106 0.6 1.52 
1453339_at 1700008I05RI
K 
RIKEN cdna 1700008I05 gene 0.5 1.41 
1442376_at ABLIM1 Actin-binding LIM protein 1 0.5 1.41 
1423556_at AKR1B7 Aldo-keto reductase family 1, 
member B7 
0.5 1.41 
1418979_at AKR1C14 Aldo-keto reductase family 1, 
member C14 
0.5 1.41 
1419621_at ANKRD2 Ankyrin repeat domain 2 (stretch 
responsive muscle) 
0.5 1.41 
1460036_at AP1S2 Adaptor-related protein complex 1, 
sigma 2 subunit 
0.5 1.41 
1454822_x_at APCDD1 Adenomatosis polyposis coli down-
regulated 1 
0.5 1.41 
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1417789_at CCL11 Chemokine (C-C motif) ligand 11 0.5 1.41 
1419693_at COLEC12 Collectin sub-family member 12 0.5 1.41 




1443814_x_at CTSH Cathepsin H 0.5 1.41 
1448792_a_at CYP2F2 Cytochrome P450, family 2, 
subfamily f, polypeptide 2 
0.5 1.41 
1451389_at DNAJC24 Dnaj (Hsp40) homolog, subfamily C, 
member 24 
0.5 1.41 
1448136_at ENPP2 Ectonucleotide 
pyrophosphatase/phosphodiesterase 2 
0.5 1.41 
1454965_at FAM171B Family with sequence similarity 171, 
member B 
0.5 1.41 
1448494_at GAS1 Growth arrest specific 1 0.5 1.41 
1430834_at GPRIN3 GPRIN family member 3 0.5 1.41 
1425357_a_at GREM1 Gremlin 1 0.5 1.41 
1433944_at HECTD2 HECT domain containing 2 0.5 1.41 
1452014_a_at IGF1 Insulin-like growth factor 1 0.5 1.41 
1449983_a_at NQO2 NAD(P)H dehydrogenase, quinone 2 0.5 1.41 
1456925_at P2RX6 Purinergic receptor P2X, ligand-
gated ion channel, 6 
0.5 1.41 
1422474_at PDE4B Phosphodiesterase 4B, camp specific 0.5 1.41 
1421979_at PHEX Phosphate regulating gene with 
homologies to endopeptidases on the 
X chromosome (hypophosphatemia, 
vitamin D resistant rickets) 
0.5 1.41 
1416166_a_at PRDX4 Peroxiredoxin 4 0.5 1.41 
1420349_at PTGFR Prostaglandin F receptor 0.5 1.41 
1448254_at PTN Pleiotrophin 0.5 1.41 
1440769_at SELRC1 Sel1 repeat containing 1 0.5 1.41 
1457275_at SYNM Synemin, intermediate filament 
protein 
0.5 1.41 
1460353_at TMEM48 Transmembrane protein 48 0.5 1.41 
1422536_at TNNI3 Troponin I, cardiac 3 0.5 1.41 
1447713_at TPM1 Tropomyosin 1, alpha 0.5 1.41 
1434340_at UQCR10 Ubiquinol-cytochrome c reductase, 
complex III subunit X 
0.5 1.41 
1451314_a_at VCAM1 Vascular cell adhesion molecule 1 0.5 1.41 
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1417156_at KRT19 Keratin 19 -2.2 0.22 
1452732_at ASPRV1 Aspartic peptidase, retroviral-like 1 -1.7 0.31 
1436218_at LGR6 Leucine-rich repeat-containing G 
protein-coupled receptor 6 
-1.6 0.33 
1455948_x_at MATN3 Matrilin 3 -1.5 0.35 
1453588_at CAR3 Carbonic anhydrase 3 -1.4 0.38 
1427013_at CAR9 Carbonic anhydrase 9 -1.4 0.38 
1425589_at HSD17B13 Hydroxysteroid (17-beta) 
dehydrogenase 13 
-1.2 0.44 
1437025_at CD28 CD28 antigen -1.1 0.47 
1438540_at COL25A1 Collagen, type XXV, alpha 1 -1.1 0.47 
1429637_at FAM198B Family with sequence similarity 198, 
member B 
-1.1 0.47 
1422462_at UBE2T Ubiquitin-conjugating enzyme E2T 
(putative) 
-1.1 0.47 
1418441_at COL8A1 Collagen, type VIII, alpha 1 -1.0 0.50 
1416641_at LIG1 Ligase I, DNA, ATP-dependent -1.0 0.50 
1418422_at SERPINB9G Serine (or cysteine) peptidase 
inhibitor, clade B, member 9g 
-1.0 0.50 
1449033_at TNFRSF11B Tumor necrosis factor receptor 
superfamily, member 11b 
(osteoprotegerin) 
-1.0 0.50 
1427537_at EPPK1 Epiplakin 1 -0.9 0.54 
1421041_s_at GSTA1 Glutathione S-transferase, alpha 1 
(Ya) 
-0.9 0.54 
1456772_at NCF1 Neutrophil cytosolic factor 1 -0.9 0.54 
1429699_at OXSM 3-oxoacyl-ACP synthase, 
mitochondrial 
-0.9 0.54 
1422924_at TNFSF9 Tumor necrosis factor (ligand) 
superfamily, member 9 
-0.9 0.54 
1416077_at ADM Adrenomedullin -0.8 0.57 
1424518_at APOL9B Apolipoprotein L 9b -0.8 0.57 
1418304_at CDHR1 Cadherin-related family member 1 -0.8 0.57 
1456084_x_at FMOD Fibromodulin -0.8 0.57 
1419139_at GDF5 Growth differentiation factor 5 -0.8 0.57 
1443939_at GM12824 Predicted gene 12824 -0.8 0.57 
1450029_s_at ITGA9 Integrin alpha 9 -0.8 0.57 
1417812_a_at LAMB3 Laminin, beta 3 -0.8 0.57 
1448978_at NGEF Neuronal guanine nucleotide 
exchange factor 
-0.8 0.57 
1421429_a_at NPNT Nephronectin -0.8 0.57 
1453069_at PIK3CB Phosphatidylinositol 3-kinase, 
catalytic, beta polypeptide 
-0.8 0.57 
1421430_at RAD51L1 RAD51-like 1 (S. Cerevisiae) -0.8 0.57 
1459415_at SPECC1 Sperm antigen with calponin 
homology and coiled-coil domains 1 
-0.8 0.57 










RIKEN cdna 4632415L05 gene -0.7 0.62 
1437841_x_at CSDC2 Cold shock domain containing C2, 
RNA binding 
-0.7 0.62 
1422534_at CYP51 Cytochrome P450, family 51 -0.7 0.62 
1440866_at EIF2AK2 Eukaryotic translation initiation 
factor 2-alpha kinase 2 
-0.7 0.62 
1452799_at FGGY FGGY carbohydrate kinase domain 
containing 
-0.7 0.62 
1456480_at FRY Furry homolog (Drosophila) -0.7 0.62 
1440021_at GPR20 G protein-coupled receptor 20 -0.7 0.62 
1417275_at MAL Myelin and lymphocyte protein, T 
cell differentiation protein 
-0.7 0.62 
1434830_at MXD1 MAX dimerization protein 1 -0.7 0.62 
1434628_a_at RHPN2 Rhophilin, Rho gtpase binding 
protein 2 
-0.7 0.62 
1418423_s_at SERPINB9E Serine (or cysteine) peptidase 
inhibitor, clade B, member 9e 
-0.7 0.62 
1451601_a_at SPNS2 Spinster homolog 2 -0.7 0.62 
1423280_at STMN2 Stathmin-like 2 -0.7 0.62 
1442914_at TMF1 TATA element modulatory factor 1 -0.7 0.62 
1456344_at TNC Tenascin C -0.7 0.62 
1460657_at WNT10A Wingless related MMTV integration 
site 10a 
-0.7 0.62 
1457682_at ARHGAP42 Rho gtpase activating protein 42 -0.6 0.66 
1448261_at CDH1 Cadherin 1 -0.6 0.66 
1423669_at COL1A1 Collagen, type I, alpha 1 -0.6 0.66 
1429210_at COL23A1 Collagen, type XXIII, alpha 1 -0.6 0.66 
1416382_at CTSC Cathepsin C -0.6 0.66 
1428347_at CYFIP2 Cytoplasmic FMR1 interacting 
protein 2 
-0.6 0.66 
1418129_at DHCR24 24-dehydrocholesterol reductase -0.6 0.66 
1455108_at EIF4E2 Eukaryotic translation initiation 
factor 4E member 2 
-0.6 0.66 
1417978_at EIF4E3 Eukaryotic translation initiation 
factor 4E member 3 
-0.6 0.66 
1433796_at ENDOD1 Endonuclease domain containing 1 -0.6 0.66 
1435436_at EPAS1 Endothelial PAS domain protein 1 -0.6 0.66 
1455872_at FAM167A Family with sequence similarity 167, 
member A 
-0.6 0.66 
1449976_a_at GPR35 G protein-coupled receptor 35 -0.6 0.66 
1455014_at HINT3 Histidine triad nucleotide binding 
protein 3 
-0.6 0.66 
1457248_x_at HSD17B7 Hydroxysteroid (17-beta) 
dehydrogenase 7 
-0.6 0.66 
1424949_at HUWE1 HECT, UBA and WWE domain 
containing 1 
-0.6 0.66 
1439954_at LEMD1 LEM domain containing 1 -0.6 0.66 
1424718_at MAPT Microtubule-associated protein tau -0.6 0.66 
1428835_at MYH14 Myosin, heavy polypeptide 14 -0.6 0.66 
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1425153_at MYH2 Myosin, heavy polypeptide 2, 
skeletal muscle, adult 
-0.6 0.66 
1418932_at NFIL3 Nuclear factor, interleukin 3, 
regulated 
-0.6 0.66 
1418252_at PADI2 Peptidyl arginine deiminase, type II -0.6 0.66 
1441026_at PARP4 Poly (ADP-ribose) polymerase 
family, member 4 
-0.6 0.66 
1427893_a_at PMVK Phosphomevalonate kinase -0.6 0.66 
1455450_at PTPN3 Protein tyrosine phosphatase, non-
receptor type 3 
-0.6 0.66 
1456980_at RAB44 RAB44, member RAS oncogene 
family 
-0.6 0.66 
1430534_at RNASE6 Ribonuclease, rnase A family, 6 -0.6 0.66 
1442786_s_at RUFY3 RUN and FYVE domain containing 
3 
-0.6 0.66 
1419238_at ABCA7 ATP-binding cassette, sub-family A 
(ABC1), member 7 
-0.5 0.71 
1434013_at ABLIM3 Actin binding LIM protein family, 
member 3 
-0.5 0.71 
1449383_at ADSSL1 Adenylosuccinate synthetase like 1 -0.5 0.71 
1437373_at AEN Apoptosis enhancing nuclease -0.5 0.71 
1441962_at ALOX5 Arachidonate 5-lipoxygenase -0.5 0.71 
1436181_at ASAP2 Arfgap with SH3 domain, ankyrin 
repeat and PH domain 2 
-0.5 0.71 
1451539_at BAIAP2L1 BAI1-associated protein 2-like 1 -0.5 0.71 
1417419_at CCND1 Cyclin D1 -0.5 0.71 
1421295_at CHRDL1 Chordin-like 1 -0.5 0.71 
1429574_at CLIC3 Chloride intracellular channel 3 -0.5 0.71 
1446326_at COL1A2 Collagen, type I, alpha 2 -0.5 0.71 
1448619_at DHCR7 7-dehydrocholesterol reductase -0.5 0.71 
1448390_a_at DHRS3 Dehydrogenase/reductase (SDR 
family) member 3 
-0.5 0.71 
1433525_at EDNRA Endothelin receptor type A -0.5 0.71 
1418648_at EGLN3 EGL nine homolog 3 (C. Elegans) -0.5 0.71 
1437071_at EIF1AX Eukaryotic translation initiation 
factor 1A, X-linked 
-0.5 0.71 
1427225_at EPN2 Epsin 2 -0.5 0.71 
1424919_at ERBB2 V-erb-b2 erythroblastic leukemia 
viral oncogene homolog 2, 
neuro/glioblastoma derived oncogene 
homolog (avian) 
-0.5 0.71 
1447685_x_at ETS2 E26 avian leukemia oncogene 2, 3' 
domain 
-0.5 0.71 
1416021_a_at FABP5 Fatty acid binding protein 5, 
epidermal 
-0.5 0.71 
1436403_at FAM171A2 Family with sequence similarity 171, 
member A2 
-0.5 0.71 
1418349_at HBEGF Heparin-binding EGF-like growth 
factor 
-0.5 0.71 
1416481_s_at HIGD1A HIG1 domain family, member 1A -0.5 0.71 
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1425553_s_at HIP1R Huntingtin interacting protein 1 
related 
-0.5 0.71 
1422155_at HIST2H3C2 Histone cluster 2, H3c2 -0.5 0.71 
1433685_a_at HJURP Holliday junction recognition protein -0.5 0.71 




1422870_at HOXC4 Homeobox C4 -0.5 0.71 
1458268_s_at IGFBP3 Insulin-like growth factor binding 
protein 3 
-0.5 0.71 
1418983_at INADL Inad-like (Drosophila) -0.5 0.71 
1449082_at MFAP5 Microfibrillar associated protein 5 -0.5 0.71 
1450391_a_at MGLL Monoglyceride lipase -0.5 0.71 
1448553_at MYH7 Myosin, heavy polypeptide 7, cardiac 
muscle, beta 
-0.5 0.71 
1441111_at MYLK4 Myosin light chain kinase family, 
member 4 
-0.5 0.71 
1449550_at MYO1C Myosin IC -0.5 0.71 
1421525_a_at NAIP5 NLR family, apoptosis inhibitory 
protein 5 
-0.5 0.71 
1450337_a_at NEK8 NIMA (never in mitosis gene a)-
related expressed kinase 8 
-0.5 0.71 
1423967_at PALM Paralemmin -0.5 0.71 
1423282_at PITPNA Phosphatidylinositol transfer protein, 
alpha 
-0.5 0.71 
1457252_x_at PLD2 Phospholipase D2 -0.5 0.71 
1447807_s_at PLEKHH1 Pleckstrin homology domain 
containing, family H (with myth4 
domain) member 1 
-0.5 0.71 
1416322_at PRELP Proline arginine-rich end leucine-rich 
repeat 
-0.5 0.71 
1418540_a_at PTPRE Protein tyrosine phosphatase, 
receptor type, E 
-0.5 0.71 
1420842_at PTPRF Protein tyrosine phosphatase, 
receptor type, F 
-0.5 0.71 
1424556_at PYCR1 Pyrroline-5-carboxylate reductase 1 -0.5 0.71 
1441964_at QK Quaking -0.5 0.71 
1436103_at RAB3IP RAB3A interacting protein -0.5 0.71 
1455750_at RALGAPA2 Ral gtpase activating protein, alpha 
subunit 2 (catalytic) 
-0.5 0.71 
1434684_at RIN3 Ras and Rab interactor 3 -0.5 0.71 
1459897_a_at SBSN Suprabasin -0.5 0.71 
1415824_at SCD2 Stearoyl-Coenzyme A desaturase 2 -0.5 0.71 
1427417_at SCML4 Sex comb on midleg-like 4 
(Drosophila) 
-0.5 0.71 
1448415_a_at SEMA3B Sema domain, immunoglobulin 
domain (Ig), short basic domain, 
secreted, (semaphorin) 3B 
-0.5 0.71 
1426318_at SERPINB1B Serine (or cysteine) peptidase 
inhibitor, clade B, member 1b 
-0.5 0.71 
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1453004_at SLC22A23 Solute carrier family 22, member 23 -0.5 0.71 
1436279_at SLC26A7 Solute carrier family 26, member 7 -0.5 0.71 
1438115_a_at SLC9A3R1 Solute carrier family 9 
(sodium/hydrogen exchanger), 
member 3 regulator 1 
-0.5 0.71 
1422103_a_at STAT5B Signal transducer and activator of 
transcription 5B 
-0.5 0.71 
1419447_s_at TBC1D1 TBC1 domain family, member 1 -0.5 0.71 
1433471_at TCF7 Transcription factor 7, T cell specific -0.5 0.71 
1429355_at TEKT5 Tektin 5 -0.5 0.71 
1418057_at TIAM1 T cell lymphoma invasion and 
metastasis 1 
-0.5 0.71 
1449334_at TIMP3 Tissue inhibitor of metalloproteinase 
3 
-0.5 0.71 
1416571_at TRAF4 TNF receptor associated factor 4 -0.5 0.71 
1435170_at TSR2 TSR2, 20S rrna accumulation, 
homolog (S. Cerevisiae) 
-0.5 0.71 




Figure 45. Typical qRT-PCR standard curve 
Typical standard curve shown here was generated from four 10-fold dilutions of cDNA 
samples prepared from Caco-2 cell lysates, using specific primers for GAPDH.  Each data 





Figure 46. Typical qRT-PCR dissociation curves 
The dissociation curves of 30 samples shown here were generated from qRT-PCR at the end 
of 40 cycles using specific primers for GAPDH.  cDNA samples were prepared from Caco-2 
cell lysates.   
 
 
Figure 47. DNA agarose gel electrophoresis images of selected PCR products 
Images shown are DNA agarose gel electrophoresis photos of the PCR products of seven 
genes (named in the figure).  Numbers in brackets indicate the predicted PCR amplicon 
sizes. 
